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SHORT ABSTRACT 
 
Nucleosides and their phosphorylated counterparts (nucleotides) may be considered 
two of the most important metabolites of the cell. Nucleotides are found primarily as 
the monomeric units comprising the major nucleic acids of the cell, RNA and DNA. 
However, they also are required for numerous other important functions within the 
cell. These functions include: 
 
1. serving as energy stores for future use in phosphate transfer reactions. These 
reactions are predominantly carried out by ATP; 
2.  forming a portion of several important coenzymes such as NAD+, NADP+ and 
coenzyme A; 
3.  serving as mediators of numerous important cellular processes such as 
second messengers in signal transduction events; 
4.  controlling numerous enzymatic reactions through allosteric effects on enzyme 
activity; 
5. serving as activated intermediates in numerous biosynthetic reactions. 
During my PhD I focused my attention on: 
1 chemistry of nucleic acids, in particular synthesis and characterization of a 
new kind of monomolecular G-quadruplex; 
2 solid phase synthesis of new base/sugar modified nucleosides; 
3 solid phase synthesis of new derivatives of cIDPR (cyclic-inosine-diphospho-
ribose) 
Interest in the field on the chemistry of G-quadruplex has intensified in recent years 
because G-quadruplex structures have roles in crucial biological processes and can 
be targeted for therapeutic intervention. G-quadruplexes might also have applications 
in areas ranging from supramolecular chemistry and nanotechnology to medicinal 
chemistry. Special attention has been devoted to structural investigation (NMR, CD, 
UV) on the complexes forme by synthesized oligonucleotides. Recently, medicinal 
chemistry research emphasizes the need of nucleosides and nucleotides analogues 
in high number and diversity, to be used as building blocks in the synthesis of new 
oligonucleotides (ON) generations. Many nucleoside and nucleotide synthetic 
analogues have been the cornerstone of antiviral therapy over the past 30 years, and 
many others exhibit anti-proliferative, antibiotic and antifungal properties. The rapid 
development of drug resistence and high toxicity that characterize the use of these 
agents, suggest the novel nucleoside drug discovery for critical medical needs. The 
availability of high-throughput screening capabilities together with the solid phase 
combinatorial synthesis of small organic molecule libraries offers a unique 
opportunity to accelerate the discovery in these fields. My research focused on solid 
phase synthesis of a collection of modified nucleosides and on solid phase synthesis 
of new derivatives of cIDPR, a mimic of natural metabolite cADPR (cyclic-adenosine-
diphospho-ribose). Ca2+ mobilization is crucial for a wide variety of cell functions and 
cADPR is a potent Ca2+ mobilizing messenger. Because of its natural instability 
chemists synthesized new stable mimics in effort to understand the mechanism of 
cADPR-mediated Ca2+ signaling pathways and to obtain lead structures for the 
development of drugs. With a solid phase approach I synthesized and characterized 
new cIDPR derivatives that will be tested as potential pharmacological tools and the 
stability of which, under physiological conditions, will be proved. 
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LONG ABSTRACT 
 
L'interesse per gli oligonucleotidi sintetici deriva dai grandi successi ottenuti in campo 
biomedico per il loro utilizzo come agenti antivirali e antitumorali. 
Oligodeossiribonucleotidi (ODN) di piccole dimensioni (15-17 basi) ed opportuna 
sequenza possono risultare degli efficaci inibitori o, più in generale, regolatori 
dell'espressione genica, interferendo con elevata selettività con le normali funzioni 
degli acidi nucleici o di specifiche proteine [1-3]. 
Gli ODN deputati per queste funzioni possono essere catalogati in base al tipo di 
bersaglio e al loro meccanismo di azione. Possono funzionare da "aptameri", cioè 
riconoscere in maniera assolutamente selettiva una proteina o agire come molecole 
"antisenso" o "antigene" i cui target sono, rispettivamente, uno specifico mRNA e un 
tratto di DNA a doppia elica. Nel quadro delle nuove terapie geniche la strategia 
antisenso, nata ad Harvard nel 1978 ad opera del gruppo di F. Zamecnik [4] ottenne i 
primi successi terapeutici nell'utilizzo di oligonucleotidi antisenso come farmaci nei 
confronti di malattie virali. La prima applicazione di queste molecole nell'ambito delle 
strategie antisenso, ha riguardato la formazione di una doppia elica ibrida tra 
l'oligonucleotide sintetico ed un tratto specifico di m-RNA: in questo modo si 
impedisce il funzionamento del ribosoma che non riconosce la doppia elica [5-7]. 
L'applicazione nel caso delle malattie virali riguardava quindi l'impiego di ODN 
sintetici diretti contro geni esogeni. Solo successivamente si è cominciato ad 
utilizzare gli ODN antisenso nei confronti di malattie dovute a superespressione di 
geni endogeni, normali o mutati per cause patologiche o per azione di fattori 
mutageni estrinseci. Attualmente sono stati ammessi all'utilizzo terapeutico soltanto 
pochi farmaci antivirali di questa classe. Tuttavia un numero elevato di oligonucleotidi 
modificati è sottoposto a sperimentazione clinica con la speranza di poterne 
dimostrare l'attività antitumorale già provata in vitro. 
Altri tipi di strategie sono basate sulla sintesi e l'introduzione nell'organismo di brevi 
tratti di DNA a doppia elica identici ad un sito di DNA e quindi capaci di operare come 
inibitori delle proteine coinvolte nella regolazione o nell'espressione e sintesi o di 
sequestrare i fattori dì trascrizione [8]. In tutti i casi descritti il risultato finale è quello 
di inibire l'espressione di una proteina. L'impiego farmacologico di ODNs sintetici e 
loro modifiche è tuttavia limitato da fattori legati alla stabilità, possibilità di 
somministrazione e biodisponibilità all'interno dell'organismo. Infatti questi composti 
sono rapidamente degradati dalle esonucleasi e dalle endonucleasi cellulari e, data 
la natura di polielettroliti idrofilici e l'assenza di specifici meccanismi di trasporto, 
hanno difficoltà a permeare le membrane cellulari. Negli ultimi anni si è tentato di 
renderli più idrofobici e più resistenti all'idrolisi enzimatica mediante modifiche 
chimiche [9]. 
Più di recente rispetto alla strategia antisenso è stata sviluppata la strategia 
antigenica che si basa sulla formazione di triple eliche fra tratti di DNA a doppia elica 
e singoli filamenti di oligodeossinucleotidi sintetici (ODNs) progettati in maniera 
specifica [10-15]. Infatti l'osservazione che tratti purinici-pirimidinici nei plasmidi 
possono formare strutture a tripla elica intramolecolari, chiamate H-DNA, ha mostrato 
che la formazione di triple eliche può giocare un ruolo importante nei processi 
cellulari. La formazione di una tripla elica può intervenire nella regolazione 
dell'espressione di un gene in almeno due modi: 1) impedendo alle proteine che 
normalmente regolano l'espressione genica di legarsi ai sito di regolazione del DNA 
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prossimale a quello di trascrizione, 2) bloccando il sito stesso di trascrizione, 
impedendo l'avanzamento lungo il gene stesso della RNA-polimerasi. 
Una tripla elica sul DNA si forma quando un terzo filamento (spesso chiamato TFO, 
acronimo di Triplex Forming Oligonucleotide) si introduce nel solco maggiore della 
doppia elica creando dei legami idrogeno di tipo Hoogsteen con le purine delle 
coppie di basi Watson-Crick. La specificità dell'interazione deriva dal riconoscimento 
specifico della coppia di basi adenina-timina da parte di una timina del terzo 
filamento o dal riconoscimento della coppia di basi guanina-citosina da parte di una 
citosina protonata del terzo filamento. 
La strategia antigenica è così basata sul riconoscimento altamente specifico di un 
tratto di DNA da parte del TFO; quest'ultimo deve legarsi al DNA, in condizioni 
fisiologiche, in maniera sufficientemente stabile per poterne modulare l'espressione 
genica. Di conseguenza studi sulla formazione di strutture a tripla elica in condizioni 
fisiologiche sono divenuti di estremo interesse. 
Una limitazione significativa per l'applicazione della formazione delle triple eliche è 
dovuta alla necessità che la doppia elica bersaglio possegga un blocco omopurinico 
sufficientemente lungo (15-17 basi) in genere piuttosto raro e biologicamente poco 
rilevante. Per aumentare il numero di potenziali tratti bersaglio nel DNA naturale, 
molti gruppi di ricerca hanno progettato e sintetizzato oligonucleotidi modificati in 
grado di legarsi più stabilmente di un TFO esclusivamente omopirimidinico. Vari 
approcci si stanno quindi sperimentando. Ad esempio l'introduzione di una giunzione 
che inverta la polarità del secondo tratto del TFO: in questo modo esso sarà in grado 
di riconoscere sequenze omopirimidiniche più brevi presenti su filamenti alternati 
della doppia elica bersaglio [16-22]. Un'altra possibilità è quella di modificare 
l'oligonucleotide trasformandolo in una catena ibrida recante alle estremità 3' e/o 5' 
degli oligosaccaridi [23], o in 3' un tratto di PNA. Queste modifiche rendono 
termodinamicamente più stabili le triplex formate con il TFO "chimerico" che risultano 
anche più resistenti rispetto agli attacchi idrolitici delle nucleasi [24, 25]. Questo 
campo di ricerca sembra essere più promettente rispetto all'uso dei PNA puri, in 
genere troppo poco solubili. Anche l'introduzione di macrocicli o di composti a 
sandwich contenenti cationi di metalli pesanti comporta una stabilizzazione di doppie 
e triple eliche; ma l'interesse principale per questi ODN o ON modificati è legato 
all'attività citotossica e antitumorale esplicata da questi composti [26-28]. 
Un altro campo di grandissimo interesse si è infine aperto con l'individuazione delle 
lunghe sequenze telomeriche a singolo filamento presenti all'estremità 3' di tutti i 
DNA eucariotici. Queste strutture sono molto ricche in guanina, base che favorisce 
l'organizzazione di strutture a quadrupla elica. L'importanza e l'attualità degli studi in 
questo campo deriva dal fatto che sequenze telomeriche del gene, ricche di 
deossiguanosine, possono formare complessi a quadrupla elica [29]. Queste 
strutture potrebbero giocare un ruolo importante nella regolazione dell'attività 
telomerasica. In particolare la telomerasi è una ribonucleoproteina composta da una 
subunita' catalitica con attività di trascrittasi inversa (hTERT) e una componente a 
RNA che funge da templato per la sintesi delle sequenze telomeriche (hTR). 
L'epressione ubiquitaria della telomerasi nelle cellule tumorali e la sua ridotta attivita' 
nelle cellule normali ha suggerito l'ipotesi del coinvolgimento di questo enzima nel 
processo di carcinogenesi [30, 31]. Infatti, l'elevata attività di questo enzima blocca i 
fenomeni di senescenza e morte nelle cellule tumorali. È stato ipotizzato che le 
sequenze telomeriche del gene, strutturandosi in quadrupla elica (quadruplex) 
riescono a regolare l'attività della telomerasi [32, 33]. Da questa ipotesi nasce l'idea 
di regolare l'attività telomerasica mediante ODNs capaci di formare strutture 
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quadruplex. Il crescente interesse verso tali strutture è inoltre legato alla scoperta 
dell'attività inibitoria che alcuni ODNs sintetici, in grado di formare quadruplex, 
mostrano nei confronti di alcune importanti proteine quali la trombina e l'integrasi 
dell'HIV-1 [34, 35], quest'ultima responsabile dell'integrazione del DNA virale in 
quello della cellula ospite. Le strutture a quadrupla elica sono caratterizzate dalla 
formazione di quartetti di guanine connesse da legami idrogeno di tipo Hoogsteen. 
Questi complessi possono essere classificati in base al numero dei filamenti 
oligonucleotidici che li compongono (uno, due, quattro) e in base all'orientamento 
degli ODNs formanti il complesso (parallelo o antiparallelo). Benché la maggior parte 
delle strutture G-quadruplex con attività biologica siano di tipo antiparallelo, recenti 
studi hanno evidenziato interessanti attività anche per quadruplex parallele. Infatti 
quadruplex parallele interagiscono selettivamente con alcune proteine [36-39], 
inoltre, è stata osservata per alcuni di questi complessi, una attività anti HIV [40-43] 
ed anche attività di aptamero verso l'ematoporfirina. Quadruplex parallele si formano 
quasi esclusivamente in complessi tetramolecolari. Sfortunatamente, in vivo, la 
formazione intermolecolare di complessi quadruplex e' molto lenta e necessita di alte 
concentrazioni di ODNs, non facilmente raggiungibili in condizioni fisiologiche. Gli 
sfavorevoli parametri cinetici e termodinamici sono quindi un ostacolo alla potenziale 
utilizzazione farmacologia di questo tipo di complessi 
Recentemente, nel gruppo presso cui ho svolto la mia attività di ricerca, è stata 
messa a punto la sintesi e la caratterizzazione strutturale (NMR; CD, UV) di un 
nuovo tipo di quadruplex parallela monomolecolare formata da oligonucleotidi legati 
a "grappolo". In particolare, la struttura oligonucleotidica a grappolo prevede che i 
quattro filamenti, formanti il complesso quadruplex, siano legati reciprocamente per 
le estremità 3' attraverso una molecola tetraramificata simmetricamente. Questa 
nuova tipologia di quadruplex dovrebbe essere caratterizzata da una maggiore 
stabilità e da una veloce cinetica di strutturazione rispetto ai corrispondenti complessi 
tetramolecolari. Nostri preliminari risultati sulla sintesi e sulla stabilità di questo nuovo 
tipo di quadruplex confermano le ipotesi fatte. La sintesi della molecola "linker" 
tetraramificata (catene dialchilfosfato) avviene su supporto polimerico insolubile. 
Ogni ramificazione contiene una funzione alcolica terminale a cui è possibile legare 
la catena oligonucleotidica. Modulando opportunamente i gruppi protettori delle 
funzioni alcoliche delle struttura ramificante e la tipologia di accrescimento della 
catena oligonucleotidica, è stato possibile ottenere ODNs a grappolo formanti 
strutture quadruplex con orientamento dei filamenti predefiniti (paralleli, antiparalleli o 
con orientazione mista). 
Il mio progetto di ricerca, in tale ambito, ha previsto l’ottimizzazione della lunghezza 
del linker tetraramificato ai fini sia di una maggiore stabilizzazione della struttura 
quadruplex, sia per poter selezionare quadruplex antiparallele da strutture 
sintetizzate a filamenti a polarità inversa. È noto che la polarità dei filamenti in una 
quadruplex riveste fondamentale importanza nelle interazioni con proteine o altre 
molecole. La strategia degli ON-grappolo trascende da tutte queste limitazioni e 
consentirebbe di preparare quadruplex antiparallele, purchè si utilizzino linker di 
opportuna lunghezza. L’eccessiva lunghezza del linker tetraramificato, infatti, sembra 
compromettere la formazione della quadruplex antiparallela, favorendo la formazione 
della struttura parallela per ripiegamento dei “loop” alchilici, come dimostrato dai dati 
ottenuti da calcoli di meccanica molecolare condotti in tale ambito e da studi NMR. 
La lunghezza del linker sembra giocare anche un ruolo di cruciale importanza sulla 
riproducibilità e la velocità dei meccanismi di “melting” e “refolding” delle strutture 
quadruplex-grappolo. 
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È stato anche valutato il diverso effetto stabilizzante dovuto alla presenza di cationi 
sodio e potassio. I dati ricavati dalla spettroscopia NMR, inseriti in software di calcolo 
(Cyana e Dyana) consentiranno di proporre valide strutture per i complessi studiati. 
 
 
Sintesi di collezioni nucleosidiche in fase solida 
 
I nucleosidi sono fondamentali in molte vie metaboliche e di particolare interesse 
risultano i loro meccanismi di riconoscimento associati ad un ampio spettro d’azione. 
I nucleosidi modificati sono alla base di una serie di terapie farmacologiche. Essi, 
mantenendo inalterate le proprietà metaboliche dei composti naturali di partenza, 
sono in grado di penetrare all’interno della cellula e di sottostare ai normali processi 
metabolici, inibendo in maniera reversibile o irreversibile gli enzimi target, così da 
bloccarne le normali funzioni. La caratteristica sostanziale di questa classe di 
molecole è la sostituzione di uno o più atomi, o gruppi funzionali, rispetto ai metaboliti 
naturali che sono i costituenti essenziali di DNA ed RNA. Essi sono in grado di 
interagire con un terzo delle classi di proteine del genoma umano, incluso polimerasi, 
chinasi, reduttasi, recettori di membrana e proteine strutturali. Tra questi composti i 
nucleosidi modificati svolgono un ruolo importantissimo; basti pensare che la 
maggior parte dei farmaci approvati per il trattamento di infezioni virali sono analoghi 
nucleosidici 
Nel corso degli ultimi anni, la sintesi degli analoghi nucleosidici ha interessato un 
numero sempre crescente di studiosi. È utile suddividere queste specie in tre grandi 
categorie a seconda delle caratteristiche strutturali che li differenziano rispetto ai 
corrispondenti composti naturali: 
 
•  Nucleosidi contenenti la base eterociclica modificata; 
•  Nucleosidi contenenti l’unità di zucchero, ribosio o 2’-deossiribosio, modificata; 
•  Nucleosidi altamente modificati nella struttura. 
 
L’approccio sintetico convenzionale per la sintesi di molecole biologicamente 
attive fa uso delle cosiddette metodiche classiche della sintesi organica, da sempre 
utilizzate nella ricerca di nuovi farmaci e di molecole d’interesse biologico in 
generale. Tali strategie prevedono essenzialmente tre fasi: 
 
• Sintesi chimica attraverso reazioni tradizionali (sintesi in soluzione); 
• Purificazione e caratterizzazione strutturale; 
• Determinazione delle proprietà biologiche del target in esame, usando saggi 
biologici convenzionali. 
 
Recentemente, invece, la ricerca nel campo della scoperta di nuovi agenti 
terapeutici, si è rivolta alla preparazione di “librerie chimiche” come potenziali fonti di 
candidati per lo sviluppo di nuovi farmaci. Le librerie chimiche costituiscono vere e 
proprie collezioni di molecole strutturalmente correlate che possono essere ottenute 
sinteticamente o biosinteticamente ed essere successivamente sottoposte a test di 
attività biologica. 
In via del tutto generale, librerie di composti si possono ottenere sia in soluzione che 
in fase solida. In soluzione esistono due approcci fondamentali: è possibile 
sintetizzare delle miscele di vari composti di complessità variabile oppure realizzare 
una sintesi parallela che produce un numero molto minore di composti, ma presenta 
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vantaggi nella caratterizzazione strutturale e nella determinazione delle proprietà 
biologiche della singola molecola. 
La sintesi di composti in fase solida, invece, (solid phase organic synthesis – SPOS) 
presenta numerosi vantaggi rispetto a quella in soluzione. Ad esempio le procedure 
di reazione risultano notevolmente semplificate in quanto complessi processi di 
purificazione ed isolamento dei prodotti sono sostituiti da semplice filtrazione con 
solventi; si può usare un largo eccesso di reagente per condurre le reazioni a 
completezza ed il supporto può essere rigenerato dopo l’uso. Inoltre le metodiche 
sintetiche in fase solida, in linea di principio, sono suscettibili di automazione. 
Solitamente, il supporto solido è costituito da una resina polistirenica funzionalizzata 
opportunamente in modo da consentire l’ancoraggio di un linker o direttamente del 
substrato. 
La disponibilità di strategie sintetiche basate su una chimica semplice ed efficiente, 
quale la chimica combinatoriale e sull’utilizzo di materiali di partenza poco costosi e 
facilmente reperibili costituisce un obiettivo molto ambito per la sintesi di mimetici di 
composti naturali. La  ricerca attuale nel campo dei nucleosidi ad attività antivirale, 
ma anche antitumorale, antifungina, etc. è indirizzata verso la scoperta di nuovi 
analoghi caratterizzati da un ampio spettro di attività biologiche e da un’elevata 
specificità d’azione al fine di minimizzare gli effetti collaterali di queste molecole.  
Per rispondere all’esigenza di avere, in tempi brevi, un elevato numero di analoghi 
nucleosidici da saggiare nelle loro eventuali proprietà farmacologiche , il mio progetto 
di ricerca ha previsto la messa a punto di una strategia di sintesi in fase solida per 
l’ottenimento di una collezione di analoghi ciclici e aciclici (2’,3’-seco-) dell’inosina e 
dei corrispondenti AICAR derivati, differenziati per la lunghezza della catena alchilica 
lineare in posizione N-1 della base ipoxantina o in N-4 del residuo 5-
amminoimidazolo-4-carbossiammide rispettivamente. 
In letteratura sono riportati diversi esempi di strategie combinatoriali in fase solida 
per la preparazione di collezioni di nucleosidi e piccoli oligonucleotidi analoghi. In 
ogni caso, qualunque sia l’approccio seguito, un requisito fondamentale è la scelta di 
una molecola “linker” appropriata che funga da ponte tra il nucleoside e il supporto 
solido. Esso deve essere sufficientemente stabile alle condizioni di reazione usate 
durante la sintesi, ma allo stesso tempo abbastanza labile nelle condizioni di 
rimozione dal supporto solido senza inficiare l’integrità dei prodotti d’interesse.  
La strategia seguita per la sintesi combinatoriale in fase solida di derivati N-1-alchilati 
dell’inosina è basata su studi, condotti in precedenza dal gruppo di ricerca presso cui 
ho svolto il mio lavoro di tesi, sulla reattività dell’ N-1-dinitrofenil-2’-deossi-inosina nei 
confronti di nucleofili all’azoto, al fine di ottenere inosine N-1 sostituite e AICAR 
derivati [22].  
Per estendere queste reazioni alla strategia combinatoriale in fase solida, è stato 
usato un supporto solido polistirenico, disponibile commercialmente, a cui è legato 
covalentemente il gruppo MMTCl (monometossi-tritil-cloruro). Questo tipo di 
supporto, già utilizzato efficientemente, come riportato in letteratura [44], per legare 
nucleosidi o zuccheri, ha la peculiarità di essere stabile in condizioni alcaline, e 
viceversa molto labile in condizioni acide. A tale supporto è stato ancorato l’ossigeno 
5’ del ribosio della 2’,3’-O-isopropiliden-N-1-(2,4-dinitrofenil)-inosina, con formazione 
del corrispondente legame etereo 5’-O-tritilico. 
Succesivamente è stata saggiata la reattività al carbonio C-2 dell’anello purinico nei 
confronti di diversi nucleofili amminici al fine di costruire una prima collezione di 
inosine modificate in N-1. Inoltre, la nota reattività di tali substrati nei confronti delle 
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basi acquose [45] ha permesso di ottenere in resa e purezza molto elevata anche i 
corrispondenti N-4-alchil AICAR derivati. 
Passo successivo è stato quello di studiare la reattività dell’anello ribosidico 
modificando le posizioni 2’ e 3’ sia per quanto concerne i derivati in N-1 dell’inosina 
che in N4 dei corrispondenti AICAR derivati. Ciò ha previsto l’aggancio diretto alla 
resina del nucleoside N-1-(2,4-dinitrofenil)-inosina non protetto alle funzioni 
ossidriliche 2’ e 3’, vista l’instabilità del legame 5’-O-etereo alle condizioni di 
rimozione dell’isopropilidene.  
La condensazione tra il nucleoside e il supporto solido è risultata selettiva a carico 
delle funzioni alcoliche primarie, in accordo con quanto riportato in letteratura. Dopo 
alchilazione della posizione N-1 dell’ inosina, seguendo la strategia prima descritta, 
è’ stata presa in esame la reazione di scissione del legame C-C 2’-3’ da parte di 
agenti ossidanti al fine di ottenere 2’,3’-seco-N1-alchil-inosine e 2’,3’-seco-N4-alchil-
AICAR derivati. Tali composti, in virtù dell’analogia strutturale con composti a 
riconosciuta attività antivirale, quali  il ganciclovir, il penciclovir ed altri, potrebbero 
costituire target molecolari estremamente interessanti nell’ambito della chemioterapia 
antivirale. 
L’azione del periodato di sodio (NaIO4) o del piombotetracetato [Pb(OAc)4] sui 
nucleosidi deprotetti è ben conosciuta [46]. La dialdeide risultante non è stata isolata, 
ma ridotta direttamente con sodio boroidruro (NaBH4) ed i prodotti di interesse sono 
stati ottenuti in buona resa. 
Lo studio ha riguardato quindi la sintesi di nuovi nucleosidi analoghi quali potenziali 
agenti terapeutici ed ha condotto all’ottenimento di derivati che verranno poi 
sottoposti a saggi biologici per poterne testare l’attività terapeutica. 
 
Sintesi in fase solida di nuovi derivati del “ADP-ribosio ciclico” (cADPR) 
 
La sintesi in fase solida di nuove collezioni nucleosidiche  da noi messa a punto ci ha 
spinto a mettere le basi per la costruzione in fase solida di nuovi derivati del cADPR. 
Il cADPR, un metabolita secondario sintetizzato a partire dal NAADP, esplica una 
funzione fondamentale nella regolazione del Ca2+, pertanto risulta di grande 
interesse disporre di un numero maggiore di informazioni circa i meccanismi 
attraverso i quali quest’azione viene regolata. Purtroppo lo studio del ruolo fisiologico 
del cADPR è fortemente limitato dal ruolo transiente di tale molecola [47]. Poiché lo 
ione calcio è coinvolto nella regolazione di diverse funzioni cellulari, come la 
contrazione dei muscoli, la secrezione dei neurotrasmettitori, di ormoni ed enzimi 
responsabili della fertilizzazione degli ovociti, nonché nell’attivazione e proliferazione 
dei linfociti, la cascata dei segnali modulata dal cADPR diventa un interessante 
target farmacologico 
L’interesse verso il cADPR trova riscontro: 1) nelle sue importanti implicazioni 
metaboliche, 2) nella esatta definizione dei suoi meccanismi di azione, 3) nel definire 
le proteine coinvolte nel suo metabolismo, 4) nel disegno di nuovi analoghi strutturali 
con attività agonista o antagonista. Il cADPR è caratterizzato da un legame N-1-
glicosidico fortemente labile, suscettibile a rapida idrolisi sia enzimatica che non, con 
formazione del prodotto di idrolisi ADP-ribosio, già in soluzione acquosa neutra. 
Da qui la necessità di sintetizzare nuovi derivati più stabili del cADPR al fine di 
chiarire il suo meccanismo di azione all’interno delle cellule, di creare dei modelli di 
studio per comprendere la relazione struttura-attività e di avere un pool di analoghi di 
cui testare la potenziale attività farmacologica. 
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In letteratura sono riportati diversi esempi di analoghi stabili del cADPR, in alcuni casi 
anche più attivi dell’analogo naturale stesso.  
Uno dei primi è stato l’ N-1-aristeromicina-adenina-difosforibosio ciclico [48] in cui 
l’ossigeno del ribosio in N-1 è sostituito da un gruppo metilenico. Questo composto 
risulta essere resistente sia all’ idrolisi chimica, sia a quella enzimatica dal momento 
che non c’è piu’ il legame N-1glicosidico presente nel cADPR. Alcune modifiche 
strutturali sull’adenina forniscono derivati più potenti del cADPR, è il caso del 3-
deaza-cADPR avente  un’attivita 70 volte superiore [49]. Ulteriori modifiche 
strutturali includono il legame pirofosfato: il cATPR è, non solo più stabile, ma anche 
più attivo nell’indurre il rilascio di Ca2+ (20 volte maggiore) rispetto alla controparte 
cADPR [50]. 
Ulteriori studi struttura-attività, eseguiti utilizzando derivati opportunamente modificati 
al ribosio in posizione N-1 e alla funzione amminica in C-6 dell’ adenina, indicano che 
questi non sono punti critici nell’attività del cADPR. Pertanto il cIDPR e diversi suoi 
analoghi sono stati sintetizzati. Essi mostrano possedere un’aumentata stabilità 
rispetto al cADPR e sembrano conservarne l’attività in alcuni sistemi cellulari, come 
le cellule-T, in cui sono stati saggiati [51]. 
Poiché la sintesi chimica in soluzione limita la possibilità di ottenere molti analoghi in 
tempi brevi, mi sono occupato di mettere a punto una metodica di sintesi in fase 
solida, per la costruzione di nuovi derivati del cIDPR utilizzando sempre un supporto 
polistirenico ad alta funzionalizzazione legante gruppi monometossitritilcloruro 
(MMTCl). Lo schema sintetico ha previsto cinque reazioni in fase solida tutte in alte 
rese. 
La reazione finale della sintesi ha previsto la formazione di un legame pirofosfato (P-
O-P) fra due fosfomonoesteri (uno presente sul 5’-OH del ribosio e l’altro presente 
sull’OH terminale del pendaglio alchilico legato all’N1 della base eterociclica) e ciò ha 
reso necessario l’utilizzo di un linker spaziatore che fosse in grado di bloccare le 
funzioni 2’ e 3’ del ribosio fungendo quindi da ponte fra il nucleoside e il supporto 
solido, lasciando così libera di reagire la funzione 5’-OH della porzione zuccherina. 
L’innovativa metodica qui proposta per la sintesi in fase solida di derivati del cIDPR 
permette di ottenere in buona resa un maggior numero di analoghi e in tempi più 
brevi grazie all’eliminazione dei processi intermedi di purificazione. 
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Chapter 1 
 
Synthesis of Tetra-End-Linked oligonucleotides forming DNA G-quadruplexes: 
structure characterization and stability 
 
 
Introduction 
 
In 1990 Guschlbauer, Chantot and Thiele published the review article “Four-Stranded 
Nucleic Acid Structures 25 Years Later: From Guanosine Gels to Telomere DNA”
1, in which they highlighted the emerging importance of the G-quartet, a hydrogen-
bonded ionophore2 first identified in 1962. 
Interest in this area has intensified in recent years because G-quadruplex structures 
have roles in crucial biological processes and can be targeted for therapeutic 
intervention3 G-quadruplexes might also have applications in areas ranging from 
supramolecular chemistry and nanotechnology to medicinal chemistry4 
Quadruplexes can be formed with one, two or four G-rich strands (Figure 1.1). 
Tetramolecular quadruplexes generally adopt a well-defined structure, in which all 
guanines are in the anti-glycosidic conformation and all strands are parallel, and 
might be useful for biotechnology applications. J.-L. Mergny (Paris, France) 
described the stability and kinetics of tetramolecular quadruplexes. He reported that 
tetramolecular quadruplexes with stacked G-quartets are extremely stable and that 
quadruplex ligands can act as molecular chaperones to increase the normally slow 
rate of tetramolecular quadruplex association, so that they form in minutes rather 
than days5 
 
 
 
Figure 1.1 G-quartet 
 
Intramolecular G-quadruplexes formed by a single DNA strand have attracted much 
interest because they might form in telomeres, oncogene promoter sequences and 
other biologically relevant regions of the genome. In contrast to tetramolecular 
quadruplexes, intramolecular structures form quickly and are more complex, showing 
great conformational diversity, such as folding topologies, loop conformations and 
capping structures. Different sequences adopt distinct topologies, but a given 
sequence can also fold into various different conformations, which can coexist. One 
of the best illustrations of this complexity are human telomere sequences, in which 
variants of the minimal four G-tract core sequence of the human telomere,  
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5’-(GGGTTA )3GGG, have been synthesized and studied by high-resolution nuclear 
magnetic resonance (NMR) or crystallography. Although the structure in Na+ solution 
was reported more than a decade ago6, the ‘potassium structure’ has been the 
subject of intense investigation, largely because the high intracellular concentration 
of K+ ions suggests that it should be the more biologically relevant form. The crystal 
structure of the human telomeric G-quadruplex in the presence of K+ was reported 
five years ago7 and is a parallel-stranded monomer, which is different from the Na+ 
solution structure that contains antiparallel strands. Recently, several groups 
reported the folding patterns and molecular structures of intramolecular telomeric G-
quadruplexes in K+ solution8. 
 
1.1. Topological classification of G-Quadruplex DNA structures 
 
Numerous reviews have appeared recently discussing the structural characterization 
and polymorphism of G-quadruplex DNA9. It is now well established that certain DNA 
and RNA sequences, possessing a preponderance of guanosine residues, can form 
unusual structures. These structures exhibit unusual mobility under gel 
electrophoresis conditions, protection of the guanosine N7 from methylation with 
dimethyl sulfate, a characteristic CD spectrum, a signature cation-dependent stability 
to thermal denaturation, and distinctive imino resonances in the 1H-NMR spectrum. 
Early observations related to these structures came from the behaviour of guanosine 
nucleotides, which form gels in a cation-dependent manner. Fibre diffraction studies 
of the gels formed by guanosine-3’-monophosphate and poly(G) established the 
fundamental building block of these unusual structures, the G-tetrad, also called the 
G-quartet (Figure 1.1). The G-tetrad consists of a planar arrangement of four 
guanine bases associated through a cyclic array of  Hoogsteen hydrogen bonds in 
which each guanine base both accepts and donates two hydrogen bonds. The 
resulting square planar array is unique due to the “hole” that is created in the center. 
The G-tetrads form four-stranded helical structures by stacking interactions. In the 
case of the poly(G), the average distance separating the stacked G-tetrads is 3.4 Å. 
The tetrads are not stacked linearly, but adopt a right-handed helix. When one or 
more tetrads are stacked in this way, a cylindrical central cavity is produced. This 
cavity, lined with the guanine O-6 carbonyl oxygens, forms a specific binding site for 
metal ions. As deduced from the ability of particular metal ions to induce gel 
formation in guanosine nucleotides, the binding of metal ions follows the order 
Sr2+>K+>>Rb+~Ba2+>NH4+>Ca2+>Na+>Mg2+ ~Cs+>Li+ 9. This contrasts sharply with 
duplex DNA, in which there is only a slight preference in metal ion binding in the 
series Cs+>K+>Li+>Na+. 
A wide array of topologies and strand stoichiometries are compatible with the 
stacking of G-tetrads in helical structures. Hardin10, expanding on the naming 
convention suggested by Cech11, has proposed the class name G-DNA for this large 
class of structures; however, current usage appears to have settled on the class 
name G-quadruplex DNA. The structure formed from poly(G) consists of four strands, 
each contributing one G-residue to each G-tetrad. In this arrangement, the four 
strands are parallel, and there is a four-fold symmetry associated with the structure. 
This type of intermolecular, parallel-stranded structure has been referred to as  
G-quadruplex, G-tetraplex, or simply G4-DNA. In accord with the naming convention 
of Sen and Gilbert12], these four-stranded, parallel structures are referred to as G4-
DNA (Figure 1.2). 
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Alternatively, G-quadruplex DNA may form from two separate DNA strands, each of 
which contributes two guanosine residues to each G-tetrad. These bimolecular G-
quadruplex DNA structures have been referred to as hairpin dimers. This class of 
structures are referred to as G’2-DNA. There are a number of strand topologies that 
might be involved in the formation of G’2-DNA, but to date only four of these have 
been observed or proposed. As Bolton has noted, there are two distinct forms of G’2-
DNA in which the loops formed by each of the two DNA strands are on opposite 
faces of the G-tetrad core13. In the edge form (Figure 1.2), the loops connect 
adjacent DNA strands. A distinct crossover form is characterized by loops that 
connect strands that are diagonally related. A G'2-DNA topology in which the loops 
connecting DNA strands lie on the same face of the G-tetrad stack has been 
proposed by Sen and Gilbert (syn-edge G’2-DNA, figure 3.2)14. An alternative 
topology for a bimolecular G-quadruplex DNA structure is a "dog-eared" structure. 
This topology requires that the DNA loops run diagonally across the faces of the G-
quadruplex that are perpendicular to the G-tetrads. Although this topology has not yet 
been observed in G’2-DNA, a recently reported intramolecular G-quadruplex DNA 
has such a dog-eared” loop15. In addition to the G’2-DNA topologies mentioned 
above, there are a variety of hypothetical topologies involving alternate strand 
distribution (i.e. three guanines in each G-tetrad from one strand and the fourth 
guanine from a second strand) or orientation (i.e. three parallel strands and one 
antiparallel strand, this latter recently observed in human telomere structure forming 
an intramolecular 3+1 G-quadruplex scaffold in K+). It is likely that future research 
may uncover examples of these alternative topologies. Just as in the case of the 
bimolecular G-quadruplex DNA structures, there are multiple topologies that are 
possible in the formation of a unimolecular, or G4'-DNA. The chair form of G4'-DNA is 
characterized by loops connecting only adjacent strands16. This form is similar to the 
unimolecular form of G'2-DNA proposed by Sundquist and Klug. The basket form has 
one loop that crosses the G-tetrad face diagonally. A strikingly different folding 
topology is that reported by Wang and Patel15 for the Na+-stabilized NMR structure of 
the Tetrahymena telomeric repeat d(T2G4)4. This sequence adopts a fold in which 
adjacent strands are connected by an edge loop on one face of the G-tetrad stack, a 
second, central lateral loop, and a terminal “dog-eared” loop running diagonally 
across one of the perpendicular faces of the G-tetrad stack. There are a multitude of 
alternative G4’-DNA fold topologies involving combinations of crossover, edge, and 
dog-eared loops; only time will tell if these topologies are energetically accessible to 
certain natural or engineered DNA sequences. 
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Figure 1.2: Different topological forms of termolecular (G4-DNA), bimolecular (G'2-DNA),and 
unimolecular (G4'-DNA) G-quadruplex structures. 
 
Related to the overall fold topology demonstrated by G’2-DNA and G4’-DNA are the 
glycosidic angles of the guanosine nucleotides forming the G-tetrads. In order for 
adjacent guanosines in antiparallel strands to form the hydrogen bonds necessary for 
G-tetrad formation, one of these guanosine must adopt a syn glycosidic 
conformation. Thus, for each topology listed above, there are alternative strand 
orientations that would result in distinct distribution of glycosidic conformations in the 
G-tetrads. For example, G’2-DNA having the edge topology can in principle adopt 
either a symmetrical form, in which the 5’-ends of the two strands are diagonally 
arranged about a common face, or an unsymmetrical form in which these two ends 
do not share any common faces. The symmetrical form requires that each G-tetrad 
have alternating syn-anti-syn-anti glycosidic conformations, whereas the 
unsymmetrical form requires syn-syn-anti-anti glycosidic conformations (Figure 1.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 G-Quadruplex DNA groove widths 
 
 
Experimentally, the symmetrical edge form is observed in the X-ray structure of 
[d(G4T4G4)]217. One consequence of this variation in glycosidic conformations, is the 
 14 
distinct nature of the grooves. The parallel G4-DNA G-tetrads, in which all G’s adopt 
the anti glycosidic conformation, affords four widths of identical medium width. In 
cases where a guanosine in the syn conformation donates hydrogen bonds to a 
neighboring guanosine in the anti conformation, the groove formed between the two 
is extremely narrow, with a phosphate to phosphate distance as small as 7-9 Å18. In 
contrast, when the hydrogen bonding polarity between adjacent syn- and anti-
guanosines is reversed, a very wide groove is formed. An intermediate width groove 
results when adjacent guanosines adopt the same glycosidic conformation  
(Figure 1.3). For example, in the structure of the symmetrical G’2-DNA having the 
edge topology, the G-tetrads are formed from guanosines of alternating anti-syn-anti-
syn conformation, with each syn-guanosine donating hydrogen bonds to an adjacent 
anti-guanosine, and accepting hydrogen bonds from the other adjacent guanosine. 
This results in a rectangular G-tetrad core with grooves of alternating wide-narrow-
wide-narrow widths. The crossover G'2-DNA has guanosines that adopt the syn-syn-
anti-anti conformations, which results in G-tetrads that adopt a parallelogram 
arrangement and the formation of alternative wide, medium, narrow, medium width 
grooves between strands. Individual DNA strands in G-quadruplex structures is also 
a source of structural diversity, manifest by altered groove geometry. Both syn-anti-
syn-anti and syn-syn-anti-anti G-tetrads typically stack upon each other such that 
consecutive G’s in each DNA strand adopt an alternating 5’-3’ syn-anti relationship. 
However, in G4’-DNA structures containing an odd number of stacked G-tetrads, 
unique syn-syn G-G steps are observed. Through a combination of the altered base-
edges and twist geometry associated with these syn-syn G-dinucleotide steps, the 
narrow grooves of these particular G4’-DNA structures provide a unique target for 
ligand design[26-31]. The ability of DNA minor groove ligands to distinguish the variable 
groove width engendered by sequence has been reported. The specific array of 
alternating groove widths in G-quadruplex DNA structures should provide a means of 
selectively targeting specific topological and conformational forms of G-quadruplex 
DNA. For example, ligands which are able to span two or more G-quadruplex 
grooves may be able to distinguish one form from another based upon the specific 
groove dimensions and their specific orientation. 
As has been observed for the association of individual guanosine nucleotides, G- 
quadruplex structures are stabilized by specific metal ion interactions19. The central 
cavity formed by stacked G-tetrads serves as a host to a variety of cations20. The 
metal cation preference for G4-DNA follows the trend K+ > Ca2+ > Na+ >Mg2+ > Li+ 
and K+ > Rb+ > Cs+, in accord with the trend observed for guanosine nucleotide gel 
formation. In the case of K+, the stacked G-tetrads in G-quadruplex DNA provide a 
bipyramidyl antiprismatic coordination geometry (Figure 1.4a), with each of eight 
carbonyl oxygens interacting equally with the cation. 
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Figure 1.4: Metal ion coordination geometry. a) K+; b) Na+. 
 
 
In the crystal structure of [d(G4T4G4)]2, a region of weak electron density was found 
between planes of stacked G-tetrads and this was assigned to bound K+21. In the 
high resolution crystal structure of [d(TG4T)]4, two G4-DNA structures stack coaxially 
upon each other, forming an extended cylindrical central cavity. Sodium ions are 
located between G-tetrad planes in the center of this cavity (Figure 1.4b), but stack 
out of phase with the G-tetrad repeats, so as to bind in the terminal G-tetrad planes. 
The selectivity of G-quadruplex DNA for K+ versus Na+ ion has been studied by 
Feigon and co-workers using 1H-NMR and the G'2-DNA formed by d(G3T4G3), as a 
model system22. In this system, the G'2-DNA binds two K+ or Na+ ions, corresponding 
to one metal ion sandwiched between each pair of G-tetrads. Using competition NMR 
experiments, Feigon and co-workers determined that there is only a modest 
difference in free energy of 1.7 kcal/mole, favoring the binding of K+ versus Na+ 
ions[37]. They suggest that this modest free energy difference is a result of the 
contributions of the relative free energies of hydration, which favors K+ binding. The 
effect of various cations on the kinetics of G-quadruplex DNA formation and the 
conformational polymorphism of G-quadruplex DNA has also been studied. Although 
original observations by Sen and Gilbert23 indicated that K+ prevented the formation 
of G4-DNA from DNA oligonucleotides containing multiple runs of G’s, this appears 
to be a kinetic, rather than thermodynamic phenomenon. G-quadruplex DNA 
structures can be trapped in metastable states in the presence of K+ ions, which 
stabilize and inhibit the interconversion of G-quadruplex DNA structures. Thomas24, 
Bolton, and Hardin25 have shown that the specific complexation of K+ by G-
quadruplex DNA leads to a preference for the formation of G4-DNA structures under 
high K+ concentrations. Low K+ concentrations, or higher Na+/K+ ratios, favour G4’-
DNA structures. Whether a linear or a folded structure is formed is dependent on the 
exact sequence and number of repeats per strand, cations have a strong influence 
on their relative stabilities. It has been found that potassium ions preferably stabilize 
linear, four-stranded parallel quadruplexes whereas sodium ions stabilize folded 
forms. Cations have profound effects on loop geometry in G4’-DNA structures. DNA 
oligonucleotides, with four runs of –GG- separated by two to four bases, can form 
chair G4’-DNA structures, but only in the presence of K+. When the -GG- runs are 
separated by four residues, a basket G4’-DNA structure can form in either Na+ or 
Na+/K+. Sequences with runs of three or four G’s separated by two to four bases can 
form basket G4’-DNA structures in the absence of K+. The presence of a purine in 
the loop can block both K+ binding and formation of the chair G4’-DNA structure. 
Modelling indicates that the requirement for K+ ion for chair formation is due to the 
a) b) 
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ability of this ion to interact with the terminal G-tetrad and residues in the adjacent 
loop. In addition to these cation-induced changes in G-quadruplex DNA topology, 
there is evidence for K+-ion facilitated formation of G-quadruplex DNA structures from 
duplex DNA precursor]. Increasing K+ causes an increased cooperativity of G4-DNA 
thermal dissociation, despite the increased stabilization of G4-DNA at these higher 
K+ concentrations. Structural transitions of G-quadruplex DNA, induced by changes 
in univalent cation concentrations (i.e. K+ and Na+), may play an important role in 
DNA replication, organization, and function. The transient changes in K+ 
concentration during the cell cycle may drive structural transitions in G-rich DNA. Low 
basal K+ concentrations (ca. 110 mM26 ) are thought to stabilize the G4’-DNA 
structures that may form from single-stranded G-rich sequences at the ends of the 
telomeres. As the cell cycle proceeds, K+ concentrations increase (ca. 130mM27 ) 
and this temporal elevation in K+ concentration initially favours the formation of G'2-
DNA structures, which may facilitate the alignment of chromosomal pairing in 
preparation for homologous recombination events. Further elevation in K+ 
concentration subsequently promotes the formation of G4-DNA structures that may 
be involved in the process of meiotic (or mitotic) telomere association. An alternative 
view is that altered K+/Na+ ratios in cancer cells may result in altered G-quadruplex 
DNA structure and function. A number of reports have documented altered K+/Na+ 
ratios in tumour cells, although the magnitude and trend of change appear to be 
tumour type specific28. These cancer cell-specific K+/Na+ ratios may effect 
conformational changes in G-quadruplex structures, resulting in altered transcription 
of particular genes and altered telomere function and maintenance. 
 
1.2. G-quadruplex: molecular recognition 
 
The wide array of G-quadruplex topologies, groove widths, loop conformations, and 
alternative DNA base-associations observed to date is probably just a small sampling 
of the structural diversity exemplified by G-quadruplex DNA. The unique features of 
G-quadruplex DNA: the association of up to four separate DNA strands, the 
hydrophobic stacking of large, planar hydrogen bonded DNA base quartets, and the 
specific interactions with metal ions, provide the basis for building up these diverse 
structures. Once formed, the G-tetrads of G-quadruplex DNA, can provide an 
"assembly floor" for the creation of unusual DNA base associations. The potential 
existence of G-quadruplex DNA in vivo opens up new vistas for the targeting of DNA 
sequences by molecular recognition of these structurally diverse DNA motifs. The 
structural uniqueness of the G-quadruplex can only aid in the realization of this 
ultimate goal in DNA sequence recognition. As shown in Figure 1.5 and Table 1.1, 
there are different ways in which molecules can interact with G-quadruplexes: by 
face recognition, edge recognition, loop recognition, or by simultaneous binding to 
the surface of the G-quartet and an adjacent loop or groove.  
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Within the context of nucleic acids, there are two major ways for adjacent 
nucleobases to recognize a G-quartet: either by stacking on its surface or by 
hydrogen bonding to an exposed edge. Molecular recognition of the G-Quartet Edges 
Hydrogen-bond donor (N2-H and C8-H) and acceptor (N3) atoms on the exposed 
edges of the G-quartet are also molecular recognition sites. These sites, which are 
located along the floor of a groove running the length of the G-quadruplex, can bind 
water, ions, amino acid side chains, and other nucleobases. Furthermore, 
neighboring loops in bimolecular and unimolecular G-quadruplexes are also 
molecular recognition sites, particularly for proteins and small molecules. 
 
Molecular recognition of G-quadruplexes by proteins 
 
DNA and RNA oligonucleotides called aptamers have been selected by in vitro 
selection to bind molecular targets29. These targets are often proteins. One well-
known aptamer is the thrombin binding aptamer (TBA), a DNA 15 mer that inhibits 
clotting. Crystallographic30 and NMR31 spectroscopic studies have shown that TBA 
forms a unimolecular G-quadruplex with two G-quartets and three loops. The 
structure and biological activity of TBA are K+-dependent. NMR spectroscopic, 
calorimetric, and ESI-MS studies have shown, however, that TBA is even more 
stable with divalent Pb2+, Sr2+, and Ba2+ ions32. Related DNA aptamers are inhibitors 
of human HIV integrase with IC50 values in the nm region33 and adopt a unimolecular 
G-quadruplex similar to TBA34. An intermolecular G-quadruplex aptamer that bound 
the V3 loop of HIV reverse transcriptase was formed by a 17-mer phosphorothioate 
oligonucleotide35. Like many G-quadruplexes, this phosphorothioate aptamer was 
extremely stable and had a dissociation half-life of 60 days. Many other protein-
binding aptamers have been proposed to form G-quadruplexes as part of their 
bioactive structure36. Although many proteins, including aptamers, oncogenic 
factors37, antibodies, and telomeric proteins, all bind G-quadruplexes, there are few 
molecular details known about quadruplex–protein interactions. The crystal structure 
of TBA bound to thrombin showed some ion pairs between the phosphate groups in 
the loops of the aptamer and Lys and Arg side chains38. A crystal structure of the 
telomeric protein of Oxytricha nova complexed to d[G4T4G4]4 is particularly 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Schematic representation showing 
some of the ways that other molecules 
recognize a bimolecular G-quadruplex. 
 
Table 1.1: Molecular recognition of G-
quadruplexes  
a) face recognition through stacking: 
• nucleobase triads and tetrads 
• aromatic molecules/telomerase inhibitors 
 
b) edge recognition through hydrogen bonding: 
• hydrogen bonding of other nucleobases 
• protein recognition: edge interaction with amino acids 
• water-nucleobase interactions 
 
c) loop recognition through hydrogen bonding and electrostatic 
interactions: 
• protein interactions: electrostatic phosphate -ammonium 
interactions 
• small molecules and water 
 
d) groove recognition through hydrogen bonding and 
electrostatic interactions 
• water interactions with the hydration spine 
• side-chain interactions with stacked aromatic molecules 
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valuable. As in the DNA solution structures, the bimolecular quadruplex in this 
complex has diagonal loops. Most of the DNA–protein contacts take place with these 
loops, rather than with the quadruplex core. However, the major DNA–protein 
interactions include: 1) electrostatic interactions, wherein the surface formed by three 
symmetry-related proteins provides a deep, electropositive cavity to hold the folded 
DNA; 2) van der Waals interactions, such as where the aromatic rings of Tyr142and 
Phe141 pack against the G-4 sugar; 3) water mediated hydrogen bonds, wherein one 
of the T4 loops forms an extensive network of water-mediated hydrogen bonds with 
the protein; 4) nucleobase– peptide packing interactions, wherein the T6 residue of 
the other loop contacts the protein using both van der Waals and H-bond 
interactions. This T6 nucleobase packs between a Leu side chain and the polarized 
Asp437–Gly438 peptide bond, while simultaneously hydrogen bonding with atoms of 
the protein side chain and main chain. In both cases where crystal structures are 
available, for the Oxytricha and for the thrombin systems, there are few direct 
interactions between the protein and the G-quadruplex core. Instead, the G-
quadruplex seems to function as a scaffold on which loops are displayed for 
molecular recognition. Certainly, the crystal structure of the unimolecular G-
quadruplex formed from the human telomeric sequence d(TTAGGG) suggests that 
the extended loops provide ideal protein-binding sites. In time, as more structural 
information becomes available, we should learn if a preference to bind loops is 
general for G-quadruplex protein interactions. 
 
1.3 Quadruplexes in telomeres or quadruplexes everywhere? 
 
Potential quadruplex-forming sequences are also widespread throughout the 
genome, especially in gene promoters (Figure 1.6). These structures are expected to 
be different from telomeric quadruplexes—not least because they will be in the 
context of doublestranded DNA —although by no means less complicated. In 
contrast to the uniform repeating G-rich sequence in telomeres, the G-rich 
sequences of gene promoters are often composed of more than four G-tracts with 
each G-tract containing unequal numbers of guanines and separated by various 
numbers of bases. Therefore, each sequence is able to form many possible 
quadruplex structures by using different combinations of G-tracts or guanines within 
a tract. 
An interesting feature of the promoter quadruplexes is the occurrence of stable 
structures with single-nucleotide doublechain-reversal loops39. Such single-
nucleotide double-chain-reversal loops have previously been found in the c-myc 
promoter G-quadruplexes40. Phan reported a new quadruplex fold formed in a wild-
type sequence of the c-kit promoter. This scaffold is extremely unusual in that an 
isolated guanine is involved in G-tetrad core formation, despite the presence of four 
guanine tracts41. Notably, this structure also contains single-nucleotide-sized loops. 
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Figure 1.6 Quadruplex in a gene promoter. 
 
For many years, the question facing biologists in the quadruplex field was whether 
quadruplex structures really exist in vivo. There is now overwhelming evidence that 
they do42 and the field has moved forward to focus on understanding the biological 
functions of various quadruplexes. D. Rhodes (Cambridge, UK) and H. Lipps (Witten, 
Germany) provided an overview of their work studying telomere regulation in the 
ciliate Stylonychia, in which quadruplex formation in telomeres can be directly 
observed in vivo using specific antibodies. By staining with the antibody throughout 
the cell cycle, they showed that telomeric quadruplex structures are resolved during 
replication. Their recent research also indicates that this quadruplex unfolding is 
mediated by telomerase, which is recruited to telomeres by phosphorylated telomere 
end binding protein β (TEBP-β). It will be interesting to see what these elegant 
studies can teach us about the biology of mammalian telomeres. N. Maizels (Seattle, 
WA, USA) described non-telomeric sequences that have a high potential for 
quadruplex formation, with particular emphasis on immunoglobulin heavy-chain 
switch regions. She made the important point that, for quadruplex formation to occur 
within the context of double-stranded DNA , duplex unwinding must occur. Therefore, 
quadruplex formation is most likely to be seen during processes such as 
transcription, replication or recombination, when the DNA duplex is actively 
denatured. Maizels discussed several proteins that bind to quadruplex-containing 
structures, including nucleolin, MutS-α, heterogeneous nuclear ribonucleoproteins 
(hnRNPs) and RecQ family helicases, such as BLM (Bloom syndrome) helicase. 
Recent whole-genome analyses by several groups have revealed that potential 
quadruplex-forming sequences are surprisingly common. For example, it is estimated 
that there might be more than 370,000 potential quadruplex-forming sequences in 
the human genome43. However, one should emphasize that these sequences remain 
putative, and that many sequences found in the human genome might well never 
adopt a quadruplex structure for several reasons. Certainly, with the possible 
exception of the c-myc promoter (Figure 1.644), the biological functions of these 
putative quadruplexes are uncertain at present. 
The intramolecular telomeric G-quadruplex has been considered to be an attractive 
target for anticancer drug design ever since quadruplex ligands were found to inhibit 
telomerase, an enzyme that is activated in most cancer cells but not in most non-
cancerous cells. In addition to the slow erosion of telomeres caused by blocking 
telomerase, it has recently become apparent that quadruplex ligands can induce 
rapid apoptosis owing to displacement of telomere-binding proteins. Many 
quadruplexspecific ligands have been identified and the crystal structures that are 
available, together with NMR data, provide a consistent view of how many ligands 
bind. Terminal stacking at the end of the quadruplex is the most frequently 
encountered method, whereas groove binding is indicated for a few molecules. E. 
Lewis (Flagstaff, AZ , USA) found two methods of interaction for a cationic porphyrin, 
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one of them suggestive of an intercalation between two G-quartets. D. Wilson 
(Atlanta, GA , USA) indicated that some quadruplex ligands might also recognize the 
grooves of a quadruplex, and used surface plasmon resonance to study the affinity 
and specificity of such molecules. For some ligands—for example, TMPyP4 
(5,10,15,20-tetra(N-methyl-4-pyridyl)porphine chloride)—the preference for 
quadruplexes over duplexes was found to be quite low. All attendees agreed that 
structural information on ligand binding is an area that requires further investigation. 
In Figure 1.7 some possible roles of quadruplex formation in vivo and therapeutic 
strategies based on quadruplex formation are presented. Antiparallel quadruplexes 
are shown for simplicity, but actual structures might vary. (A) Quadruplex formation in 
the single-stranded regions of telomeres. Ligands that stabilize the quadruplex might 
lead to cellular senescence by preventing telomere extension mediated by 
telomerase (TEL), and might also induce rapid apoptosis by displacing telomere-
binding proteins, for example, protection of telomeres 1 (POT1). (B) Quadruplex 
formation in the context of duplex DNA is now suspected for many gene promoter 
regions, especially oncogene promoters. The quadruplex structure is a transcriptional 
repressor for some oncogenes, for example, c-myc, and quadruplex-stabilizing 
ligands might act to block transcription. (C) Quadruplexes can also form in RNA and 
might hinder translation. (D) Ribosomal genes (rDNA), which are located in the 
nucleolus of the cell, contain a high concentration of potential quadruplex-forming 
sequences. These rDNA quadruplexes seem to be the target of CX-3543, a 
quadruplex-binding small molecule that is now in clinical trials as an anticancer agent 
(quarfloxin; Cylene Pharmaceuticals, San Diego, CA , USA). CX-3543 localizes to 
nucleoli and prevents nucleolin protein (NCL) from binding to rDNA quadruplexes, 
leading to inhibition of ribosome biogenesis. (E) AS1411 (Antisoma, London, UK) is a 
quadruplex-forming oligonucleotide that is now being tested in human clinical trials. 
This molecule also targets nucleolin protein and seems to bind to the cell surface 
form of the protein, which is present at high levels in cancer cells, leading to 
internalization of the complex. AS1411 can affect the molecular interactions and 
transport of nucleolin, thereby inhibiting many cancer cell survival pathways. 
 
 
 
Figure 1.7 Quadruplexes in biology and as therapeutic agents or targets. 
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1.4 Applications of quadruplexes: bio- and nano-technologies 
 
Quadruplexes show also promise as components for nanowires, ion channels, and 
building blocks for directing the assembly of nanoscale components into 
sophisticated structures.  
Fiber diffraction studies on crystalline GMP and poly-(guanylic acid) had shown that 
these compounds self-assemble into rods of stacked G-quartets45. In the mid-1990s, 
the research groups of both Henderson and Sheardy further established that G-rich 
DNA formed nanometer assemblies46. They showed by using gel electrophoresis that 
d(G4T2G4), in the presence of K+ and Mg2+ ions formed high molecular weight 
assemblies that were well resolved from the smaller G-quadruplex [d(G4T2G4)]4. The 
polymers were extraordinarily stable; heating at 80°C or dissolving in 8 M urea did 
not denature them. Marsh and Henderson coined the term “G-wires” to describe the 
continuous, parallel-stranded DNA superstructures formed when the 5’-end of one 
DNA-duplex with G-G pairs associates with the 3’-end of a similar duplex47. Marsh 
and Henderson proposed that G-wires could be useful in nanotechnology, nano-
electronics and biosensor development.  
G-quadruplexes can organize themselves to build transmembrane ion channels. 
NMR studies have shown that base pairs in DNA G-quadruplexes open slowly and 
G-quadruplex dissociation is often quite slow, taking days or weeks. These results 
suggest that ions move without disruption of the G-quartet, thus making the G 
quadruplex analogous to an ion channel.   
While DNA aptamers have potential as therapeutics and diagnostics, they also have 
applications in bioanalytical chemistry. Small molecules and proteins can be 
separated by using G-quadruplex DNA as stationary phases in chromatography or 
electrophoresis. DNA aptamers featuring an intramolecular G-quadruplex served as 
the stationary phase for the separation of the isomeric dipeptides Trp–Arg and Arg–
Trp48. DNA G-quadruplex aptamers labeled with fluorescent dyes have also served 
as a prototype for biosensors49. In particular, FRET has been used to study the 
secondary structure of G-rich DNA oligonucleotides50. FRET is a distance-dependent 
method for detecting conformational changes over distances of 10–100Å. FRET has 
also been used to monitor the formation of molecular “nanomotors” from single-
stranded DNA51.  
DNA is prone to structural polymorphism, potentially expanding the repertoire of 
nanostructures that may be formed with this nucleic acid. Among these unusual DNA 
structures, G-quadruplexes are of special interest because they have well defined 
conformations, are relatively stable under physiological conditions, are highly 
polymorphic, and are likely to form higher order structures. A motion can result from 
a reversible equilibrium between two conformational states. Several types of 
movements have been described with DNA machines: rotation52 and ‘‘scissorslike’’ 
opening and closing53. The transition between these two states may be induced by a 
change in experimental conditions or by the addition of a ‘‘DNA fuel’’  that provides 
the energy source for this change. A change in buffer composition or temperature 
may lead to a transition in the chirality of a double helix, which in turn may induce a 
movement. Although other dynamic chemical devices that undergo analogous 
structural modifications have recently been proposed54, they are not nucleic acid-
based and use a totally different chemical stimulus as a propellant. The system 
presented by Mergny et al51 has a large stroke amplitude, may easily be followed by 
fluorescence, and is DNA encoded. The principle of operation is illustrated in Figure. 
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1.8 and corresponds to a simple two-step cycle, with two structurally defined 
endpoints. 
 
 
 
Figure 1.8 Switching between an intramolecular quadruplex (left) and a duplex (right). 
 
An intramolecular quadruplex is formed by the folding of a 21-base oligonucleotide 
(F21T) that contains four blocks of three guanines mimicking the vertebrate telomeric 
motif. The schematic topology proposed here corresponds to the Na+ solution 
structure. The fluorescent group and the quencher group are depicted by green and 
orange triangles, respectively. The C-fuel strand is complementary to the F21T 
sequence, with six extra bases allowing duplex nucleation with the G-fuel strand. 
When C-fuel opens F21T, a duplex takes place and fluorescence signal is detected; 
in the closing step a G-fuel is added and quadruplex refolds; no fluorescence is 
detected because fluorophore and quencher are now close to each other. 
By alternatively adding stoichiometric amounts of the C-fuel and G-fuel strands, F21T 
may be opened and closed repeatedly. 
This system could be used to approach alternatively or separate chemically reactive 
groups, or to obtain precise control of movements on the nanometer scale. 
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1.5 The aim of the work 
 
G-quadruplexes (G4s) are unique structures formed by Hoogsteen-type base pairing 
between four guanines and involving chelation of a metal ion. G4s can be formed by 
intramolecular folding of guanine-rich sequences or by intermolecular association of 
two or four sequences leading to the formation of dimeric or tetrameric complexes. 
The biological importance of these structures is three-fold: 1) the occurrence of short 
G-rich sequences able to fold into G-quadruplex structures at the ends of telomeric 
DNA in eukaryotic chromosomes; 2) the high prevalence of G-rich sequences in a 
large number of eukaryotic and prokaryotic genomes, and the increasing number of 
G-quadruplexes arising from these sequences, 3) their presence in the scaffold of 
several aptamers that have the ability to selectively bind to biologically relevant 
proteins and small molecules.,61,62,63,  
G-quadruplexes have the ability to form an array of conformations differing in 
structural features such as the molecularity, the relative orientation of the strands 
involved in the structure, the size of the loops connecting the strands, and the 
glycosidic conformation of guanosine residues (syn or anti). The structural variability 
of G-quadruplexes further increases considering their capacity to accommodate A-, 
T-, and C-tetrads,,67, as well as tetrads formed by modified residues., 
Finally, the topology and the chemical nature of the loops contribute to the structural 
variability of G-quadruplexes. Several studies have been devoted to the effects of the 
loops on G-quadruplex stability and structure.71,72,73,74 Nucleotidic loops can lead to 
polymorphic G-quadruplex species whose structure depends on the length and base 
composition of the loops as well as the cation species present in solution. We 
recently reported the synthesis of a new G-quadruplex forming oligodeoxynucleotide 
in which the 3'-ends of four ODN strands were linked together by a non-nucleotidic 
tetra-end-linker (TEL). This ODN analog, also called tetra-end-linked oligonucleotide 
(TEL-ODN) was able to form a parallel G-quadruplex provided with high thermal 
stability. These initial studies have been extended to other TEL-ODNs in which four 
d(TGGGGT) fragments were tethered to the TEL with different orientations (1-4, 
Figure 1.9). The results indicated that all the synthesized TEL-ODNs 1-4 formed 
monomolecular parallel G-quadruplex structures. Analogs 1 and 2 containing all 3'-
linked or 5'-linked ODN tracts, respectively, formed very stable parallel G-
quadruplexes (Figure 1.9, I and II, respectively) whereas analogs 3 and 4, containing 
mixed 3'- or 5'-linked ODN tracts, formed relatively less stable parallel G-
quadruplexes (Figure 1, III and IV, respectively). Spectroscopic data and molecular 
modelling simulations of 3 and 4 suggested that these analogs could adopt the 
parallel-stranded arrangement shown by III and IV because of the considerable size 
of the TEL, which is big enough to fold around the G-quadruplex scaffold. 
In this report we have extended our previous studies to investigate the influence of 
the TEL size on the molecularity, topology, and stability of the G-quadruplex 
complexes resulting from TEL-ODNs. For this study we have synthesized, by using 
the reported solid phase procedure, a new set of four TEL-d(TGGGGT)4 ODNs (S1 to 
S4, Figure 1.9) in which the four ODN tracts are linked to one of the four branches of 
the new Short-TEL (S-TEL). The TEL-ODNs  S1-4 have been studied in comparison 
to the corresponding L1-4 TEL-ODNs bearing the Long-TEL76 (L-TEL). 
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Figure 1.9 TEL-ODNs 
 
The S-TEL linker, like its progenitor, can be regarded as a single primary di-branched 
linker (A in 9, Scheme 1.1) connected to two secondary di-branched linkers (B in 9, 
Scheme 1.1). The shortening of the TEL linker has been achieved by embodying in 
A and B the ad hoc functionalized glycerol moieties whose synthetic 
phosphoramidite precursors 8a and 8b are shown in Scheme 1.1 Conversely, by 
using the long linker (7a or 7b) in A e B, the L-TEL could be achieved. In the solid 
phase synthesis the primary linker A allows the attachment of the ODN to the 
polymeric support, and the linkers B bear the 3'- or 5'-ends of the ODN tracts. The 
first synthetic pathway (Scheme 1.1) resulted in the synthesis of TEL-ODNs 1 and 2 
in which the four ODN strands are parallel oriented and linked to the four TEL arms 
by their 3'-ends or 5’-ends, respectively. 
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Scheme 1.1 Synthetic procedure for TEL-ODNs L1-2 and S1-2 i: for L1-2 two coupling cycles with 7a;  
for S1-2 two coupling cycles with 8a; ii: for TEL-ODNs 1 synthesis using 3’-phosphoramidite building 
blocks; for TEL-ODNs 2 synthesis using 5’-phosphoramidite building blocks iii: detachement from 
solid support and deprotection with conc. NH4OH (7 h, 55°C). 
 
 
The second synthetic pathway (Scheme 1.2) lead to the synthesis of TEL-ODNs 3 
and 4 each containing antiparallel oriented strands. Circular dichroism (CD), CD 
melting, 1H NMR spectroscopy, molecular modelling and electrophoresis experiments 
have been employed to explore the propensity of synthesized TEL-ODNs to fold into 
G-quadruplexes and to investigate their structures and stabilities. 
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Scheme 1.2 Synthetic procedure for TEL-ODNs  L3-4 and S3-4. i: for L3 coupling with linker 7b;  for 
S3 coupling with linker 8b;  ii: DMT removal and coupling with linker 7a or 8a respectively for L3 or S3; 
iii: DMT removal and ODN synthesis with 3'-phosphoramidites; iv: Fmoc removal and coupling with 
appropriate linker 7a or 8a; v: DMT removal and ODN synthesis with 5'-phosphoramidites; vi: for L4 a 
coupling cycle with 7a and then 7b;  for S4 a coupling cycle with 8a and then 8b; vii: Fmoc removal 
and ODN synthesis with 5'-phosphoramidites; viii: detachment from solid support and deprotection 
with conc. NH4OH  (7 h, 55°C). 
 
 
1.6 Synthesis and Purification of TEL-ODNs type 1, 2, 3 and 4. 
 
For the synthesis of TEL-ODNs 1, 2, 3 and 4 we used a hydroxy-functionalized solid 
support 6 and the reactive bifunctional linkers 7 and 8. In the first approach (Scheme 
1.1) support 6, by way of two coupling cycles with 7a or 8a performed on an 
automatic DNA synthesizer, yielded supports 9 bearing a symmetrical L- or S-TEL 
having the four primary alcohols protected by DMT groups. Supports 9 were then 
used to synthesize either L1, S1 and L2, S2 in which the four ODN strands are 
attached to the TEL via the 3' or 5'-end. The reaction of 3' or 5' -phosphoramidite 
nucleotide building blocks with 9 furnished the polymer bound TEL-ODNs 10. The 
treatment of 10 with concentrated NH4OH furnished L1, S1 and L2, S2.  
For the preparation of L-3 and S-3 we adopted a synthetic strategy (Scheme 1.2) 
based on the use of the linkers 7b and 8b in which the two alcoholic functions are 
orthogonally protected with Fmoc and DMT groups. Support 6, by reaction with the 
phosphoramidite linker 7b (or 8b) yielded supports 11 that, after DMT deprotection 
and successive reaction with 7a (or 8a), furnished the tri-functionalized support 12. 
Six coupling cycles with 5'-phosphoramidite nucleotides and a final capping step of 
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the 5'-OH ends, gave 13. Removal of the Fmoc protecting group and coupling with 7a 
(or 8a) yielded the support 14 on which the second ODN domain was assembled 
using 3'-phosphoramidite nucleotides to obtain polymer bound TEL-ODNs 15.  
The synthetic pathway used to obtain TEL-ODNs L-4 and S-4 (Scheme 1.2), 
involved the reaction of 6 with 7a (or 8a) and subsequently with 7b (or 8b) to obtain 
the supports 16. Removal of DMT protecting groups, followed by ODN synthesis with 
5'-phosphoramidite nucleotides allowed the assembly of the first pair of ODN chains. 
After Fmoc deprotection, the remaining ODN pair having opposite polarity was then 
assembled using 3'-phosphoramidite nucleotides thus obtaining 17. Detachment from 
the solid support and complete deprotection of type 3 and 4 TEL-ODNs were 
achieved by treating the supports 15 and 17, respectively, with concentrated NH4OH 
as described for 1 and 2. Purification and analysis of crude products 1, 2, 3 and 4 
were carried out using HPLC. The 1H NMR and MALDI-MS data confirmed the purity 
of the products. Purified samples of 1, 2, 3 and 4 were dissolved in Na+ and K+ 
buffers and annealed to form G-quadruplexes. 
 
 
 
1.7 CD and CD Thermal Analysis 
 
In order to compare the propensity of each synthesized TEL-ODN to form a G-
quadruplex structure, we carried out CD studies. CD spectra are used to assess the 
nature of G-quadruplex folding, though there is some debate about the CD signature 
of antiparallel and parallel G-quadruplexes. The vast majority of published reports are 
consistent with the observation that antiparallel G-quadruplexes display a maximum 
near 295 nm in the presence of sodium or potassium ions, while parallel G-
quadruplexes exhibit a maximum around 265 nm.,78,79, However researchers must 
take into account that a growing number of exceptions to this rule is coming out.81,82 
The L1-4 and S1-4 samples, annealed at the concentration of 1.0 x 10-5 M, were 
analyzed by CD in 80 mM and 40 mM Na+ (data not reported) and K+ buffers at 25 
°C. The CD spectra of all the samples, with the notably exceptions of L4 and S4, 
exhibited very similar CD profiles regardless the nature of the cation and the medium 
ionic strength. In Figure 1.10 are reported the CD spectra in 80 mM Na+ buffer, 
characterized by a maximum centred around 264 nm and a minimum centred around 
244 nm,  which were in agreement with the presence in solution of parallel stranded 
G-quadruplexes. In the case of L4 and S4 the CD profiles showed two maxima 
centred at 264 nm (the higher) and 289 nm (the lower) thus indicating that a small 
amount of antiparallel G-quadruplex species could coexist in Na+ buffer. 
These data suggest that all the TEL-ODNs 1 and 2, no matter what the TEL size is, 
fold into parallel G-quadruplexes (types I and II, respectively, in Figure 1.9) when 
annealed in Na+ or K+ buffers, indicating that the shortening of the TEL does not 
hinder the formation of parallel G-quadruplex structures. For TEL-ODNs 3 and 4, 
both embodying antiparallel ODN strands, the CD spectra disclosed the formation of 
parallel G-quadruplexes even in the presence of the S-TEL. Furthermore, it is to be 
noted that the replacement of the L-TEL with the S-TEL did not modify the intensity 
ratio between the two CD maxima observed in the CD spectra of L4 and S4 in Na+ 
buffer at 25 °C. As anticipated in our previous report22 the CD spectra recorded for 
ODNs type 3 and 4 are coherent with the formation of type III and IV monomolecular 
parallel G-quadruplexes.  
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Figure 1.10 CD profiles of  L1-4 (left column) and S1-4  (right column) in 40mM Na+ buffer (dotted 
line) and in in 40mM K+  buffer (solid line) at 25°. 
 
To evaluate the influence of TEL size on the stability of the resulting TEL-
quadruplexes, CD thermal denaturation experiments were performed in 80 mM and 
40 mM Na+ and K+ buffers. The CD value (mdeg) at 264 nm was monitored in the 
range 25-90 °C at a heating rate of 0.5 °C/min. Since within the temperature range 
examined low or irrelevant mdeg variation were observed in 80 mM Na+ and K+ 
buffers, the here reported data are referred to the melting data recorded in 40 mM 
Na+ buffer (Figure 1.11). Sigmoidal profiles could be observed only for L1 and L3 
from which the relative Tm values were calculated (62 and 64 °C, respectively). For 
L2 and L4 a well defined and derivatizable sigmoidal profile was not observed. It is to 
be noted that the melting curves of L1-4 display a significant decrease of the mdeg 
value since from the beginning of the melting run. This behaviour, especially for L2 
and L4, as well as to induce a not negligible error in the determination of the Tm 
values, could suggest the co-existence of several kinds of structures that melt at low 
temperature. An analogous behaviour was observed in the melting curves of S1-4. In 
 29 
particular, S2 and S4 showed a marked multiphasic profile which prevented the Tm 
determination of the resulting G4s. However the melting profiles of S1 and S2 
indicated that their fusions were not complete even at 90 °C suggesting that S1 and 
S2 folded into G4s more stable than those originated from the corresponding L-TEL 
analogs in the same buffer condition.  
 
 
 
 
Figure 1.11 CD at 264 nm melting profiles (25-90 °C, 0.5 °C/min) of  L1-4 (dotted line) and S1-4  
(solid line) in 40mM Na+ buffer. 
 
1.8 Native Gel Electrophoresis. 
 
We carried out non-denaturing PAGE experiments to investigate the electrophoretic 
behaviour of the L1-4 (Figure 1.12A) and S1-4 samples (Figure 1.12B), both 
annealed in 80 mM Na+ buffer.  
We observed that L1-4, annealed at 400 μM TEL-ODN concentration, showed 
prevalently a defined band with a mobility comparable to that of the tetramolecular 
(TG4T)4. These bands, which we hypothesize corresponding to the intramolecular G-
quadruplexes (I, II, III and IV, Figure 1.9), were not present in all S1-4, for which a 
marked slow smear was observable (Figure 1.12B). Similar migration profiles were 
observed in 80 mM K+ buffer (data not shown). PAGE experiments performed in 40 
mM of Na+ gave substantially the same results. A different annealing condition was 
examined for the S1-4 TEL-ODNs to investigate the effect of TEL-ODN concentration 
on the smear. In the PAGE reported in Figure 4B the lanes a and b contain S1-4 
annealed at 400 μM and 10µM TEL-ODN concentrations respectively. We observed 
that the 10µM TEL-ODN diluted annealing condition leads to a reduction of the smear 
which could be attributed to the formation of amorphous aggregates that dissociate 
during the PAGE run. This hypothesis is corroborated by the CD melting data that 
show in the case of S1-4 analogues a multi-phasic profile that could be attributed to 
the melting of the aggregates as above described. 
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Figure 1.12 Non denaturing 20% PAGE (pH 7.0). L1-4 (PAGE A) annealed at 400 μM TEL-ODN 
concentration in 80 mM Na+ buffer. S1-4 (PAGE B) annealed at 400 μM TEL-ODN concentration 
(lanes S1a-S4a) and annealed at 10 μM TEL-ODN concentration (lanes S1b-S4b) in 80 mM Na+ 
buffer. 
 
1.9 1H NMR Studies on L- and S-TEL-ODNs  
 
1H NMR studies at 25, 45, 65 and 85 °C on L- and S- TEL-ODN samples 1, 2, 3, and 
4  were performed at 0.5 mM quadruplex concentration in H2O/D2O (9:1, v/v) in 10 
mM KH2PO4, 0.2 mM EDTA and 70 mM KCl, pH 7.0. All spectra recorded at 25 °C 
show the presence of broad signals in the range 10.9-11.8 ppm attributable to 
exchange of protected imino protons involved in Hoogsteen N(1)/O(6) hydrogen 
bonds of G-quartets.78,83, In all cases, an increase in the temperature resulted in the 
sharpening of all imino proton signals. This phenomenon could be tentatively 
explained by the presence in solution of amorphous aggregates of monomolecular G-
quadruplexes, which melt at temperatures above 25 °C. In the case of L1-3 and S1, 
the aggregates are almost completely melted at 45 °C. In fact at this temperature four 
well resolved signals are detected in the imino proton region. No further sharpening 
of imino proton signals was observed at 65 and 85 °C (Figure 1.13). 
The 1H NMR spectrum of S2 and  S3 show broader imino proton signals at 25 °C 
than those observed for L1-3 and S1 that progressively sharpen when the 
temperature is increased from 25 to 65 °C. For S3, the imino proton signals are 
significantly attenuated at 85 °C with a complete loss of the signal at 11.6 ppm at this 
temperature. These data suggest that S3 folds into a less stable G-quadruplex 
compared to those formed by L1-3 and S1 and that more stable and/or extended 
aggregates may be present in solution. The imino proton regions for L4 and S4 are 
almost superimposable at 25 °C. Very broad, overlapped signals are observed at 25 
°C that progressively sharpen as the temperature is increased to 85 °C. At this 
temperature four G-tetrad signals are still clearly visible for S4, while the signal at 
11.6 ppm is almost completely undetectable for L4. The NMR data indicate that all L 
and S TEL-ODN analogs fold into a G-quadruplex structure when annealed in K+ 
buffer. Furthermore, the data suggest that all analogs fold into very similar parallel G-
quadruplex structures, presumably monomolecular, at 65 and 85 °C since at these 
temperatures all the imino proton signals occur at about the same chemical shift. 
TEL-ODN S2-4  seem to favour the formation of more extended/stable aggregates. 
 
TG4T S1a   S1b   S2a   S2b   S3a    S3b   S4a   S4b TG4T  L1     L2     L3     L4    col 
A B 
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The 1H NMR spectra in Na+ buffer (data not shown) suggested the formation of G-
quadruplex structures with lower thermal stability as well as the presence in solution 
of aggregates at lower temperatures for each of the S TEL-ODN analogs (Figure 
1.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13. Imino proton region of 500-MHz 1H-NMR spectra of L1-4 and S1-4  in 80 mM K+ buffer. 
 
 
1.10 Molecular Modelling  
 
Molecular modeling was employed to investigate the propensity of TEL-ODNs 
assembled with the short TEL (S1-4) to adopt parallel G-quadruplex structures. The 
energy minimized structures obtained are shown in Figure 6. Inspection of the 
minimized structure of S1 and S2 reveals that, despite its shorter length, the S-TEL is 
still able to connect the four 3′ and 5′ strands ends, respectively, without causing any 
distortion in the overall G-quadruplex structure. Specifically, the integrity of G-tetrad 
stacking and Hoogsten hydrogen bonding interactions are maintained after energy 
minimization.  
In the case of S3 and, to a greater extent, S4, the models clearly show that the 
linkers are too short to span the distance between the linked 5′ and 3′ ends of the 
strands assembled in a parallel G-quadruplex structure, requiring the involvement of 
the four thymidines directly linked to the TEL to function as an extended linker. 
Although the overall integrity of the G-tetrads core is maintained after energy 
minimization for S3 and S4, a detailed analysis of the nature of the H-bonding within 
the G-tetrads reveals some important differences. Specifically, while optimum 
distances and angles between H-bond donor and acceptor atoms are observed in the 
case of S3, significant deviations are observed for S4 resulting in less stable 
hydrogen bonding between the G residues of each tetrad so that only two or three 
hydrogen bonds in each G-tetrad are retained in the minimized G-quadruplex 
structure (Figure 1.14). 
The molecular modelling studies appear to be consistent with the experimental CD 
and NMR data revealing that the G4s formed by L1-4 are more stable than the 
corresponding originated by S1-4. On the base of molecular modelling data the  
relative stability of S-TEL-d(TGGGGT)4 G4s follows the order S1≅S2≥S3>S4. 
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Figure 1.14 Molecular modelling data related to the relative stability of S-TEL-d(TGGGGT)4. 
 
 
1.11 Conclusions 
 
In this paper we have investigated the G-quadruplex structures formed by several 
TEL-d(TGGGGT)4 analogs which differ both for the relative orientation of the four 
ODN strands attached to the non-nucleotidic TEL, as well as for the TEL size. The 
molecularity, topology and stability of the resulting TEL-G-quadruplexes have been 
investigated using a combination of methods. CD spectra indicate that all TEL-ODN 
analogs, independently from the TEL size and the structural orientation of the ODN 
strands, formed parallel TEL-G-quadruplexes. Molecular modelling results point out 
the ability of the S-TEL to fold around the G4 scaffold, thus allowing the formation of 
monomolecular G-quadruplexes such as I-IV depicted in Figure 1. 1H NMR studies 
confirmed the folding into parallel G4s for all the here reported TEL-ODN species. 
Furthermore, the non-denaturing PAGE experiments of S1-4 showed significant 
smearing with no single well defined G4 band. We attributed the significant smearing 
observed in PAGE experiments to the formation of amorphous aggregates made of 
single G-quadruplex scaffolds, which melt at low temperature and are not detectable 
by the MS technique. This hypotheisis was also corroborated by the 1H NMR 
analyses at increasing temperature. The role of the TEL size seems to be crucial in 
the formation of these aggregates since they were observed almost exclusively for 
the S-TEL ODNs.  
We do not believe that the observed aggregates belong to polymeric species like V 
and VI (Figure 1.9) on the basis of the following considerations: i) no polymeric 
species have been detected in the MALDI mass spectra; ii) no defined bands 
attributable to dimeric or polymeric species have been detected in the PAGE 
experiments; iii) the thermal stability of type V and VI polymeric species would have 
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had to be as stable, or even more stable, than the corresponding monomolecular 
analogs.  
In conclusion we have characterized a small set of parallel TEL-G-quadruplexes 
whose parallel topology was independent of the nature of the cation species in 
solution and of the TEL size. Furthermore, the parallel orientation of the G-
quadruplex structures leads to a predictable TEL loop arrangement on either the 5'-
face, the 3'-face or on one side of the G-quadruplex scaffold. These findings, 
together with the ability to affect the stability of the TEL-G-quadruplexes through 
modification of the TEL, indicate that the TEL-ODNs are useful models to study 
ligand-quadruplex interactions. Furthermore, we believe that TEL-G-quadruplexes 
with suitable sequences could be used as new kind of aptamers, decoys and 
molecular probes.  
 
1.12 Experimental 
 
1.12.1 Reagents and Equipment.  
 
Chemicals and solvents were purchased from Fluka-Sigma-Aldrich. Reagents and 
phosphoramidites for DNA syntheses were purchased from Glen Research. ODN 
syntheses were performed on a PerSeptive Biosystems Expedite. HPLC analyses 
and purifications were performed with a JASCO PU2089 pump system equipped with 
an UV detector model 2075 Plus using a Merck Hibar (5 m, 250-10) column. 
Linkers 7a-b were purchased from Glen Research. Tentagel carboxy resin, used as 
starting material for preparation of solid support 6, was purchased from 
Novabiochem. Preparation of 6 was carried out in a short column (10 cm length, 1 
cm i.d.) equipped with a sintered glass filter, a stopcock and a cap as previously 
described.22 The ODNs were assembled by a PerSeptive Biosystems Expedite DNA 
synthesizer using phosphoramidite chemistry. UV spectra were collected using a 
Jasco V-530 spectrophotometer. CD spectra and thermal denaturation experiments 
were collected with a Jasco J-715 spectropolarimeter equipped with a JASCO ETC-
505T temperature controller unit. NMR spectra were recorded on a Varian Unity 
Inova 500 MHz spectrometer. MALDI-TOF mass spectrometric analyses were 
performed on a Bruker Autoflex mass spectrometer using a picolinic/3-hydroxy-
picolinic acid mixture as the matrix. ESI-MS were performed on a Applied Biosystem 
API 2000 mass spectrometer in positive mode. The ODN concentration was 
determined spectrophotometrically at λ = 260 nm and 90 °C, using the molar 
extinction coefficient ε = 57800 cm-1M-1 calculated for the unstacked oligonucleotide 
by the nearest neighbour mode. 
 
1.12.2 Syntheses of linkers 8a-b. 
 
8a. 0.34 g (3.6 mmol) of 1,2,3-propantriol dried by repeated coevaporations with 
anhydrous pyridine and then dissolved in 8 mL of the same solvent, were reacted 
with 2.5 g (7.2 mmol) of 4,4'-dimethoxytrytilchloride at R.T. for 12 h. The reaction was 
quenched by addition of water and the resulting mixture, taken to dryness and 
redissolved in benzene, was purified on a silica gel column giving 1.63 g (2.34 mmol, 
65% yield) of 1,3- bis-(O-DMT)-propantriol, in mixture with the full protected 
derivative. The bis-tritylated compound was dissolved in dry CH2Cl2 (5 mL) and N,N-
diisopropylethylamine was added (0.860 mL, 4.6 mmol) followed by 2-cyanoethyl-
N,N-diisopropylchlorophosphoramidite (0.48 mL, 2.76 mmol). The mixture was stirred 
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for 1 h at R.T. then diluited with ethyl acetate (50 mL) and washed with saturated 
sodium chloride solution (4 × 25 mL). The organic phase was dried over sodium 
sulphate and evaporated to an oil in the presence of toluene (10 mL). The product 
was purified by short column chromatography on Kieselgel 60H (10 g) eluting with 
CH2Cl2/ethyl acetate/2,6-lutidine 50:50:2. (v/v/v)  The product was dried to give a 
white powder (90% yields). 1H-NMR (400 MHz) ppm (acetone, d6) 1.05 (d, 12H, 
CHCH3), 2.97 (m, 2H, CHCH3), 3.52 (d, 4H, CH2ODMT), 3.82 (s, 12H, OCH3), 3.87 
(m, 1H, CHOP), 4.05 (s, 2H, CH2CN), 6.82-7.55 (m, 26H, aromatic protons). ESI-MS 
calculated for C53H59N2O8P m/z: 882.11, found: 883.40 (M + H)+. 
8b. 0.34 g (3.6 mmol) of 1,2,3-propantriol dissolved in 8 mL of pyridine, were reacted 
with 0.325 g (0.9 mmol) of 4,4'-dimethoxytrytilchloride at R.T. for 12h to afford after 
purification the monotrityl derivative as main product (0.343 g, 0.8 mmol, 80%). This 
latter was protected at the remaining primary hydroxyl group by reaction with 
fluorenylmethoxycarbonylchloride (Fmoc-Cl 232 mg, 0.9 eq) in anhydrous CH2Cl2. 
Phosphoramidite derivative was prepared as just described for obtaining 8a. 1H-NMR 
(400 MHz) ppm (acetone, d6): 1.05 (d, 12H, CHCH3), 2.97 (m, 2H, CHCH3), 3.52 (d, 
2H, CH2ODMT), 3.82 (s, 6H, 4OCH3), 4.05 (s, 2H, CH2CN),  4.14 (m, 1H, CHOP), 
4.31(d, 2H, CH2OFmoc), 4.46 (t, 1H, CH-fluorenyl), 4.78 (d, 2H, CH2-fluorenyl),  6.80-
7.65 (m, 21H, aromatic protons). ESI-MS calculated for C47H51 N2O8P m/z: 802.34, 
found: 803.80 (M + H)+. 
 
1.12.3 Syntheses and Purifications of TEL-ODNs L1-2 and S1-2 
 
50 mg of support 6 (0.18 meq/g) were used for each synthesis in the automated DNA 
synthesizer following standard phosphoramidite chemistry, using 45 mg/mL of 
solution of phosphoramidite 7a in two coupling cycles for the synthesis of L1, or using 
8a (two coupling cycles) for the synthesis of S1 followed by reaction with 3'-
phosphoramidite (for L1 and S1) or 5'-phosphoramidite (for L2 and S2) nucleotide 
building block (six cycles, 45 mg/mL in anhydrous CH3CN) to obtain the polymer 
bound ODN 10. The coupling yields were consistently higher than 98% (by DMT 
spectrophotometric measurements). The solid support 10 was then treated with conc. 
aq. ammonia solution for 7 hours at 55 °C. The filtered solution and washings were 
concentrated under reduced pressure and purified by HPLC on a Nucleogel SAX 
column eluted with a linear gradient of the following buffers. Buffer A: 20 mM 
NaH2PO4, pH 7.0 containing 20% CH3CN; buffer B: 1 M NaCl, 20 mM NaH2PO4, pH 
7.0, containing 20% CH3CN; linear gradient from 0 to 100% B in 30 min, flow rate 
1mL/min. The collected products were desalted by gel filtration on a Sephadex G25 
column eluted with H2O/ethanol (9:1,v/v) to obtain, after lyophilization, pure L1, L2, 
S1 and S2 (82, 80, 74, and 76 OD260 units, respectively). The TEL-ODNs were 
characterized by MALDI TOF-MS (negative mode): L1 found: 8820 (calcd. 8821.7); 
S1 found: 8225 (calcd. 8226.9).  
 
1.12.4 Syntheses and purifications of TEL-ODNs 3 and 4  
 
For the synthesis of L3, and S3 50 mg of support 6 (0.18 meq/g) was reacted, in the 
automated DNA synthesizer, with 7b (for L3) or 8b (for S3) following standard 
phosphoramidite chemistry yielding support 11 (0.17 meq/g of DMT groups). After 
removal of DMT protecting groups by DCA, the second coupling cycle was performed 
in the same manner using phosphoramidite 7a (for L3) or 8a (for S3) thus obtaining 
support 12 (0.30 meq/g of DMT groups). 12 was then subjected to six coupling cycles 
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using 3'-phosphoramidite nucleotide building blocks (45 mg/mL in CH3CN), followed 
by final DMT removal and 5'-OH capping with Ac2O, to yield ODN functionalized 
support 13. The removal of Fmoc groups was achieved by treatment with 
piperidine/DMF solution (2:8, v/v, 30 min R.T.). The resulting support was then 
reacted with phosphoramidite 7a or 8a as above described thus obtaining 14 (0.27 
meq/g of DMT groups). After removal of DMT protecting groups the second ODN 
domain was assembled by six coupling cycles with 5'-phosphoroamidite nucleotide 
building block as described for support 12 yielding the polymer bound ODN 15.  
For the synthesis of L4 and S4, support 6 (50 mg) was functionalized with 
appropriate 7a or 8a and then 7b or 8b, as described before, yielding the tetra-
branched support 16 (0.28 meq/g of DMT groups). After removal of the DMT 
protecting groups, the first two ODN chains were assembled, using 3'-
phosphoramidite nucleotide building blocks. After capping of the terminal 5'-OH 
functions by Ac2O treatment, the Fmoc groups were removed as previously 
described, and two successive ODN chains were assembled using 5'-
phosphoroamidite nucleotide building blocks, thus obtaining the polymer bound ODN 
17. TEL–ODNs were detached from the supports 15 and 17, deprotected and purified 
as previously described. After lyophilization, the final pure products L3, S3, L4, and 
S4. (65, 72, 69 and 80 OD260 units, respectively) were characterized by MALDI TOF-
MS (negative mode): L3 found: 8820 (calcd. 8821.7); S3 found: 8225 (calcd. 8226.9); 
L4 found: 8820 (calcd. 8821.7); S4 found: 8225 (calcd. 8226.9). 
 
1.12.5 Preparation of Quadruple Helices (Annealing).  
 
G-quadruplexes types I, II, III and IV were formed by dissolving L1-4 and S1-4 in the 
appropriate phosphate buffers and annealed by heating to 90 °C for 20 min followed 
by slow cooling to room temperature. The solutions were equilibrated at 25 °C for 24 
hours before performing the experiments.  
 
1.12.6 Native gel electrophoresis.  
 
Native gel electrophoreses were run on 20% non-denaturing polyacrylamide gels in 
1× TB buffer, pH 7.0 with 40 mM NaCl (or KCl). The TEL-ODNs were dissolved in 0.1 
mM EDTA, 10 mM NaH2PO4, 30 mM NaCl (40mM Na+ buffer), or 0.1 mM EDTA, 10 
mM NaH2PO4, 70 mM NaCl (80mM Na+ buffer) at a quadruplex concentration of 400 
µM or 10 µM and annealed as described earlier. Samples were loaded at a final 
concentration of 200 µM TEL-ODNs in a buffer solution containing 6% glycerol that 
was added just before gel loading. The gels were run at room temperature at 
constant voltage (100V) for 2.5 h. The bands were visualized by UV shadowing and 
after “stain all” colouration. 
 
1.12.7 CD Experiments.  
 
G-quadruplexes CD spectra were collected using a Jasco J-715 spectropolarimeter 
using  a 0.1 cm path length quartz cuvette at 25 °C. The ODNs were prepared at a 
quadruplex concentration of 1.0 × 10-5 M in the appropriate buffer. Spectra were 
collected over a wavelength range of 200 - 320 nm with a scanning speed of 100 
nm/min, a response time of 16 s, and a bandwidth of 2.0 nm. A background scan of 
buffer alone was subtracted from all scans. CD thermal denaturation experiments 
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were followed by recording the CD values at 264 nm in a temperature range of 25-90 
°C at a heating rate of 0.5 °C/min. 
 
1.12.8 1H NMR Experiments. 
 
1H NMR data were collected on Unity INOVA 500 and Mercury VX 400 Varian 
spectrometers equipped with a broadband inverse probe with z-field gradient, and 
processed using the Varian VNMR software package. 1D NMR spectra were 
acquired as 16384 data points with a recycle delay of 1.0 s at temperatures of 25, 45, 
65 and 85 °C. Data sets were zero filled to 32768 points prior to Fourier 
transformation and apodized with a shifted sinebell squared window function. Pulsed-
field gradient DPFGSE sequence was used for H2O suppression. All NMR samples 
were prepared at 0.5 mM quadruplex concentration in H2O/D2O (9:1, v/v) in 10 mM 
KH2PO4, 0.2 mM potassium EDTA and 70 mM KCl (K+ buffer) and 10 mM NaH2PO4, 
0.2 mM sodium EDTA or 70 mM NaCl (Na+ buffer). 
 
1.12.9 Molecular Modelling.  
 
The conformational features of the TEL-ODNs S1-4 have been explored by means of 
a molecular modelling study. All the calculations were performed on a personal 
computer running the HyperChem 7.5 suite of programs. The AMBER force field 
using AMBER 99 parameter set was used. The initial coordinates for the starting 
model of [d(TGGGGT)]4 G-quadruplex were taken from the NMR solution structure of 
the [d(TTGGGGT)]4 G-quadruplex (Protein Data Bank entry number 139D), choosing 
randomly one of the four available structures. The initial [d(TGGGGT)]4 G-quadruplex 
model were built by deletion of the 5'-end thymidine residue in each of the four 
TTGGGGT strands. The complete structures of S1-4 were then built using the 
HyperChem 7.5 building tool. Partial charges for each atom of the TEL were 
assigned using the Gasteiger-Marsili algorithm implemented in the QSAR module of 
HyperChem suite. The resulting coordinates of the TEL atoms were energy-
minimized in vacuum keeping all DNA coordinates frozen (500 cycles of the steepest 
descent method). The calculations were performed using a distance-dependent 
macroscopic dielectric constant of 4*r, and an infinite cut-off for nonbonded 
interactions to partially compensate for the lack of solvent used. Hydrogen bond and 
glycosidic torsion angle constraints were used according to NMR and CD data. 
Upper and lower distance limits of 2.0 Å and 1.7 Å for hydrogen-acceptor distance, 
and 3.0 Å and 2.7 Å for donor-acceptor distance were employed (20 kcal/mol·Å2). 
Glycosidic torsion angles were constrained to a range of -160°/-70° as required for a 
parallel G-quadruplex having all guanines in the anti orientation (16 Kcal/mol·Å2). In 
each case, the entire system was energy minimized using the conjugate gradient 
method until convergence to an rms gradient of 0.1 kcal/mol·Å was reached. In the 
next step the coordinates of all the thymidines and TEL atoms where subjected to a 
restrained molecular dynamics simulation. The system was initially heated from 0 to 
1000 K during the first 33 ps of simulation, the simulation then proceeded for 250 ps 
at 1000 K and was followed by 24 ps of cooling to 273 K. Finally, all the restraints 
were removed and the systems were energy minimized using 1000 cycles of the 
steepest descent method followed by the conjugate gradient method until 
convergence to a rms gradient of 0.1 kcal/mol·Å. 
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Chapter 2 
 
Synthesis of combinatorial libraries of nucleosides, specifically inosine 
analogues 
 
Introduction 
 
Nucleoside research has historically been an area of keen interest for small 
molecole drug discovery due predominately to the medicinal value and biological 
importance of these molecules. Apart from being the genomic building blocks, 
nucleosides interact with roughly one-third of the protein classes in the human 
genome, including polymerases, kinases, reductases, motor proteins, membrane 
receptors, and structural proteins, all targets of biological importance.  
The binding motifs of these nucleosides are associated with a broad array of targets 
of therapeutic importance in biological systems. It was early recognized that, 
introducing diversity into the carbohydrate or the base subunits of nucleosides, 
represents promising strategies to identify specific receptor ligands, enzyme 
inhibitors, or nucleoside function modifiers. Nucleoside analogues, showing very 
complex and interesting structures, have been isolated from t-RNA (5-
methylcytidine, 3’-methyluridine), marine organism and several other microbiological 
forms. Naturally occurring nucleosides analogues demonstrate selective activities, 
such as protein synthesis inhibitors (puromycin), glycosyl transferase inhibitors 
(tunicamycin), methyl transferase inhibitors (sinefungin) and antibiotic activity 
(coformicine A and adenomicine). The discovery that some nucleoside analogues 
can possess biological activities has been a significant breakthrough especially in 
antiviral and anticancer chemotherapy. In this regard, the isolation from natural 
sources, but especially synthetic work have lead to the discovery of a large variety of 
new analogues. After decades of drug discovery and development effort from 
hundreds of academic laboratories and pharmaceutical companies, approximately 
50-nucleoside- and nucleotide-related drugs, have been approved by the US Food 
and Drug Administration, and pushed to the market, and over 80 
nucleosides/nucleotides are in the (pre) clinical studies for various therapeutic 
indications, including antiviral1 , anticancer2 , antibiotic3 and antifungal4 .  
In the search for antiviral nucleoside analogues, structural modifications of the 
heterocyclic bases and/or modifications on the sugar moiety of natural nucleosides, 
can be attempted. In the latter, the main modifications involved changes in the (2-
deoxy)-D-ribofuranose moiety like, inversion of hydroxyl group configurations, their 
substitution/functionalisation by various synthetic groups, or cleavage of the sugar 
ring leading to acyclic nucleosides. Other structural modifications have also been 
attempted such as replacement by a methylene group or a sulfur atom of the 
endocyclic oxygen, transposition of the latter and/or additional insertion of a second 
heteroatom in the sugar moiety. Currently, nucleoside analogues are prominent 
drugs in the management of several viral infections. The nucleoside analogues at 
present formally approved for the treatment of viral infections are shown in Figure 
2.1 Acyclovir is an important antiviral in hepatitis C (HCV) treatment, while 
Lamivudine (3’-thiocytidine, 3TC) is a nucleoside analogue used for treatment of 
hepatitis B virus (HBV), the 5-iodouridine is employed in Herpes Simplex infections 
(HSV). Furthermore, it must be considered that the most commonly used anti-HIV 
drugs are nucleoside analogues,  including Zidovudine (AZT, azidothymidine), Hivid 
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(ddC, zalcitabine), Zerit (d4T, stavudine) and some others, all possessing high 
activity in antiretroviral therapies4. They mimic natural nucleosides and target a 
unique, but complex viral polymerase that is essential for viral replication. Some 
nucleosides show also antiproliferative properties, for example  arabinosylcytidine 
and 5-azacytidine are both utilized in the treatment of leukaemia, while 5-fluorouracil 
(5-FU) is employed in breast tumour (Figure 2.1). 
 
 
Figure 2.1: Nucleoside analogues currently used in antiviral therapy. 
 
For salvage to be efficient, mediated transport of nucleosides and nucleobases 
across the plasma membrane has to occur. Then metabolic activation of nucleosides 
and nucleobases takes place, modulating their pharmacological action. The 
biochemical mechanism can be of various type, but in most cases the 5’-
phosphorilation of the sugar moiety is the first step. The nucleoside 5’-phosphate is 
then converted into a triphosphate derivative that inhibits, in different way, the 
replication of DNA or RNA. However, some drugs such as AZT, ddI, 3TC etc. rapidly 
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develop drug resistance and show mitochondrial, bone-marrow and other toxicity. 
The increasing resistance of pathogens, the often severe side effects of nucleosides 
in chemotherapy, and the lack of selective ligands for adenosine receptor 
subclasses, despite extensive medicinal chemistry research, emphasizes the need 
for nucleoside analogues in high number and diversity. In addition, the availability of 
high-throughput screening capabilities, together with the combinatorial synthesis of 
small organic molecule libraries, offers a unique opportunity to accelerate the 
discovery of novel pharmaceutical targets and leads, especially, with biologically 
priviledged scaffolds, such as nucleosides in hand.  
 
2.1.  Nucleoside analogues  
 
The design of selective, specific and non-toxic antiviral, but also anticancer agents, 
has presented extraordinary challenges compared with the design of other 
antimicrobial agents. This is primarily because, in contrast to bacteria and parasites 
that are equipped with their own metabolic machinery for reproduction and growth, 
viruses rely on the host cellular machinery for replication and propagation. 
Consequently, there are few virus-specific molecular targets that are amenable to 
antiviral intervention. In addition, drug resistance to antiviral agents is a major 
problem as many viruses mutate rapidly under the selective pressure of the antiviral 
therapy. In recent times, however, and largely owing to the AIDS epidemic and 
advances in molecular virology, the structure and function of a few virus-specific 
molecular targets such as proteases and helicases have been revealed. 
Furthermore, in the past decade , a repertoire of discovery tools in terms of structure 
and mechanism–based drug design, such as delucidations on nucleoside analogues 
uptake and export, their activaction, mechanism of action and mitochondrial toxicity, 
have provided novel strategies for the design of antiviral agents against new 
molecular targets. In this regard different sites of diversity on both purine- and 
pyrimidine-nucleoside scaffolds have been introduced, schematically represented in 
Figure 2.2, bearing a myriad of functional groups. Generally, nucleosides analogues 
can be catalogued in “Base-modified” and “Sugar-modified” nucleoside 
analogues.  
 
 
 
 
 
 
 
 
 
Figure 2.2: Nucleoside, nucleotide modifications 
 
Notwithstanding these advances, progress in the discovery of new antiviral 
therapeutics has remained slow, and current antiviral chemotherapy  is heavily 
dependent on a “cocktail” of antiviral agents. New antiviral agents, with unique 
mechanisms of action, are urgently needed, given the propensity of viruses to 
mutate rapidly under the selective pressure of chemotherapy. In the last years, the 
combinatorial chemistry has emerged as very efficient tool to produce a large 
number of new molecules differing in punctiform manner around a core structure of 
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active compounds. Solid phase combinatorial strategies have been mainly used in 
the nucleoside field. 
2.2. Nucleoside analogue uptake 
 
The intracellular concentration of nucleosides and nucleobases is of great 
importance for the success of antiviral and anticancer therapies and,  to some 
extent, it is the result of the metabolic background of the specific cell line used for 
infection studies, its particular suit of enzymes and transporters. Transporter-
mediated pathways are involved in either the uptake or the efflux of nucleoside and  
nucleobase derivatives. From a biochemical point of view, four different types of 
transport processes for nucleoside-related drugs are involved: 1) equilibrative 
uniport; 2) substrate exchange; 3) concentrative Na+ - or H+-dependent uptake and 
finally 4) substrate export through primary ATP-dependent active efflux pump. These 
mechanisms are mainly related to the following set of transporter families: 
Concentrative Nucleoside Transporter (CNT), Equilibrative Nucleoside Transporter 
(ENT), Organic Anion Transporter (OAT) and Organic Cation Transporter (OCT), 
Peptide Transporter (PEPT) and Multidrug Resistance Protein (MRP)5 . The scheme 
in figure 4.3 shows an idealistic  epithelial cell expressing all known nucleoside-
based antiviral drug transporters, emphasizing their location, either apical or 
basolateral, which ensure, when necessary, vectorial flux of substrates across the 
epithelium. Although information regarding the plasma membrane domains, in which 
they are inserted, has recently became available, the location for some specific 
transporters, such as Multidrug Resistance Proteins (MRP8) is still in doubt and so 
they are shown at the lateral side of the cell.  
 
Figure 2.3: Major transporters implicated in the uptake and efflux of nucleoside-derived drugs used in 
antiviral therapy. A model of an idealized polarized epithelial cell, with the apical and basolateral 
membrane domains. 
 
Equilibrative uniport works down the substrate concentration gradient and thus, it is 
in principle a reversible mechanism that responds only to the transmembrane 
substrate gradient tending to equilibrate it. This would be the case for the basolateral 
Equilibrative Nucleoside Transporter (ENT) carriers. The working model for an 
exchanger, particularly an obligatory exchanger, implies that efficient translocation of 
the substrate occurs only if both molecules are bound at both sides of the membrane 
to allow substrate exchange. An example of this mechanism depicted in Figure 2.3 
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is that the Organic Anion Transporter, also located at the basolateral plasma 
membrane, which exchanges an extracellular organic anion with a dicarboxylic acid, 
such as alphaketoglutarate. This process may be thermodynamically favourable, 
due to the ability of certain cells to concentrate dicarboxylates thanks to a 
complementary transporter, such as SDCT2 (also show in Figure 2.3), which allows 
the cell to concentrate alpha-ketoglutarate in a Na+-dependent manner. The latter is 
an example of the fourth mechanism of transport processes listed above. Coupling 
with Na+ also occurs for other transporters, such as Concentrative Nucleosides 
Transporters (CNTs), implicated in the uptake of natural nucleosides, whereas H+-
dependent uptake is involved into Peptide Transporters (PEPTs). These two basic 
mechanisms of concentrative transport, Na+- and H+-dependent, require tight 
coupling with carriers responsible for the immediate recovery of the ionic 
transmembrane gradients, the Na+, K+-ATPase and the Na+/H+ exchanger. In 
contrast to these secondary and tertiary active transport mechanism, ATP-
dependent primary export pumps, responsible for antiviral drug efflux, have recently 
been identified. This would be the case of the Multidrug Resistance Protein isoforms 
(MRPs), shown in Figure 2.3, which mediates efflux, also in an energy-dependent 
manner, against substrate concentration, thanks to a direct coupling with ATP 
hydrolysis. The hypothesis that transporters belonging to the same gene family are 
responsible for the uptake of structurally related compounds is valid, at least for 
those responsible for uptake processes other than export pumps such as MRPs. 
Nevertheless, structurally related molecules can often be substrates of completely 
unrelated carrier proteins. However, when natural substrates are modified for 
pharmacological purposes, the spectrum of transporter proteins able to recognize 
them  may vary. 
 
2.3. Nucleoside analogue activaction 
 
Phosphorylation is required for mutagenesis and nucleotide metabolism 
interference. Nucleosides are phosphorylated by intracellular kinases to their active 
fraudulent nucleoside triphosphate (TP) analogue form, which compete with the 
natural dNTP for incorporation into the elongating proviral DNA. Since all current 
nucleoside-TP analogues lack a 3’-hydroxyl group, incorporation results in chain 
termination. The fact that a specific nucleoside-TP analogue competes with its 
natural nucleotide each time, and also it appears in the active site near the reverse-
transcribing viral RNA chain, produces multiple opportunities for their blockade 
during a single round of reverse transcription. The long intracellular half-life of many 
nucleoside-TP analogues can result in a significant post-antibiotic effect6. Factors 
that influence their efficacy and dose frequency include the drug concentration 
versus time profile in plasma (pharmacokinetics), the efficiency of cellular uptake of 
the nucleoside analogues, levels of phosphorylation  to their correspondent TP- 
derivatives, and their inhibition costant (Ki) with the target (viral DNA-polymerases, 
reverse transcriptase, respectively in DNA and RNA viruses).   
  
2.4. Mechanism of action of nucleoside analogues  
 
Although all orally available drugs target the viral polymerase, nucleoside analogues 
have different mechanisms of action on the viral genome replication machinery. 
Several drugs such as adefovir, entecavir and amdoxovir inhibit the priming of 
reverse transcription, a unique enzymic reaction that results in the synthesis of a 
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short DNA primer covalently attached to a conserved tyrosine residue of the viral 
polymerase. Other compounds inhibit the elongation of viral minus-strand DNA, such 
as lamivudine, emtricitabine and elvucitabine. The mechanism of action of clevudine 
involves a weak effect on the priming reaction but a stronger inhibitory activity on 
plus-strand DNA synthesis. The mechanism of action of telbivudine has not been 
described so far. Based on these distinct modes of action, one may speculate that 
the combination of drugs targeting different steps of viral genome replication may 
lead to an additive or synergic effect7. Therefore, the evaluation of the combination 
of drugs such asemtricitabine and clevudine, which are under clinical investigation, 
is relevant for the future development of combination therapy. Nucleoside analogues 
are also an emerging field of novel anticancer drugs, that is revolutionizing cancer 
therapy. In addition to inhibiting DNA replication by one or more mechanisms, these 
compounds may produce effects subsequent to their incorporation into the DNA; for 
example, premature DNA chain termination, structural lesions in the DNA product, 
and effects on transcription of modified DNA. Since charged nucleotides were 
believed normally do not enter the cells and considered ineffective as drugs, 
nucleosides have proved critical as therapeutic agents. Nucleosides and their 
analogues are precursors, that are intracellularly phosphorylated (‘activated’) into 
nucleotides (dNTPs), and act to inhibit or are incorporated by DNA polymerases in 
vivo (Figure 2.4).  
 
Figure 2.4: The intracellular formation of nucleotide triphosphate for araC and gemcitabine (gemC), 
as well as, their incorporation into new DNA. 
 
Some two of these nucleoside analogues are currently used in chemotherapy or are 
in clinical trials or development. Examples include arabinofuranosylcytosine (araC)8 
and 5-FU (the first for the treatment of non-solid tumors like leukemia, while the 
latter involved in breast tumour treatment),  and 2’,2’-difluorodeoxycytosine 
(gemcitabine)9 (for treatment of various non-solid and solid tumours, Figure 2.5). 
Promising applications of nucleotides analogues in antiviral and anticancer therapy 
are currently evaluated. 
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Figure 2.5: Nucleoside structures highlighting the differences on the groups on the 2’-carbon of the 
ribose-ring. A. Naturally occurring nucleosides  dCTP andrCTP, and B. sugar-modified nucleoside 
analogues, araC, 2’FdC and gemcitabine. 
 
2.5. Mitochondrial toxicity of nucleoside analogues  
 
Generally, the mechanism of action of nucleoside analogues is based upon the 
intracellular phosphorylation to their 5’-triphosphate form which can interact with 
virus-specific polymerases, acting as a competitive inhibitor or an alternate substrate 
for these target enzymes, usually preventing further viral nucleic acid chain 
elongation. Long-term  toxicities associated with nucleosides phosphorylation may 
be related to over-activation of this process. Elevated cell activation results in high 
nucleic acid synthesis and an up-regulation of kinases that phosphorylate 
nucleosides. Most of the clinical manifestations, resemble mitochondrial disease, 
and histological evidence, demonstrates abnormal mitochondria (mt) and/or mtDNA 
depletion in affected tissues. Studies show that nucleoside tri-phosphates 
competitively inhibit mtDNA polymerase gamma in vitro, the sole enzyme 
responsible for the base excision repair of oxidative damage to mitochondrial DNA. 
This in turn may decrease the number of mitochondrial respiratory chain proteins, 
inhibit aerobic respiration, induce oxidative stress, increase mutation in mtDNA, and 
result in mitochondrial and/or tissue failure, evidenced by the toxic accumulation of 
non-esterified fatty acids, dicarboxylic acids and free radical damage. 
 
2.6. Nucleotide analogues 
 
Since the discovery that monophosphorylated forms of nucleosides can be carried in 
cells by the Multidrug Resistance Proteins (MRP), and known that, 
monophosphorylated (MP) derivatives show smallest drug-induced cytotoxicity,  AZT 
MP (Schuetz et al. 1999), d4T MP (Reid et al., 2003) and 5-FU MP (Guo et al., 
2003) have been synthesized and evaluated in MRP uptake, in their activities and  
toxicities. Adefovir dipivoxil (ADV), the first prototype nucleotide analogue, has been 
approved recently for HBV therapy10 . ADV seems relatively non-toxic upon longer-
term use, overcome viral resistance to chemotherapy, and prevent viral replication 
rebound following cessation of therapy. Towards this objective, there is genuine 
optimism  that selected nucleotide analogues could become front-line agents to be 
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used in combination with nucleosides and other agents in antiviral therapy producing 
improved pharmacological effects. Furthermore, nucleotide analogues can be useful 
tools in investigating the DNA polymerase mechanism. Considering the irreplaceable 
role of DNA polymerases in numerous important molecular biological core 
technologies, future potentials for biotechnological applications could be envisaged 
for nucleotide analogues. However, all these promising applications are limited by 
the broad tissue distribution of MRP proteins, including endothelia, most epithelia, 
smooth muscle and immune system cells (Adachi et al.,2002). However, the list of 
tissues and/or cell types is increasing, although there is discrepancy between the 
detection of the mRNA and the corresponding protein. Unfortunately, although the 
pharmacology of these transporter proteins is being studied, there is little information 
about the regulation of MRP activity, with the exception of the evidence that specific 
isoforms can be over-expressed in particular tumours. 
 
2.7. Solid-phase synthesis of nucleoside analogues 
 
A variety of different modified nucleosides derivatives, above reported, were 
synthesized by the classical approaches in solution, which is expensive and time 
consuming. Combinatorial synthesis of large diverse libraries and high-throughput 
screening technologies have recently emerged as powerful drug discovery 
paradigms. Various solid-phase, solution-phase11, liquid phase12, and third-phase 
combinatorial approaches have been successfully utilized for the generation of 
different oligomeric  and small molecule libraries for a wide range of biological 
screenings. Unfortunately, these power technologies, especially parallel solid-phase 
combinatorial strategies13, have not been applied to the nucleoside chemistry for 
small molecule drug discovery yet although di/tri-and oligonucleotides14 were 
synthesized on solid support, and the modified solid supports have been used as 
acylating agent to acylate nucleosides derivatives15. Several key considerations had 
to be taken into account in order to develop a strategy for the combinatorial solid-
phase synthesis of nucleosides analogues in high number and short period of time, 
to explore wide biological activities: i) most applicable linkers do not meet the 
general requirements for the solid phase synthesis of nucleoside libraries: stable 
enough under the required reaction conditions during synthesis, and labile enough to 
be cleaved easily from solid support without affecting nucleoside products; ii) limited 
positions on nucleoside can be attached on solid support; iii) limited types of 
reactions can be utilized and limited number of sites can be utilized and limited 
number of sites can be combinatorialized on the nucleoside skeletons, which 
prevent the generation of large diverse nucleoside libraries; iv) it is more difficult to 
get high quality and purity nucleoside libraries without purification compared to other 
small molecule libraries. Only in the most recent years, a variety of solid phase 
combinatorial strategies have been reported for the preparation of nucleoside and 
small oligonucleotide analogues libraries. In these approaches both the chemical 
stability and the position of the linkage with the polymeric support, play an important 
role in the selection of the chemical treatments allowing the nucleobase or sugar-
phosphate modifications. For example, a solid support binding uridine or thymidine 
nucleosides by the acid labile 5′-O-trityl linkage has been used to prepare libraries of 
N-4-alkylated cytidine derivatives16. Another recently reported nucleoside 
functionalized support uses an alkaline labile 5′-O-succinyl linkage to bind the 6-
chloro-2-nitro inosine derivative to produce a set of N-6- or N-2 alkylated adenosine 
derivatives17.  Also the 2′,3′-acetal linkage has been used to bind purine and 
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pyrimidine nucleosides to a solid support which has employed  to introduce chemical 
diversities both on the base (C-6 of purine and C-4 of pyrimidine) and on the 5′-
ribose position18. In another approach, a pyrimidine or purine nucleoside is anchored 
to the polymeric support by the N-3 or N-1 base position, respectively, through a N-
alkyl-β-thioether function19-21, which results stable to both the acidic and basic 
conditions. The above supports have been used to prepare 2′, 3′-ribose modified 
nucleoside or nucleotide analogues. Furthermore, CPG support loading 5′-DMT-
nucleosides by the classical 3′-succinyl linkage22-23 or by a 3′ acyloxyaryl phosphate 
linker24, have been successful exploited to prepare very large nucleic-acid-bases 
(NABTM) libraries of nucleosidic 5′-phosphoramidate derivatives, and nucleic acid 
fragments to be tested in their antiviral activity25. 
 
2.8. The aim of the work 
 
Although hundreds of purine and pyrimidine nucleosides were synthesized for a 
variety of biological and biomedical studies only a handful of N1-alkylated-inosine 
derivatives and the corresponding 2’,3’- seco-nucleosides were reported. 
To thoroughly explore the biological and biomedical properties of these analogues, 
the design and synthesis of these derivatives were performed by combinatorializing 
the N1-(2,4-dinitro)-phenyl derivatized position with a variety of amino building 
blocks, obtaining a first small library of N1-alkylated inosine and AICAR derivatives. 
Moreover, the supports bearing N1-alkylated inosine and AICAR derivatives, 
furnished, by a solid phase cleavage of the 2’, 3’ ribose bond, a set of new N1-
alkylated-2’,3’-secoinosine derivatives and AICAR derivative ones, in high yields. 
 
2.9. Chemistry 
  
In an effort to enlarge the nucleoside chemical reactivity on the solid phase, and thus 
the number of obtainable structurally diverse analogues, the synthesis and 
exploitation of the new acid labile nucleoside functionalized supports 4 and 5, which 
bind the N-1-dinitrophenyl-inosine derivatives 2 or 3 through the ribose 5′-position, is 
reported. These supports have been employed in the solid phase synthesis of the N-
1 substituted inosine 8a-e, 9a-e, the related 2′, 3′-seconucleoside derivatives 11a-e 
and the AICAR derivatives 14 and 15. The solid phase strategy, here proposed, is 
based on our previous studies on the C-2 reactivity of N-1-dinitrophenyl-2′-deoxy-
inosine towards N-nucleophiles26-27, to obtain N-1 substituted inosine and AICAR 
derivatives. The reported reaction mechanism (Figure 2.6) indicates that, when a 
strong electron-withdrawing group, such as the 2,4-dinitrophenyl (DNP), nitro group28 
(NO2) or arylsulfonyl29 one (ArS) is attached to the N-1 atom of the hypoxanthine ring, 
the C-2 carbon become electrophilic enough to react with amino nucleophiles (R-
NH2), leading to N1 substituted inosine derivative, by a fast opening and re-closure of 
the six terms purine cycle. It is to be noted that, as a consequence of the purine 
rearrangement, the endocyclic N-1 atom is substituted by the nitrogen atom of the 
nucleophilic reactant. This purine reactivity has been also exploited by others to 
introduce a modified base into oligonucleotides30. 
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Figure 2.6: The nitrogen of nucleofile substitutes the purine N-1 nitrogen. 
. 
To exploit this reaction in a solid phase strategy to obtain a small library of N-1 alkyl 
inosine derivatives, we bound the 1-(2,4-dinitrophenyl)-2′,3′-O-isopropylideneinosine 
2, or the corresponding unprotected inosine derivative 3 to the commercially 
available polystyrenemonomethoxytrityl chloride (MMTCl) resin by 5′-O-trityl ether 
linkage (iii, Scheme 2.1). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1: Acid labile N-1-(2,4-dinitrophenyl)-nucleoside functionalized supports 4 and 5  
 
Inosine derivative 2 was synthesized by the reaction of the commercially available 
2′,3′-O-isopropilidene inosine (1) with 2,4-dinitrochlorobenzene (DNClB), essentially 
as previously described31(i, Scheme 2.1). The 2′,3′-deprotected-inosine-derivative 3, 
was obtained treating 2  with aqueous formic acid  (5 h, r.t., 90 % yield, Scheme 2.1, 
ii). The reaction of the MMTCl polystyrene resin (1.3 meq/g) with 2 or 3 (2 equiv.) in 
anhydrous pyridine at room temperature and in presence of 4-(N,N-dimethylamino)-
pyridine (DMAP), afforded the support 4 or 5 respectively, in almost quantitative 
yields (iii, Scheme 2.1). The structure and the loading of the supports 4 and 5 were 
confirmed analyzing, by NMR and quantitative UV experiments, the released inosine 
derivatives 2 and 3, respectively, by treatment with 2% TFA in DCM (8 min r.t.).  
Support 4 and 5 were then reacted with several N-nucleophiles (R2-NH2, Table 2.1 
entry a-e) to give supports 6a-e and 7a-e, respectively (scheme 4.2). In a typical 
reaction, 100 mg (0.13 mmol) of support 4 (or 5), swollen in DMF, was left in contact 
with the R2-NH2 nucleophile (5.0 mmol) in 1.5 mL of DMF under shaking (8 h, at 50 
°C). After washings with DMF and MeOH, the support was dried under reduced 
pressure and the reaction yield was evaluated detaching the nucleoside material 
from a weighted amount of resin. The reaction of 4 or 5 with ethylenediamine (Table 
2.1, entry f) furnished, as expected, the supports 12 and 13 bearing 2′-3′-
isopropilidene-AICAR and AICAR, respectively, in almost quantitative yields. The 
structure of the support 6, 7, 12, and 13 were ascertained analyzing and purifying by 
HPLC, 1H NMR and MS analyses the corresponding detached crude materials 8, 9, 
14, and 15. The product yields and the 1H NMR data are reported in Table 2.1.  
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Table 2.1: Reactions of the support 2 Products 4, 6, and 8. N.T: not tested 
a Starting from resin 2. b 400 MHz, (CD3OD) significative protons at ppm. cStarting from resin 3. 
 
 
 
The second goal of this research work was aimed to combining the set of the base 
modified nucleoside (support 7) with a ribose modification (Scheme 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.2: i: 2 or 3 (1.5 eq) in pyridine (1.5 mL/250 mg of resin), DMAP (0.05eq.), 24 h r.t; ii: R-
NH2/DMF (1:1,w/w), 8 h 50 °C; iii: TFA 5% solution in DCM; iv: EDA/DMF (1:1, w/w) 8 h 50 °C; v: 
NaIO4 (50 eq.) in DMF/H2O (1:1,v/v), 12 h, 60 °C; resin washings and treatment with NaBH4 (20 eq.) 
in EtOH, 2 h, r.t. 
 
As indicative example, the well known C2′-C3′ bond oxidative cleavage of the ribose 
moiety by reaction with metaperiodate followed by the reduction of the di-aldehyde 
derivative which leads to 2′,3′-seconucleosides32, was examined. In a typical reaction 
the support 7a-e (100 mg, 0.13 mmol) was left in contact with a solution of NaIO4 (1.3 
mmol) in DMF/H2O (1.5 mL, 1:1,v/v) and shaken for 12 h at 60 °C. The resulting 
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support, after washings with DMF and EtOH, was treated with NaBH4 (2.6 mmol) in 
1.5 mL of EtOH and shaken for 2.0 h at r.t. After washings, the resin 10a-e was dried 
under reduced pressure and analyzed by detachment of the nucleoside material by 
TFA treatment. HPLC analyses indicated that the 2′,3′-secoinosine derivatives 11a-e 
were obtained in 75-85% yield. The structures of 11a-e were confirmed by 1H-NMR 
(Table 2.1) and MS analyses. The above oxidative cleavage performed in EtOH/H2O 
(at several ratios and temperatures) afforded the seco-nucleosides in lower reaction 
yields most probably due to the scanty swelling of the polystyrene matrix in these 
solvents mixtures. 
 
2.10. Conclusions 
 
In conclusion, the synthesis of new N-1-dinitrophenyl-inosine based solid supports (4 
and 5) in which the nucleoside are anchored to a MMT-polystyrene resin by the 5′ 
position, was performed. The supports 4 and 5, reacting at C-2 position of the purine 
base with R-NH2 nucleophiles, were converted in the N-1 alkylated inosine supports 
(6 and 7) and AICAR derivatives supports (12 and 13) in very high yields. The 
detachment of the nucleosidic material, from the above supports, furnished small 
libraries of N-1 alkylated inosine (8a-e and 9a-e) and AICAR derivatives (14-15), 
having the ribose moiety both protected and unprotected at the 2′,3′-hydroxyl 
functions, in high purities (90-98%). In a further solid-phase reaction, the set of the N-
1 alkylated inosine of the supports 7a-e  were combined with the cleavage of the 
2′,3′-ribose bond. These reactions furnished the new group of solid supports 10a-e 
bearing base modified acyclo-nucleosides. Supports 10a-e released, under acidic 
conditions, N-1 alkylated-2′,3′-secoinosine derivatives 11a-e in good purity (75-85 %). 
It reasonable to suppose that  the supports 6, 7, 10, 12 and 13, bearing a nucleoside 
derivative can be fruitfully utilized in a combinatorial manner to introduce a number of 
further derivatizations/conjugations both on the 1-(hydroxyalkyl) function and/or on 
the ribose or seco-ribose moieties. Briefly, this research work reports the parallel 
solid-phase combinatorial approach for the rapid synthesis of new N1-alkylated 
inosine and N1-alkylated-2’,3’-secoinosine derivative libraries. MMT-Cl polystyrene 
resin was confirmed to be an efficient solid support for nucleoside library synthesis. 
Hydroxyl groups at the 5’-position were preferentially involved into attach the 
nucleoside scaffold onto the MMT-Cl polystyrene resin. The DNP group is an 
excellent leaving group for various nucleophilic substitutions on the inosine base to 
synthesize high quality nucleoside libraries. The method seems good also to prepare 
a N1-alkylated-2’,3’-secoinosine collection. All these new inosine derivatives, with 
various modifications at N1-position and at 2’,3’-bond of the sugar moiety, will be 
screened against a wide range of biological assays. Further studies are currently in 
progress in this direction to obtain new and largest libraries of nucleoside analogues. 
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2.11 Experimental Session 
 
2.11.1 General Methods 
 
4-Methoxytrityl chloride resin (1% divinylbenzene, 200–400 mesh, 1.3 mmol g-1 
substitution) was purchased from CBL Patras, Greece. Anhydrous solvents were 
used for reactions. All the other reagents were obtained from commercial sources 
and were used without further purification. The reactions on solid phase were 
performed using glass columns (10 mm diameter, 100 mm length) with fused-in 
sintered glass-disc PO (bore of plug 2.5 mm), which were shaken on an orbital 
shaker, or round bottom flask, when reactions were performed at high temperatures. 
The 1H NMR spectra were performed on a Varian Mercury Plus 400 MHz using 
CD3OD and CDCl3 as solvents; chemical shifts were reported in parts per million (δ) 
relative to residual solvent signals: CD2HOD 3.31, CHCl3 7.26. The UV spectra were 
recorded on a Jasco V-530 UV spectrophotometer. Mass spectra were recorded on 
an Applied Biosystems API 2000 mass spectrometer using electron spray ionization 
(ESI) technique in positive mode. Column chromatography was performed on silica 
gel (Merck, Kieselgel 60, 0.063–0.200 mm). Analytic TLC detections were performed 
using F254 silica gel plates (0.2 mm, Merck). TLC spots were detected under UV 
light (254 nm). 
Abbreviations: DMF = N,N-dimethylformamide, Py = pyridine, MeOH = methanol, 
EtOH = ethanol, DNClB = 2,4-dinitrochlorobenzene, K2CO3 = potassium carbonate, 
MMT-Cl= 4-methoxytrityl chloride polystyrene resin, DMAP= 4,4’-
dimethylaminopyridine, NaIO4 = sodium m-periodate, NaBH4 = sodium borohydride,  
s’s = singlets, d’s = doublets, m’s = multiplets, q’s = quartets 
 
2.11.2 General Procedures 
 
N-1-(2,4-dinitrophenyl)-2’,3’-O-isopropylideneinosine (compound 2). A mixture 
of 1 (1.0 g, 2.6 mmol), DNClB (1.87 g, 8.1 mmol) and K2CO3 ( 897 mg, 6.5 mmol) 
was stirred in anhydrous DMF (16 mL) at 80 °C for 2.5 h. After cooling, the mixture 
was filtered and the solid was washed with CHCl3. The filtrate and washings, 
evaporated to dryness under reduced pressure, were purified on a silica gel column 
eluted with increasing amount of CH3OH in CHCl3 (from 0 to 5%) to give 1.208 g of 2 
(as 1: 1 mixture of atropoisomers at N-1-phenyl bond) as pale yellow amorphous 
solid (98% yield). 
2, 1H-NMR (400 MHz) ppm (CDCl3) 1.30 (s, 3H, CH3), 1.45 (s, 3H, CH3), 3.65-4.0 (m, 
2H, 2x5’-H), 4.5 (m, 1H, 4’-H), 5.10 (m, 1H, 3’-H), 5.30 (m, 1H, 2’-H), 6.00 (m, 1H, 1’-
H), 7.70 (m, 1H, o-H), 8.10 (m, 2H, H-8, H-2), 8.70 (m, 1H, m-H), 9.00 (m, 1H, m-H); 
ESI-MS calculated m/z: 474.11, (C19H18N6O9), found: 513.50 (M + H)+. 
 
N-1-(2,4-dinitrophenyl)-inosine (compound 3). A solution of 2 (500 mg, 1.05 
mmol) in aqueous HCO2H (60%, 14 mL) was stirred at 50°C for 2 h. After the solvent 
was evaporated under reduced pressure and the residue was purified on a silica gel 
column eluted with increasing amount of CH3OH in CHCl3 (from 0 to 20%) to give 
451 mg, 99% of 3. 
3, 1H-NMR (400 MHz) ppm (CD3OD) 3.72-3.95 (m, 2H, 2x5’-H), 3.9 (m, 1H, 4’-H), 
4.15 (m, 1H, 3’-H), 4.35 (m, 1H, 4’-H), 4.60-4.70 (m, 1H, 2’-H), 6.10 (m, 1H, 1’-H), 
8.00 (m, 1H, orto-H), 8.50 (m, 2H, H-8, H-2), 8.76 (m, 1H, meta-H), 9.06 (m, 1H, 
meta-H); ESI-MS calculated m/z: 434.08 (C16H14N6O9), found: 435.32 (M + H)+. 
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Support 4. A suspension of  MMT-Cl  resin (500 mg, 0.65 mmol, 1.3 mmol/g), N-1-
(2,4-dinitrophenyl)-2’,3’-O-isopropylideneinosine, 2 (370 mg, 0.78 mmol, 1.2 eq), 
DMAP (6 mg, 0.05 mmol) in 1.5 mL of anhydrous pyridine was shaken at room 
temperature for 24 h. The resin was filtered and washed sequentially with pyridine-
DMF (1:1 v/v, three times) and then with dichloromethane (three times). The obtained 
resin was dried under vacuum  for 1h.  
1.0 mL of a solution of 2% TFA in CH2Cl2 was added to 20 mg of weighted resin. The 
reaction mixture was shaken for 8 min, then the solution was filtered into a vial. The 
resin was washed with CH2Cl2, and filtered. The combined filtered were evaporated 
in vacuo. Quantitative UV experiment was performed on detached nucleoside (λmax = 
245 nm, ε = 20100, H2O). The solid support 4 was obtained in almost quantitative 
yield (1.26 mmol g-1, 97%). 
 
Support 5. A suspension of  MMT-Cl  resin (1.0 g, 1.3 mmol, 1.3 mmol/g), N-1-(2,4-
dinitrophenyl)-inosine, 3 (676 mg, 1.56 mmol), DMAP (12 mg, 0.1 mmol) in 1.5 mL of 
anhydrous pyridine was shaken at room temperature for 24h. The resin was filtered 
and washed sequentially with pyridine-DMF (1:1 v/v, three times) and then with 
dichloromethane (three times). The obtained resin was dried under vacuum for 1h. 
1.0 mL of a solution of 2% TFA in CH2Cl2 was added to 20 mg of weighted resin. The 
reaction mixture was shaken for 8 min, then the solution was filtered into a vial. The 
resin was washed with CH2Cl2, and filtered. The combined filtered were evaporated 
in vacuo. Quantitative UV experiment was performed on detached nucleoside (λmax = 
245 nm, ε = 20100, H2O). The solid support 4 was obtained in almost quantitative 
yield (1.26 mmol g-1, 97%). 
 
2.11.3 Synthesis of N-1-alkylated-inosine library 
 
Support 6a-f. Approximately 80 mg (0.1 mmol) of starting resin 4 was dispensed in 6 
reaction wells. To each well of resin were added 100 µL of anhydrous DMF and 
0,5mL of the (a-e) appropriate amine (see Table 1) in DMF. The reaction mixtures 
were shaken for 4h at 50°C, then filtered and washed with DMF (three times), MeOH-
DMF (1:1 v/v, four times), MeOH (three times), MeOH-CH2Cl2 (1:1 v/v, four times), 
and finally with dichloromethane (two times). The resultant resins 6a-f were dried 
under nitrogen. 
 
Cleavage. Compounds 8a-e and 14. To the dried resin in each well was added 2 
mL of a solution of 2% TFA in CH2Cl2. The reaction mixtures were shaken for 8 min, 
then the solution were filtered into a pre-labeled and pre-weighted vials. The resins 
were washed with MeOH, and filtered in the same corresponding vials. To the 
combined filtrates was added toluene. The solvents were evaporated under vacuum  
to provide compounds 8a-e. The reaction of 4 with ethylenediamine (Table 1, entry f) 
furnished, as expected, the support 12, bearing the 2’,3’-isopropilidene-AICAR which 
corresponding detached form 14 was obtained in almost quantitative yields. 
 
8a= 98% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 0.98 (t, 3H, 
CH3), 1.36 (s, 3H, CH3), 1.60 (s, 3H, CH3), 1.40-1.76 (m’s, 4H, 2xCH2), 3.66-3.80 (m, 
2H, 2x5’-H), 4.12 (t, 2H, CH2N), 4.32-4.39 (m, 1H, 4’-H), 5.00 (m, 1H, 3’-H), 5.26 (m, 
1H, 2’-H), 6.02 (d, 1H, 1’-H), 8.36-8.41 (s’s, 1H each, H-8, H-2). ESI-MS calculated 
m/z: 364.17 (C17H24N4O5) found: 364.35 (M + H)+. 
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8b= 92% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 1.36 (s, 3H, 
CH3), 1.60 (s, 3H, CH3), 1.94-2.04 (m, 2H, CH2), 3.66-3.80 (m, 2H, 2x5’-H), 3.82 (t, 
2H, CH2O), 4.19 (t, 2H, CH2N), 4.32-4.39 (m, 1H, 4’-H), 5.00 (m, 1H, 3’-H), 5.26 (m, 
1H, 2’-H), 6.01 (d, 1H, 1’-H), 8.26-8.41 (s’s, 1H each, H-8, H-2). ESI-MS calculated 
m/z: 352.11 (C15H20N4O6) found: 353.28 (M + H)+. 
 
8c= 98% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 1.36 (s, 3H, 
CH3), 1.60 (s, 3H, CH3), 1.94-2.04 (m, 2H, CH2), 3.60 (t, 2H, CH2O), 3.66-3.80 (m, 
2H, 2x5’-H), 4.20 (t, 2H, CH2N), 4.32-4.39 (m, 1H, 4’-H), 5.00 (m, 1H, 3’-H), 5.26 (m, 
1H, 2’-H), 6.02 (d, 1H, 1’-H), 8.32-8.41 (s’s, 1H each, H-8, H-2). ESI-MS calculated 
m/z: 366.15 (C16H22N4O6) found 367.32 (M + H)+. 
 
8d= 98% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 1.37 (s, 3H, 
CH3), 1.40-1.49 (m, 2H, CH2), 1.42-1.81 (m’s, 9H, CH3, 3xCH2), 3.56 (t, 2H, CH2O), 
3.67-3.80 (m, 2H, 2x5’-H), 4.12 (t, 2H, CH2N), 4.33-4.39 (m, 1H, 4’-H), 5.00 (m, 1H, 
3’-H), 5.26 (m, 1H, 2’-H), 6.02 (d, 1H, 1’-H), 8.35-8.40 (s’s, 1H each, H-8, H-2). ESI-
MS calculated m/z: 394.19 (C18H26N4O6) found: 395.44 (M + H)+. 
 
8e= 92% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 1.37 (s, 3H, 
CH3), 1.60 (s, 3H, CH3), 3.67-3.80 (m, 2H, 2x5’-H), 3.92 (m, 1H, CHN), 3.98 (m’s, 4H, 
2xCH2O), 4.35 (m, 1H, 4’-H), 5.28 (m, 1H, 2’-H), 6.00 (d, 1H, 1’-H), 8.32-8.38 (s’s, 1H 
each, H-8, H-2). ESI-MS calculated m/z: 382.15 (C16H22N4O7 ) found: 382.32 (M + 
H)+. 
 
14= 98% yields starting from resin 4; 1H-NMR (400 MHz) ppm (CD3OD) 1.37 (s, 3H, 
CH3), 1.60 (s, 3H, CH3), 3.67-3.80 (m, 2H, 2x5’-H), 4.35 (m, 1H, 4’-H), 5.28 (m, 1H, 
2’-H), 5.66 (d, 1H, 1’-H), 8.04 (s, 1H, H-2). ESI-MS calculated m/z: 298.13 
(C12H18N4O5) found: 299.23 (M + H)+. 
 
Support 7a-f. Approximately 150 mg (0.15mmol) of starting resin 5 was dispensed in 
6 reaction wells. To each well of resin were added 100µL of anhydrous DMF and 0,5 
mL of the appropriate amine (see Table 1) in DMF. The reaction mixtures were 
shaken for 4 h at 50 °C, then filtered and washed with DMF (three times), MeOH-
DMF (1:1 v/v, four times), MeOH (three times), MeOH-CH2Cl2 (1:1 v/v, four times), 
and finally with CH2Cl2 (two times). The resultant resins 7a-f were dried under 
nitrogen. An half of each one resin (7a-f) was dispensed in other 6 reaction wells and 
cleavaged. The remaining ones were stored as starting material for synthesis of the 
N-1-alkylated-2’,3’-secoinosine library.  
 
Cleavage. Compounds 9a-e and 15. To the dried resin in each well was added 2 
mL of a solution of 2% TFA in CH2Cl2. The reaction mixtures were shaken for 8 min, 
then the solution were filtered into a pre-labeled and pre-weighted vials. The resins 
were washed with  MeOH, and filtered in the same corresponding vials. To the 
combined filtrates was added toluene. The solvents were evaporated under vacuum  
to provide compounds 9a-e. The reaction of 5 with ethylenediamine (Table 1, entry f) 
furnished, as expected, the support 13 bearing the AICAR  compound, which 
corresponding detached form 15 was obtained in almost quantitative yields. 
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9a= 98% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD) 0.98 (t, 3H, 
CH3), 1.40-1.76 (m’s, 4H, 2xCH2), 3.72-3.95 (m, 2H, 2x5’-H), 4.12 (t, 2H, CH2N), 4.15 
(m, 1H, 3’-H), 4.35 (m, 1H, 4’-H), 4.60-4.70 (m, 1H, 2’-H), 6.02 (m, 1H, 1’-H), 8.36-
8.41 (s’s, 1H each, H-8, H-2). ESI-MS calculated m/z: 324.15 (C14H20N4O5) found: 
325.35 (M + H)+. 
 
9b= 95% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD)  3.72-3.95 
(m, 2H, 2x5’-H), 3.82 (t, 2H, CH2O), 4.19 (t, 2H, CH2N), 4.15 (m, 1H, 3’-H), 4.35 (m, 
1H, 4’-H), 4.60-4.70 (m, 1H, 2’-H), 6.01 (m, 1H, 1’-H), 8.26-8.42 (s’s, 1H each, H-8, 
H-2). ESI-MS calculated 312.11 (C12H16N4O6) found 313.28, (M + H)+. 
 
9c= 96% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD)  1.98 (m, 2H, 
CH2), 3.60 (t, 2H, CH2O), 3.72-3.95 (m, 2H, 2x5’-H), 4.20 (t, 2H, CH2N),  4.15 (m, 1H, 
3’-H), 4.35 (m, 1H, 4’-H), 4.60-4.70 (m, 1H, 2’-H), 6.02 (m, 1H, 1’-H), 8.32-8.41 (s’s, 
1H each, H-8, H-2). ESI-MS calculated m/z: 326.12 (C13H18N4O6) found:327.20 (M + 
H)+. 
 
9d= 98% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD)  1.42-181 
(m’s, 6H, 3xCH2), 3.56 (t, 2H, CH2O), 3.72-3.95 (m, 2H, 2x5’-H), 4.12 (t, 2H, CH2N), 
4.15 (m, 1H, 3’-H), 4.35 (m, 1H, 4’-H), 4.60-4.70 (m, 1H, 2’-H), 6.02 (m, 1H, 1’-H), 
8.35-8.40 (s’s, 1H each, H-8, H-2). ESI-MS calculated m/z: 354.15 (C15H22N4O6) 
found: 355.45 (M + H)+. 
 
9e= 90% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD)  3.92 (m, 1H, 
CHN), 3.98 (m’s, 4H, 2xCH2O), 3.72-3.95 (m, 2H, 2x5’-H), 4.15 (m, 1H, 3’-H), 4.35 
(m, 1H, 4’-H), 4.60-4.70 (m, 1H, 2’-H), 6.00 (m, 1H, 1’-H), 8.32-8.38 (s’s, 1H each, H-
8, H-2). ESI-MS calculated m/z: 342.12,( C13H18N4O7), found: 342.30, (M + H)+. 
 
15= 98% yields starting from resin 5; 1H-NMR (400 MHz) ppm (CD3OD) 3.72-3.95 
(m, 2H, 2x5’-H), 4.15 (m, 1H, 3’-H), 4.35 (m, 1H, 4’-H), 4.60-4.70 (m, 1H, 2’-H), 5.66 
(m, 1H, 1’-H), 8.04 (m, 2H, H-2). ESI-MS calculated m/z:258.10 (C9H14N4O5) found: 
259.30 (M + H)+. 
 
2.11.4 Synthesis of N-1-alkylated-2’,3’-secoinosine derivative library 
 
Support 10a-e. The resins 7a-e (75 mg of each one, 0.075 mmol) were treated with 
a solution of NaIO4 (168mg, 0.75mmol)) in DMF/H2O (1.5 mL, 1:1 v/v), and shaken 
for 12 h at 60 °C. The resulting supports after washings with DMF and EtOH, were 
left in contact with a solution of NaBH4 (60 mg, 1.5 eq) in 1.5 mL of EtOH-H2O (1:1, 
v/v) for 2 h at room temperature. After washings with EtOH, the obtained supports 
10a-e were dried under reduced pressure and analyzed detaching the nucleoside 
material by TFA treatment.  
 
Cleavage. Compounds 11a-e. To the dried resin in each well was added 2 mL of a 
solution of 2% TFA in CH2Cl2. The reaction mixtures were shaken for 8 min, then the 
solution were filtered into a pre-labeled and pre-weighted vials. The resins were 
washed with  MeOH, and filtered in the same corresponding vials. To the combined 
filtrates was added toluene. The solvents were evaporated under vacuum  to provide 
compounds 11a-e. 
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11a= 85% yields starting from resin 7a; 1H-NMR (400 MHz) ppm (CD3OD) 0.96 (t, 
3H, CH3), 1.38-1.75 (m’s, 4H, 2xCH2), 3.20 (m, 1H, 4’-H), 3.90 (m’s, 4H, 2xCH2O), 
4.00 (t, 2H, CH2N), 4.22 (m, 2H, CH2O), 6.04 (t, 1H, 1’-H), 8.26-8.30 (s’s, 1H each, 
H-8, H-2). ESI-MS calculated m/z: 326.16 (C14H22N4O5) found: 349.05 (M + Na)+.  
 
11b= 85% yields starting from resin 7a; 1H-NMR (400 MHz) ppm (CD3OD) 3.20 (m, 
1H, 4’-H), 3.83 (t, 2H, CH2O), 3.90 (m’s, 4H, 2xCH2O), 4.20 (t, 2H, CH2N), 4.40 (m, 
2H, CH2O), 6.04 (t, 1H, 1’-H), 8.24-8.28 (s’s, 1H each, H-8, H-2). ESI-MS calculated 
m/z: 326.16 (C14H22N4O5) found: 349.05 (M + Na)+.  
 
11c= 84% yields starting from resin 7a; 1H-NMR (400 MHz) ppm (CD3OD) 1.98 (m, 
2H, CH2), 3.20 (m, 1H, 4’-H), 3.60 (t, 2H, CH2O), 3.90 (m’s, 4H, 2xCH2O), 4.21 (t, 2H, 
CH2N), 4.40 (m, 2H, CH2O), 6.03 (t, 1H, 1’-H), 8.26-8.31 (s’s, 1H each, H-8, H-2). 
ESI-MS calculated m/z: 326.16 (C14H22N4O5) found: 349.05 (M + Na)+.  
 
11d= 82% yields starting from resin 7a; 1H-NMR (400 MHz) ppm (CD3OD) 1.43-1.79 
(m’s, 6H, 3xCH2), 3.20 (m, 1H, 4’-H), 3.55 (t, 2H, CH2O), 3.90 (m’s, 4H, 2xCH2O), 
4.11 (t, 2H, CH2N), 4.40 (d, 2H, 2’-H), 6.03 (t, 1H, 1’-H), 8.25-8.28 (s’s, 1H each, H-8, 
H-2). ESI-MS calculated m/z: 326.16 (C14H22N4O5) found: 349.05 (M + Na)+.  
 
11e= 75% yields starting from resin 7a; 1H-NMR (400 MHz) ppm (CD3OD) 3.20 (m, 
1H, 4’-H), 3.90 (m, 4H, 2xCH2O), 3.95 (m, 1H, CHN), 4.02 (m’s, 4H, 2xCH2O), 4.40 
(m, 2H, CH2O), 6.05 (t, 1H, 1’-H), 8.29-8.04 (s’s, 1H each, H-8, H-2). ESI-MS 
calculated m/z: 326.16 (C14H22N4O5) found: 349.05 (M + Na)+.  
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Chapter 3 
 
Synthesis of N-4-alkyl and ribose-modified AICAR analogues on solid support 
 
Introduction 
 
Nucleosides and their phosphorylated counterparts constitute an important class of 
biomolecules possessing a pivotal role in cellular metabolism and signal 
transmission. For example, they are involved in nucleic acid replication and in a very 
wide number of interactions with enzymes, structural proteins, and other biological 
targets of therapeutic importance. Many nucleoside analogues are currently used in 
therapy antivirals1 and others are active compounds exhibiting antineoplastic2, 
antibiotic, and antifungal properties3. The research of new active nucleosides is still 
very dynamic and promising; substances such as nelarabine4, entecavir5, 
clofarabine6 and azacitidine7 are examples of anticancer and antiviral drugs recently 
approved by U.S. FDA. Particular attention has recently been paid to 5-
aminoimidazole-4-carboxamide-1-β-D-ribofuranosyde (AICAR) since its 5’-
phosphorylated derivative (ZMP), a key biosynthetic precursor of purine nucleotides, 
is an activator of AMP-activated protein kinase (AMPK)8 A possible therapeutic 
importance of its exploitation arises from the fact that the AICAR-induced AMPK 
activation strongly inhibits the basal and the insulin-stimulated glucose uptake, the 
lipogenesis, the glucose oxidation, as well as the lactate production in fat cells9. It 
has been also found that the control of protein kinase C (PKC) activation is correlated 
with the pathogenesis of diabetic retinopathy10. 
Long-term exercise is well known to improve the glucose homeostasis and insuline 
action in insulin-resistant subjects and iso ne of the cornerstones in the treatment of 
Type 2 diabetes mellitus. Furthermore, it has been shown that regular exercise can 
partly prevent or delay the onset of the disease11. The ameliorated insulin sensitivity 
after exercise is mainly due to enahanced insulin action on skeletal muscle, the 
predominat tissue for insuline stimulated glucose disposal. In skeletal muscle, 
insuline stimulation leads to activation of a specific intracellular signaling cascade 
involving the insuline receptor substrate (IRS) family, the lipid kinase 
phosphatidylinositol (PI) 3-kinase, and also the serine/threonine kinase PKB/Akt.12. 
Activation of the insuline-signaling cascade leads to a recruitment of the insulin-
sensitive glucose transporter (GLUT-4) from an intracellular pool to the surface 
membrane, thus allowing glucose to enter cell. This transport of glucose across the 
sarcolemma throught GLUT-4 is thought to be the rate-limiting step for glucose 
utilization. 
The 5’-AMP-activated protein kinase (AMPK) has recently been suggested as a 
potential candidate in the signaling process in response to exercise. Interestingly, 
both long-term treatment of rats with AICAR, which is an AMPK activator resulted in 
anhanced expression of GLUT-4 in skeletal muscles. Furthermore, the increased 
GLUT-4 expression is associated with a concomitant fiber type-related increase in 
the level of maximally insulin-stimulated glucose uptake13, suggesting that at least 
parts of this beneficial adaptation to long-term exercise can be mimicked through 
chronic AMPK activation.  
Furthermore, the extracellular role of adenosine and other nucleosides as 
endogenous cell function modulators indicates the adenosine receptors as significant 
targets with wide therapeutic potential. In this context, AICAR has been indicated as 
a promising prodrug, which induces benefits in patients suffering from autism, 
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cerebral palsy, insomnia, schizophrenia, and other neuropsychiatric symptoms 
generally associated to chronic low levels of adenosine14. 
 
The de novo purine biosynthetic pathway consist of 10 enzymatic reactions that 
convert 5’-phosphoribosyl-1-pyrophosphate to IMP (Inosine-5'-monophopsphate). 
This pathway is used by virtually all organisms to produce purine nucleotides that are 
essential for many cellular processes. Consequently, this pathway has attracted 
considerable attention for the development of inhibitors, in particolar for cancer 
chemotherapy since rapid dividing cells require large amounts of purines. The 
penultimate and final reactions of this pathway are catalyzed by a bifunctional protein 
with two distinct active sites: 5-aminoimidazole-4-carboxamide ribonucleotide 
transformylase (AICAR Tfase)15 and inosine monophosphate cyclohydrolase (IMP 
CHase). AICAR Tfase catalyzes the transfer of the formyl group from (6RαS)-10-
formyltetrahydrofolate (10-f-H4F) to ZMP producing 5-formyl-ZMP, wich is then 
subsequently cyclized by IMP CHase to form IMP16 (Figure 3.1). 
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Figure 3.1 Reactions catalyzed by AICAR Tfase and IMP CHase. 
 
 
 
3.1 Chemical synthesis of AICAR and its derivatives 
 
In recent years, the syntheses of a number of AICAR derivatives, such as the 2-aryl17 
4-N-benzyl18, 4-substituted19, 5-substituted20, 5-hydroxyl (Bredinin)21, triazolyl-
riboside (Ribavirin)22, 2’,3’-secoriboside derivatives23 have been reported in the 
literature. 
Recently, the production of large nucleoside analogue libraries has emerged as an 
important synthetic goal to chase the high efficiency and velocity of the current 
biological screenings. In this frame, the solid-phase synthesis, associated with a 
combinatorial approach, offers the advantage of combining the rapid synthesis with 
an easily obtainable molecular diversity around a single core scaffold. 
The synthesis of AICAR from inosine by using p-toluensulfonyl or methoxymethyl 
(MOM) groups as N-1-substituents was descrive by Shaw24. According to this report, 
treatment of these N-1-substituted inosines by aqueous alkali in refluxing ethanol 
could simultaneously open the pyrimidine ring and remove the N-1-substituent to 
afford the AICAR. 
A more recent paper make use of a (2-methoxyethoxy)methyl (MEM) as the 
substituent of choice to perform this transformation from inosine to AICAR25 
(Scheme 3.1). 
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Scheme 3.1 Synthesis of AICAR from Inosine. 
 
In this paper Kohyama presumed that the ring-opening reaction proceeded prior to 
the deprotection of benzyloxymethyl group since inosine was non detected during 
this alkaline hydrolysis. The formamidine moiety of N1-benzyloxymethylinosine is 
considered to be hydrolyzed, followed by elimination of benzyl alcohol, to imine 
intermediate, which is then converted to AICAR (Scheme 3.2). 
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Scheme 3.2 Degradation of N1-benzyloxymethylinosine to AICAR 
 
In 2006, Casanova et al26 performed a synthesis to obtain N-4-alkyl AICAR 
analogues on the basis of the known reactivity of position 1 of inosine. Thus, 
treatment of inosine with the corresponding alkyl, allyl, benzyl halide in 
dimethylacetamide (DMAC) and in presence of 1,8-diazabicylco[5.4.0]undec-7-ene 
(DBU)27 afforded the N-1-substitued inosines (56-89% yields) that, treated with 
NaOH 5 M in refluxing ethanol afforded N-4-alkyl AICAR derivatives (46-53% yield). 
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3.2 The aim of the work 
 
The production of large nucleoside analogue libraries has emerged as an important 
synthetic goal to chase the high efficiency and velocity of the current biological 
screenings. In this frame, the solid-phase synthesis, associated with a combinatorial 
approach, offers the advantage of combining the rapid synthesis with an easily 
obtainable molecular diversity around a single core scaffold. 
Here a new solid-phase synthetic strategy is reported, to obtain AICAR analogue 
libraries. The methodology has been tested in the synthesis of the two small AICAR 
libraries 10a–g and 15a–g (Scheme 3.3) where the nucleosides are modified on the 
4-carboxamide residue or both at the 4-carboxamide and the ribose moiety, 
respectively. 
 
 
 
 
Scheme 3.3 (i) R–NH2 (38.0 equiv) in DMF, 8 h, 50 °C; (ii) 1 M K2CO3 in DMF, 15 h, 50 °C; (iii) 
EDA/DMF (1:1, w/w) 8 h, 50 °C; (iv) 2% TFA solution in DCM; (v) 5 M NaOH in EtOH, 6 h, reflux; (vi) 
NaIO4 (10 equiv) in DMF/H2O (1:1, v/v), 12 h, 60 °C or Pb(OAc)4 (15 equiv), in DCM, 2 h, rt; resin 
washings and treatment with NaBH4 (20 equiv) in EtOH, 2 h, rt. 
 
Our synthetic approach uses as starting material the recently proposed N-1-
dinitrophenyl-inosine solid support 4 synthesized as depicted in Scheme 3.3. 
Support 4 reacting with R–NH2 nucleophiles is converted into N-1 alkyl-inosine solid 
supports 8a–g from which the AICAR libraries 10a–g and 15a–g could be obtained 
(Scheme 3.3). Previously, we utilized support 4 to prepare small libraries of N-1 
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alkyl-inosines and their corresponding 2’,3’-secoriboside derivatives28 We also 
demonstrated that when 4 reacts with ethylenediamine (EDA), the AICAR support 7 
can be obtained in an almost quantitative yield28,29. 
Under alkaline conditions, N-1 alkyl-inosines react at the C-2 of the purine system to 
give 4-N-alkyl AICAR derivatives by pyrimidine ring cleavage and concomitant 
extrusion of the C-2 carbon itself. Therefore, we decided to extend this process to the 
solid-phase chemistry aiming at two main targets: (i) to efficiently prepare a set of 4-
N-alkyl AICAR derivatives (10a–g) as well as the corresponding precursor solid 
supports (9a–g) from N-1 alkyl-inosine supports 8a–g; (ii) to combine the set of 
AICAR derivatives with a ribose modification (2’,3’-secoribosyl derivatives) thus 
producing the new kind of products 15a–g, as well as the related solid supports 13a–
g, which are in turn potentially useful for further AICAR derivatization/ modification. 
Support 4 was obtained by binding 1-(2,4-dinitrophenyl)-inosine 3 (Scheme 3.4) to 
the commercially available polystyrenemonomethoxytrityl chloride (MMTCl) resin by 
5’-O-trityl ether linkage. Inosine derivative 3 was synthesized by the reaction of the 
commercially available 2’-3’-O-isopropylidene inosine 2 with 2,4 dinitrochlorobenzene 
(DNCB), followed by 2’-3’ deprotection by aqueous formic acid treatment as 
previously described28.  
 
Scheme 3.4 (i) DNCB (2.2 equiv), K2CO3 (2.0 equiv), 2 h, 80 °C; (ii) HCOOH/H2O (6:4, v/v), 4 h, rt; (iii) 
3 (1.5 equiv) in pyridine (1.5 mL/250 mg of resin), DMAP (0.2 equiv), 24 h rt. 
 
The reaction of the MMTCl resin (1.3 mequiv g-1) with 3 in the presence of 4-(N,N-
dimethylamino)pyridine (DMAP), in anhydrous pyridine, afforded support 4 in almost 
quantitative yield. Reaction of 4 with several N-nucleophiles (R–NH2, Table 3.1) 
furnished the N-1 alkylinosine supports 8a–g. In the above reactions, the R–NH2 
nucleophiles react with the strongly activated purine C-2 atom to give the open 
intermediates 5 possessing an N-alkyl formamidine group. The successive fast ring 
re-closure, favored by the loss of 2,4-dinitroaniline as leaving group, led to N-1-alkyl-
inosines 8a–e (93–95% yields). We observed that in the case of sterically hindered 
amines (entries f and g), the reaction stopped at intermediate products 5, which, after 
detachment from the support, could be isolated and characterized (6f and g).  
As previously demonstrated, treatment with carbonate in DMF (at 50 °C) converted 
these open-pyrimidine species 5 in the N-1-alkyl-inosine supports 8f and g (80–85% 
yields) by the six-membered ring re-closure30. Reaction yields obtained for 8a–g 
were evaluated quantifying the N-1-alkyl-inosines 11a–g released from a weighted 
amount of supports 8a–g by treatment with 2% (v/v) TFA in DCM taking into account 
that the starting support 4 had a nucleoside functionalization of 1.26 mequiv g-1. 
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Table 3.1 reaction on the support 4. 
 
The corresponding N-4-alkyl AICAR supports 9a–g were then obtained by cleavage 
of the pyrimidine ring in supports 8a–g by NaOH treatment (5 M in EtOH, reflux, 85–
90% reaction yields). TFA treatment of supports 9a–g released the crude AICAR 
derivatives 10a–g, which were purified by HPLC. The overall yield (starting from 
support 4) of the pure obtained nucleosides 10 and 11 are reported in Table 3.1. The 
structures and the purity of the products were confirmed by 1H NMR spectroscopy 
and ESI-MS data. In a typical reaction starting from 20 mg of solid support 4, and 
considering an average molecular weight of 320 g mol-1, 6–7 mg of each crude 
AICAR derivatives 10a–g could be obtained in 70–85% purity. 
Next, we explored the possibility of performing the 2’,3’-oxidative cleavage of the 
ribose moiety in supports 9a–g. In a first attempt, we employed the previously 
tested28 reaction conditions, namely sodium metaperiodate followed by borohydride 
reduction of the di-aldehyde products. In a typical reaction, the supports 9a–g were 
left in contact with a solution of NaIO4 (10 equiv excess) in DMF/H2O and shaken for 
12 h at 60 °C. The resulting supports, after washing, were treated with NaBH4 in 
EtOH and shaken for 2.0 h at room temperature to give supports 13a–g that were 
analyzed by detaching the nucleosidic material by TFA treatment. 
The HPLC analyses and purifications indicated that the above reactions, leading to 
15c–f, proceeded with 75–80% yields, whereas complex reaction mixtures were 
obtained for supports 13a,b,g leading to very low quantities of the corresponding 
products 15a,b,g (5–7% yields). These results suggest that the presence of the 4-N-
(ω−hydroxyalkyl) portion on the AICAR supports 9a,b,g leads to large side reactions 
when the products were reacted with sodium metaperiodate. In the case of AICAR 
support 7, the reaction furnished support 14 from which the AICA-2’,3’-secoriboside 
16 could be obtained in 70% overall yield (from 4) after the usual TFA treatment. 
This prompted us to test the alternative pathway where the C2–C3 scission of the 
ribose moiety, with formation of 2’,3’-secoribosides 12a–g, was accomplished prior to 
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the pyrimidine ring degradation. Following this route, ribose cleavage of 8a–g 
furnished 12a–g in good reaction yields (75–80%, from 8), which in turn were 
converted into the pyrimidine-degraded supports 13a–g from which the products 
15a–g were obtained as described above (80–88% yields from 12). The success of 
this pathway demonstrated that the presence of a 2’,3’-secoribosyl moiety does not 
interfere with the alkaline degradation of the purine ring leading to the AICA 
heterocyclic system. Though a 75–80% yield for the ribose cleavage could seem 
acceptable, we considered this result not completely satisfactory for a solid-phase 
reaction supporting a combinatorial synthetic strategy. In fact, the above reaction 
causes a reduction in the overall yield and purity of the derivatives 15a–g (60–70% 
yields from 4). In order to further improve the yield of the C2–C3 bond cleavage in 
ribose, lead tetraacetate (LTA)31 was used in DCM or DMF. Though the process was 
accomplished at several LTA/8a–g ratios and varying the reaction time, no significant 
improvement of the 2’,3’-secoribosyl derivatives 12a–g was obtained after the usual 
NaBH4 treatment (60–65% yields). However, it is to be noted that in both oxidative 
cleavage procedures (i.e., sodium metaperiodate or LTA) the predominant side 
products resulted to be the corresponding unreacted inosines 11a–g. 
 
3.3 Biological results 
 
All compounds were tested for their effect on cellular proliferation using a human 
breast cancer cell line (MCF-7). The proliferative effects were evaluated in the 
absence of 5% fetal calf serum (FCS), while the anti-proliferative effects were 
evaluated in the absence of serum. The proliferationwas evaluated by a standard 
colorimetric procedure (MTT test)32 after 24 and 48 h in triplicate using 1 mM of each 
compound dissolved in water or in 10% ethanol to improve solubility. The toxicity of 
the 10:90 ethanol/water solution was tested separately. No significant effect on 
proliferation was observed for any compound tested. Further experiments using 
different conditions and cell lines are currently undergoing. 
 
3.4 Conclusions 
 
In conclusion, we have successfully utilized the N-1-dinitrophenyl- inosine solid 
support 4, where the nucleoside is anchored to an MMT-polystyrene resin by the 5’-
ribose position, to synthesize small libraries of inosine and AICAR derivatives. The 
following solid-phase reactions have been carried out on this support and its 
derivatives: (i) the N-1 alkylation of purine by reaction of 4 with a variety of amines 
(90–95% yields); (ii) the alkaline cleavage of the N-1-alkyl-inosine base leading to 
AICAR derivatives (85–90% yields); (iii) the 2’,3’-oxidative cleavage of the ribose 
moiety (75–80% yields). The proposed synthetic pathways allowed the preparation of 
small libraries of the N-1 alkyl-inosines 11a–g, N-4-alkyl AICAR derivatives 10a–g, 
and the corresponding 2’,3’-secoriboside derivatives 15a–g. It is to be noted that the 
reported solid-phase reactions proceed with yields comparable to, or higher than, 
those obtainable from the corresponding procedures in solution. Furthermore, the 
proposed solid-phase procedures furnished a new group of solid supports bearing 
inosine derivatives (8a–g, 12a–g) or AICAR derivatives (9a–g, 13a–g), which can be 
utilized in a combinatorial manner to achieve a number of further 
derivatizations/conjugations both on the imidazolyl residue and/or on the ribose or 
2’,3’-secoribose moiety. 
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3.5. Experimental 
 
3.5.1. General 
 
4-Methoxytrityl chloride resin (1% divinylbenzene, 200–400 mesh, 1.3 mmol g-1 
substitution) was purchased from CBL Patras, Greece. Anhydrous solvents were 
used for reactions. All the other reagents were obtained from commercial sources 
and were used without further purification. The reactions on solid phase were 
performed using glass columns (10 mm diameter, 100 mm length) with fused-in 
sintered glass-disc PO (bore of plug 2.5 mm), which were shaken on an orbital 
shaker, or round bottom flask, when reactions were performed at high temperatures. 
Mps were determined on a Reichert Thermovar apparatus. IR spectra were collected 
on a Jasco FT-IR-430 spectrometer. The 1H NMR spectra were performed on a 
Varian Mercury Plus 400 MHz using CD3OD and CDCl3 as solvents; chemical shifts 
were reported in parts per million (δ) relative to residual solvent signals: CD2HOD 
3.31, CHCl3 7.26. RP-HPLC analyses of crude products were carried out on a Jasco 
UP-2075 Plus pump using a 5 mm, 4.8x150 mm C-18 reversephase column eluted 
with a linear gradient of CH3CN in 0.1 M TEAB (pH 7.0, from 0 to 60% in 60 min, flow 
1.0 mL min-1) equipped with a Jasco UV-2075 Plus UV detector. The UV spectra 
were recorded on a Jasco V-530 UV spectrophotometer. Mass spectra were 
recorded on an Applied Biosystems API 2000 mass spectrometer using electron 
spray ionization (ESI) technique in positive mode. The High Resolution MS were 
recorded on a Bruker APEX II FT-ICR mass spectrometer using electron spray 
ionization (ESI) technique in positive mode. Column chromatography was performed 
on silica gel (Merck, Kieselgel 60, 0.063–0.200 mm). Analytic TLC detections were 
performed using F254 silica gel plates (0.2 mm, Merck). TLC spots were detected 
under UV light (254 nm). 
Abbreviations: DMF = N,N-dimethylformamide, Py = pyridine, MeOH = methanol, 
EtOH = ethanol, DNClB = 2,4-dinitrochlorobenzene, K2CO3 = potassium carbonate, 
MMT-Cl= 4-methoxytrityl chloride polystyrene resin, DMAP= 4,4’-
dimethylaminopyridine, NaIO4 = sodium m-periodate, NaBH4 = sodium borohydride, 
NaOH = sodium hydroxide, LTA = lead tetraacetate, s’s = singlets, d’s = doublets, 
m’s = multiplets, q’s = quartets 
 
 
 
3.5.2 Synthesis 
 
1-(2,4-Dinitrophenyl)-2’,3’-O-isopropylideninosine (2) 
 
A mixture of 2’,3’-O-isopropylideninosine (1) (1.00g, 3.24 mmol), DNClB (820 mg, 
4.05 mmol), and K2CO3 (560 mg, 4.05 mmol) was suspended in anhydrous DMF (5 
mL) and stirred at 80 °C for 3 h. The reaction was monitored by TLC (CHCl3/MeOH, 
95:5). After cooling, the mixture was filtered and the solid was washed with CHCl3. 
The filtrates and washings, collected and evaporated to dryness, were purified on a 
silica gel column eluted with increasing amounts of MeOH in CHCl3 (from0 to 5%) to 
give 2 as a pale yellow amorphous solid consisting of a 1:1 mixture of atropisomers 
at the N(1)–phenyl bond (1.20 g, 80%); mp 235–237 °C; νmax (CHCl3) 3417, 3106, 
1710, 1538, 1348 cm-1; 1HNMR δH (CDCl3) 9.04 (br s,1H, H-3 DNP), 8.72–8.62 
(m,1H, H-5 DNP), 8.11, 8.14 (2´ s, 2H, H-2 and H-8), 7.81–7.72 (m,1H, H-6 DNP), 
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6.07–5.96 (m, 1H, H-1’), 5.22–5.11 (m,1H, H-2’), 5.10–5.02 (br s,1H, H-3’), 4.53 (br 
s, 1H, H-4’), 4.02–3.75 (m, 2H, H-5’a,b), 2.90 (br s, 1H, OH, exchange with D2O), 
1.64, 1.39 (2s, 6H, 2CH3); UV (MeOH) λmax 246 nm, ε = 20,200; HRESIMS calcd for 
C19H18N6NaO9: 497.1033, found: 497.1056 (M+Na)+. 
 
1-(2,4-Dinitrophenyl)inosine (3) 
Compound 2 (1.20 g, 2.60 mmol) was dissolved in HCOOH/H2O (6:4, v/v, 16 mL) 
and left at room temperature for 4 h. The reaction was monitored by TLC 
(CHCl3/MeOH, 6:4). The mixture was evaporated to dryness to furnish 3 (1.13 g, 
99%) as a pale yellow amorphous solid that constituted a 1:1 mixture of atropisomers 
at the N(1)–phenyl bond. The product was used without further purification; mp 210–
212 °C; νmax (neat) 3402, 3098, 1704, 1546, 1343, 1217 cm-1; 1H NMR δH (CD3OD) 
9.05 (s, 1H, H-3 DNP), 8.82– 8.72 (m, 1H, H-5 DNP), 8.49, 8.52 (2s, 2H, H-2 and H-
8), 8.08–7.98 (m, 1H, H-6 DNP), 6.14–6.06 (m, 1H, H-1’), 4.70–4.60 (m, 1H, H-2’), 
4.40–4.32 (m, 1H, H-3’), 4.19–4.12 (m, 1H, H-4’), 3.94–3.74 (m, 2H, H-5’a,b); UV 
(H2O) λmax 246 nm, ε = 20,100; HRESIMS calcd for C16H14N6NaO9: 457.0720, found: 
457.0715 (M+Na)+. 
 
3.5.3. General procedure for the scaffold synthesis 
 
Loading of 3 on solid support 
 
1-(2,4-Dinitrophenyl)inosine (3) (1.13 g, 2.60 mmol) was evaporated with dry pyridine 
(3x1.5 mL) and then coupled with the MMTCl resin (1.30 g, 1.69 mmol), and swollen 
with dry pyridine (8 mL) in the presence of DMAP (0.35 mmol, 42.0 mg) for 24 h at 
room temperature. The resin was filtered and washed with CH2Cl2 (3x5 mL), 
CH2Cl2/MeOH (1:1, v/v, 3x5 mL), and MeOH (3x5 mL), and finally dried in vacuo. The 
reaction yield was evaluated by cleavage of the nucleoside from the solid support by 
treatment with 2% (v/v) TFA in DCM (8 min, rt) followed by quantitative UV 
experiment (3, λmax = 246 nm, ε = 20,100, H2O). The solid support 4 was obtained in 
almost quantitative yield (1.26 mmol g -1, 97%). 
 
Treatment of solid support 4 with N-nucleophiles a–g (products 8a–g, 11a–g) 
 
Solid support 4 (100 mg, 0.13 mmol), previously swollen in DMF, was left in contact 
with amines a–g (5.0 mmol) in DMF (1.5 mL) under shaking for 8 h at 50 °C. The 
reaction of 4 with amines a–e furnished, after usual washings, supports 8a–e. In the 
case of amines f and g, after detachment from the support as described above, 
intermediates 6f and g could be obtained, after HPLC purification, in 90 and 85% 
yields, respectively. Alternatively, supports 5f–g were treated with a 1 M solution of 
K2CO3 in DMF (15 h, 50 °C) thus giving supports 8f and g. After filtration and 
washings with DMF (3x5 mL), DMF/MeOH (1:1, v/v, 3x5 mL), and MeOH (3x5 mL), 
supports 8a–g were dried under reduced pressure. The yields of N-1-alkyl-inosines 
11a–g (80–95%, from 4, Table 3.1) were calculated by quantifying the products 
obtained by HPLC purification of the crude nucleoside material released from a 
weighted amount of resin (as described above) and taking into account that the 
starting support 4 had a 1.26 mol g-1 nucleoside functionalization. 
 
Formation of 4-N-alkyl AICAR derivatives 10a–g 
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Supports 8a–g (100 mg, 0.10–0.12 mmol) were treated with NaOH (5 M in EtOH) for 
6 h at reflux. After filtration and washings with EtOH (3x5 mL), EtOH/H2O (1:1, v/v, 
3x5 mL), H2O (3x5 mL), and MeOH (3x5 mL), supports 9a–g were dried under 
reduced pressure. The reaction yields (8/9, 80–90%) and the overall yields of 4-N-
alkyl AICAR derivatives 10a–g (72–86% from 4) were evacuate on isolated products 
after HPLC purification of the material released from a weighted amount of resin, as 
described above. 1H NMR spectra (see later) confirmed the purity of the products. 
 
Formation of 4-N-alkyl AICA-2’,3’-secoriboside derivatives 15c–f (pathway 
9→13→15) 
 
Supports 9c–f (100 mg, 0.09–0.11 mmol) were left in contact with a solution of NaIO4 
(235 mg, 1.1 mmol) in DMF/H2O (1.5 mL, 1:1, v/v) and shaken for 12 h at 60 °C. The 
resulting supports, after washings with DMF (3X5 mL), DMF/H2O (1:1, v/v, 3x5 mL), 
H2O (3x5 mL), and then with EtOH (3x5 mL), were treated with NaBH4 (2.2 mmol) in 
EtOH (1.5 mL) and shaken for 2.0 h at room temperature. After filtration and 
washings with EtOH (3x5 mL), EtOH/H2O (1:1, v/v, 3x5 mL), H2O (3x5 mL), and 
MeOH (3x5 mL), supports 13c–f were dried under reduced pressure. Reaction yields 
(9→13, 75–80%, Table 3.1) were evaluated by HPLC analysis and purification of the 
crude 4-N-alkyl AICA-2’,3’-secoriboside derivatives 15c–f released from a weighted 
amount of resin, as descrive above. The same reactions, performed on 9a,b,e 
furnished very low quantities of the corresponding 15a,b,e. 
 
Formation of 4-N-alkyl AICA-2’,3’-secoriboside derivatives 15a–g (pathway 
8→12→13→15) 
 
Supports 8a–g (100 mg, 0.10–0.12 mmol) were left in contact with a solution of 
NaIO4 (235 mg, 1.1 mmol) in DMF/H2O (1.5 mL, 1:1, v/v) and shaken for 12 h at 60 
°C. The resulting supports, after washings with DMF (3x5 mL), DMF/H2O (1:1, v/v, 
3x5 mL), H2O (3x5 mL), and then with EtOH (3x5 mL), were treated with NaBH4 (2.2 
mmol) in EtOH (1.5 mL) and shaken for 2.0 h at room temperature. After filtration and 
washings with EtOH (3x5 mL), EtOH/ H2O (1:1, v/v, 3x5 mL), H2O (3x5 mL), and 
MeOH (3x5 mL), supports 12a–g were dried under reduced pressure. Reaction 
yields (8→12, 75–80%) were evaluated by HPLC analysis and purification of the 
crude 1-N-alkyl-inosine-2’,3’-secoriboside derivatives released from a weighted 
amount of resin, as described above. Alternatively, supports 8a–g (100 mg, 0.10–
0.12 mmol) were left into contact with a solution of LTA (235 mg, 1.1 mmol) in DCM 
(1.5 mL) and shaken for 24 h at room temperature. The resulting supports, after 
usual washings, were treated with NaBH4 (2.2 mmol) in EtOH (1.5 mL) as described 
above, thus obtaining supports 12a–g in 60–65% reaction yield (8→12) calculated by 
HPLC on the released material. Then, supports 12a–g were treated with 5 M NaOH 
in EtOH as described above for the reaction 8→9 thus giving supports 13a–g. The 
TFA treatment of 13a–g furnished 15a–g (80–88% from 12a–g), which were purified 
by HPLC as described above for 10a–g. The overall yields of pure 15a–g (from 4) 
resulted to be in the range 58–67% (Table 3.1). 
 
3.5.4 Synthesized scaffolds 
 
5-[(Cyclohexylamino)methyleneamino]-1-(β-D-ribofuranosyl) imidazole-4[N-(2,4-
dinitrophenyl)]carboxamide (6f) 
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Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3423, 3302, 2917, 1656, 
1204, 1111 cm-1; 1H NMR δH (CDCl3) 12.36 (s, 1H, NH, exchange with D2O), 9.18–
9.13 (m, 2H, H-6 and H-3 DNP), 8.70 (br s, 1H, H-2), 8.48 (dd, 1H, J = 9.8, 2.4 Hz, H-
5 DNP), 7.47 (s, 1H, CH=N), 5.78 (br s, 1H, H-1’), 4.62–4.59 (m, 1H, H-2’), 4.38–4.41 
(m, 2H, H-30 , H-4’), 3.94–3.87 (m, 2H, 2H-5’), 3.45 (br s, 1H, CHN), 2.20–1.20 (m, 
10H, 5CH2); UV (MeOH) λmax 275 nm, ε = 13,300; HRESIMS calcd for 
C22H27N7NaO9: 556.1768, found: 556.1779 (M+Na)+. 
 
5-[(1R,2S,3R,4R)-2,3-Dihydroxy-4-((hydroxymethyl)- 
cyclopentyl)aminomethyleneamino]-1-(β-D-ribofuranosyl)imidazole- 4[N-(2,4-
dinitrophenyl)]carboxamide (6g) 
 
Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3430, 3320, 2904, 1668, 
1264, 1128 cm-1; 1H NMR δH (CDCl3) 9.20 (d, 1H, H-5 DNP), 9.03 (s, 1H, H-3 DNP), 
8.64 (s, 1H, H-2), 8.42 (d, 1H, H-6 DNP), 7.73 (s, 1H, CHN), 6.03 (d, 1H, H-1’), 4.63–
4.60 (m, 1H, H-2’), 4.40–4.36 (m, 2H, H-3’ , H-2’), 4.22–4.18 (m, 2H, H-4’, H-3’), 
3.76– 3.72 (m, 2H, CH2O), 3.62–3.59 (m, 2H, CH2O), 3.23–3.20 (m, 1H, H-1’’), 2.02–
1.98 (m, 2H, H-4’’ , H-5’’a), 1.62–1.59 (m, 1H, H-5’’b), 1.18 (s, 3H, CH3), 1.31 (s, 3H, 
CH3); UV (CHCl3) λmax 276 nm,  ε =12,900; HRESIMS calcd for C25H31N7NaO12: 
644.1928, found: 644.1945 (M+Na)+. 
 
1-(3-Hydroxypropyl)inosine (11a) 
 
Amorphous solid, mp 215–218 °C; νmax (neat) 3390, 2930, 1700, 1450, 1232 cm-1; 1H 
NMR δH (CD3OD) 8.41 (br s, 1H, H-2), 8.34 (s, 1H, H-8), 6.00 (d, 1H, J = 5.0 Hz, H-
1’), 4.64–4.60 (m, 1H, H-2’), 4.34–4.29 (m, 1H, H-3’), 4.20 (t, 2H, J=4.0 Hz, CH2N), 
4.15–4.11 (m, 1H, H-4’), 3.86 (dd, 1H, J=12.2, 2.6 Hz, H-5’a), 3.75 (dd, 1H, J=12.2, 
2.6 Hz, H-5’b), 3.60 (t, 2H, J=6.3 Hz, CH2O), 2.03–1.94 (m, 2H, CH2CH2N); UV 
(MeOH) λmax 249 nm, ε =9900; HRESIMS calcd for C13H19N4O6: 327.1305, found: 
327.1291 (M+H)+. 
 
1-(5-Hydroxypentyl)inosine (11b) 
 
Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3375, 2929, 1679, 1427, 
1240 cm-1; 1H NMR δH (CD3OD) 8.40 (br s, 1H, H-2), 8.35 (s, 1H, H-8), 6.02 (d, 1H, 
J=5.5 Hz, H-1’), 4.64–4.60 (m, 1H, H-2’), 4.33–4.29 (m, 1H, H-3’), 4.14–4.08 (m, 3H, 
H-4’, CH2N), 3.87 (dd, 1H, J=12.1, 2.6 Hz, H-5’a), 3.75 (dd, 1H, J=12.1, 2.6 Hz, H-5’ 
b), 3.60 (t, 2H, J=6.2 Hz, CH2O), 1.85–1.77 (m, 2H, CH2), 1.61–1.56 (m, 2H, CH2), 
1.48–1.38 (m, 2H, CH2); UV (MeOH) λmax 249 nm, ε =10,000; HRESIMS calcd for 
C15H22N4NaO6: 377.1437, found: 377.1453 (M+Na)+. 
 
1-Propylinosine (11c) 
 
Amorphous solid, mp 185–187 °C; νmax (neat) 3324, 3302, 1702, 1240 cm-1; 1H NMR 
δH (CD3OD) 8.43 (br s, 1H, H-2), 8.35 (s, 1H, H-8), 6.01 (d, 1H, J=5.5 Hz, H-1’), 
4.64–4.60 (m, 1H, H-2’), 4.34–4.31 (m, 1H, H-3’), 4.18–4.11 (m, 1H, H-4’), 4.07 (t, 
2H, J=7.3 Hz, CH2N), 3.87 (dd, 1H, J=12.5, 2.6 Hz, H-5’a), 3.75 (dd, 1H, J=12.5, 2.6 
Hz, H-5’b), 1.83–178 (m, 2H, CH2CH3), 0.98 (t, 3H, J=7.0 Hz, CH3); UV (MeOH) λmax 
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252 nm, ε=9700; HRESIMS calcd for C13H18N4NaO5: 333.1175, found: 333.1207 
(Mþ+Na)+. 
 
1-Butylinosine (11d) 
 
Amorphous solid, mp 170–172 °C; νmax (neat) 3334, 3296, 1693, 1384, 1232 cm-1; 1H 
NMR δH (CD3OD) 8.41 (br s, 1H, H-2), 8.36 (s, 1H, H-8), 6.02 (d, 1H, J=5.5 Hz, H-
1’), 4.64–4.60 (m, 1H, H-2’), 4.34– 4.30 (m, 1H, H-3’), 4.14–4.08 (m, 3H, H-4’, CH2N), 
3.87 (dd, 1H, J=12.1, 2.6 Hz, H-5’a), 3.75 (dd, 1H, J=12.1, 2.6 Hz, H-5’b), 1.80–1.71 
(m, 2H, CH2), 1.45–1.35 (m, 2H, CH2), 0.98 (t, 3H, J=7.7 Hz, CH3); UV (MeOH) λmax 
252 nm, ε = 9800; HRESIMS calcd for C14H21N4O5: 325.1512, found: 325.1490 
(M+H)+. 
 
1-Benzylinosine (11e) 
 
Amorphous solid, mp 217–220 °C (lit.33 219–222 °C); νmax (neat) 3383, 3298, 1698, 
1490, 1212 cm-1; 1H NMR δH (CD3OD) 8.44, 8.33 (2s, 2H, H-2, H-8), 7.32–7.26 (m, 
5H, Ph), 6.00 (d, 1H, J=5.9 Hz, H-1’), 5.29 (s, 2H, CH2Ph), 4.69–4.63 (m, 1H, H-2’), 
4.33–4.30 (m, 1H, H-3’), 4.13–4.09 (m, 1H, H-4’), 3.87 (dd, 1H, J=12.5, 2.9 Hz, H-
5’a), 3.75 (dd, 1H, J=12.5, 2.9 Hz, H-5’b); UV (MeOH) λmax 249 nm, ε = 10,100; 
HRESIMS calcd for C17H18N4NaO5: 381.1175, found: 381.1173 (M+Na)+. 
 
1-Cyclohexylinosine (11f) 
 
Amorphous solid, mp 188–191 °C; νmax (neat) 3344, 3286, 1706, 1368, 1238 cm-1; 1H 
NMR δH (CD3OD) 8.37, 8.32 (2s, 2H, H-2, H-8), 6.00 (d, 1H, J=5.9 Hz, H-1’), 4.64–
4.60 (m, 1H, H-2’), 4.34–4.30 (m, 1H, H-3’), 4.22–4.19 (m, 1H, CHN), 4.11–4.10 (m, 
1H, H-4’), 3.85 (dd, 1H, J=12.0, 2.9 Hz, H-5’a), 3.72 (dd, 1H, J=12.0, 2.9 Hz, H-5’b), 
2.00–1.30 (m, 10H, 5CH2); UV (MeOH) λmax 246 nm, ε = 9800; HRESIMS calcd for 
C16H23N4O5: 351.1668, found: 351.1699 (M+H)+. 
 
1-[(1R,2S,3R,4R)-2,3-(Isopropylidenedioxy)-4 
(hydroxymethyl)cyclopentyl]inosine (11g) 
 
Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3380, 3298, 1685, 1703, 
1430, 1210; 1H NMR δH (CD3OD) 8.40 (br s, 1H, H-2), 8.36 (s, 1H, H-8), 6.04 (d, 1H, 
J=5.4 Hz, H-10), 5.23–5.19 (m, 1H, H-200), 4.73–4.70 (m, 1H, H-300), 4.60–4.58 (m, 
2H, H-1’’, H-2’), 4.33–4.29 (m, 1H, H-3’), 4.10–4.09 (m, 1H, H-4’), 3.75–3.83 (m, 4H, 
H-5’a,b, H-6’’a,b), 2.40–2.12 (m, 3H, H-4’’, H-5’’a,b), 1.16 (s, 3H, CH3), 1.30 (s, 3H, 
CH3); UV (MeOH) λmax 253 nm, ε =9500; HRESIMS calcd for C19H26N4NaO8: 
461.1648, found: 461.1620 (M+Na)+. 
 
5-Amino-1-(β-D-ribofuranosyl)imidazole-4-[N-(3-hydroxypropyl)]carboxamide 
(10a) 
 
Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3402, 3322, 1678, 1220  
cm-1; 1H NMR δH (CD3OD) 7.31 (s, 1H, H-2), 5.54 (d, 1H, J=6.6 Hz, H-1’), 4.50–4.45 
(m, 1H, H-2’), 4.24–4.20 (m, 1H, H-3’), 4.06–4.03 (m, 1H, H-4’), 3.79 (dd, 1H, J=12.1, 
2.6 Hz, H-5’a), 3.74 (dd, 1H, J=12.1, 2.6 Hz, H-5’b), 3.63 (t, 2H, J=6.2 Hz, CH2O), 
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3.31 (2H, CH2N, partly covered by solvent signal), 1.81–1.74 (m, 2H, CH2); UV 
(MeOH) λmax 268 nm, ε =10,700; HRESIMS calcd for C12H20N4NaO6: 339.1280, 
found: 339.1302 (M+Na)+. 
 
 
5-Amino-1-(β-D-ribofuranosyl)imidazole-4-[N-(5-hydroxypentyl)]carboxamide 
(10b) 
 
Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3409, 3338, 2934, 1623, 
1255 cm-1; 1H NMR δH (CD3OD) 7.38 (s, 1H, H-2), 5.56 (d, 1H, J=6.2 Hz, H-1’), 
4.50–4.46 (m, 1H, H-2’), 4.23–4.19 (m, 1H, H-3’), 4.08–4.05 (m, 1H, H-4’), 3.77 3.72 
(m, 2H, H-5’a,b), 3.55 (t, 2H, J=6.2 Hz, CH2O), 3.31 (2H, CH2N, partly covered by 
solvent signal),1.62–1.55 (m, 4H, 2CH2),1.48–1.42 (m, 2H, CH2); UV (MeOH) λmax 
268 nm, ε =10,900; HRESIMS calcd for C14H24N4NaO6: 367.1594, found: 367.1586 
(M+Na)+. 
 
5-Amino-1-(β-D-ribofuranosyl)imidazole-4- (N-propyl)carboxamide (10c) 
 
Amorphous solid, mp 202–205 °C; νmax (neat) 3330, 2980, 1702, 1210, 1166 cm-1; 1H 
NMR δH (CD3OD) 7.36 (s, 1H, H-2), 5.54 (d, 1H, J=6.6 Hz, H-1’), 4.50–4.45 (m, 1H, 
H-2’), 4.24–4.20 (m, 1H, H-3’), 4.09–4.06 (m, 1H, H-4’), 3.79 (dd, 1H, J=11.7, 2.6 Hz, 
H-5’a), 3.74 (dd, 1H, J=11.7, 2.6 Hz, H-5’b), 3.31 (2H, CH2N, partly covered by 
solvent signal), 1.63–1.57 (m, 2H, CH2CH3), 0.98 (t, 3H, J=7.3 Hz, CH3); UV (MeOH) 
λmax 267 nm, ε =10,400; HRESIMS calcd for C12H20N4NaO5: 323.1331, found: 
323.1324 (M+Na)+. 
 
5-Amino-1-(β-D-ribofuranosyl)imidazole-4-(N-butyl)carboxamide (10d) 
 
Amorphous solid, mp 222–225 °C; νmax (neat) 3398, 3347, 1702, 1239, 1120 cm-1; 1H 
NMR δH (CD3OD) 7.32 (s, 1H, H-2), 5.52 (d, 1H, J=5.5 Hz, H-1’), 4.50–4.46 (m, 1H, 
H-2’), 4.20–4.16 (m, 1H, H-3’), 4.13–4.10 (m, 1H, H-4’), 3.79 (dd, 1H, J=12.5, 2.9 Hz, 
H-5’a), 3.74 (dd, 1H, J=12.5, 2.9 Hz, H-5’b), 3.31 (2H, CH2N, partly covered by 
solvent signal), 1.60–1.51 (m, 2H, CH2), 1.45–1.36 (m, 2H, CH2), 0.96 (t, 3H, J=7.3 
Hz, CH3); UV (MeOH) λmax 267 nm, ε =10,300; HRESIMS calcd for C13H22N4NaO5: 
337.1488, found: 337.1480 (M+Na)+. 
 
5-Amino-1-(b-D-ribofuranosyl)imidazole-4-(N-benzyl)carboxamide (10e) 
 
Amorphous solid, mp 170–173 °C (lit.33 171–172 °C); νmax (neat) 3334, 3256, 1456, 
1696, 1198 cm-1; 1H NMR δH (CD3OD) 7.38–7.30 (m, 6H, Ph, H-2), 5.55 (d, 1H, 
J=6.6 Hz, H-1’), 4.54–4.48 (s, 3H, CH2Ph, H-2’), 4.19–4.16 (m, 1H, H-3’), 4.08–4.05 
(m, 1H, H-4’), 3.79 (dd, 1H, J=12.1, 2.9 Hz, H-5’a), 3.74 (dd, 1H, J=12.1, 2.9 Hz, H-
5’b); UV (MeOH) λmax 270 nm, ε =11,400; HRESIMS calcd for C16H20N4NaO5: 
371.1331, found: 371.1325 (M+Na)+. 
 
5-Amino-1-(β-D-ribofuranosyl)imidazole-4-(N-cyclohexyl)carboxamide (10f) 
 
Amorphous solid, mp 210–212 °C; νmax (neat) 3320, 3295, 1689, 1197, 1172 cm-1; 1H 
NMR δH (CD3OD) 7.35 (s, 1H, H-2), 5.54 (d, 1H, J=7.0 Hz, H-1’), 4.50–4.45 (m, 1H, 
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H-2’), 4.24–4.19 (m, 1H, H-3’), 4.07–4.04 (m, 1H, H-4’), 3.82–3.72 (m, 3H, H-5’a,b, 
CHN), 2.00–1.30 (m, 10H, 5CH2); UV (MeOH) λmax 267 nm, ε =10,800; HRESIMS 
calcd for C15H24N4NaO5: 363.1644, found: 363.1635 (M+Na)+. 
 
5-Amino-1-(b-D-ribofuranosyl)imidazole-4-[N-((1R,2S,3R,4R)-2,3-
isopropylidenedioxy)-4-(hydroxymethyl)cyclopentyl]carboxamide (10g) 
 
Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3349, 3325, 1706, 1217, 
1122 cm-1; 1H NMR δH (CD3OD) 7.37 (br s, 1H, H-2), 5.57 (d, 1H, J=5.5 Hz, H-1’), 
5.19–5.15 (m, 1H, H-2’’), 4.55–4.40 (m, 3H, H-2’, H-1’’, H-3’’), 4.26–4.22 (m, 1H, H-
3’), 4.13–4.09 (m, 1H, H-4’), 3.80–3.68 (m, 4H, H-5’a,b, H-6’’a,b), 2.30 2.10 (m, 3H, H-
4’’ , H-5’’a,b),1.18 (s, 3H, CH3),1.31 (s, 3H, CH3); UV (MeOH) λmax 268 nm, ε =10,500; 
HRESIMS calcd for C18H28N4NaO8: 451.1805, found: 451.1812 (M+Na)+. 
 
5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxyethyl] imidazole-4-[N-(3-
hydroxypropyl)]carboxamide (15a) 
 
Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3378, 3327,1698,1220 cm-1; 
1H NMR δH (CD3OD) 7.34 (s, 1H, H-2), 5.60 (t, 1H, J=5.7 Hz, H-1’), 3.87–3.83 (m, 
2H, CH2O), 3.75–3.64 (m, 2H, CH2O), 3.61–3.49 (m, 5H, CH, 2CH2O), 3.31 (2H, 
CH2N, partly covered by solvent signal), 1.80–1.75 (m, 2H, CH2); UV (MeOH) λmax 
268 nm, ε =10,200; HRESIMS calcd for C12H22N4NaO6: 341.1437, found: 341.1445 
(M+Na)+. 
 
5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxyethyl] imidazole-4-[N-(5-
hydroxypentyl)]carboxamide (15b) 
 
Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3370, 3323,1702,1210 cm-1; 
1H NMR δH (CD3OD) 7.35 (s, 1H, H-2), 5.62 (t, 1H, J=5.9 Hz, H-1’), 3.95–3.85 (m, 
2H, CH2O), 3.78–3.64 (m, 2H, CH2O), 3.60–3.50 (m, 5H, CH, 2CH2O), 3.32 (2H, 
CH2N, partly covered by solvent signal), 1.64–1.54 (m, 4H, 2CH2), 1.48–1.38 (m, 2H, 
CH2); UV (MeOH) λmax 268 nm, ε =10,100; HRESIMS calcd for C14H26N4NaO6: 
369.1750, found: 369.1756 (M+Na)+. 
 
5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxyethyl] imidazole-4-(N 
propyl)carboxamide (15c) 
 
Amorphous solid, mp 225–229 °C; νmax (neat) 3384, 3332, 1705, 1264, 1176 cm-1; 1H 
NMR δH (CD3OD) 7.36 (s, 1H, H-2), 5.62 (t, 1H, J=3.3 Hz, H-1’), 3.90–3.83 (m, 2H, 
CH2O), 3.78–3.62 (m, 2H, CH2O), 3.61–3.49 (m, 3H, CH, CH2O), 3.30 (2H, CH2N, 
partly covered by solvent signal), 1.65–1.56 (m, 2H, CH2), 0.96 (t, 3H, J=7.2 Hz, 
CH3); UV (MeOH) λmax 267 nm, ε =10,300; HRESIMS calcd for C12H22N4NaO5: 
325.1488, found: 325.1480 (M+Na)+. 
 
5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxyethyl]imidazole-4-(N-
butyl)carboxamide (15d) 
 
Amorphous solid, mp 218–222 °C; νmax (neat) 3398, 3340, 1702, 1241, 1160 cm-1; 1H 
NMR δH (CD3OD) 7.34 (s, 1H, H-2), 5.60 (t, 1H, J=3.3 Hz, H-1’), 3.91–3.84 (m, 2H, 
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CH2O), 3.79–3.65 (m, 2H, CH2O), 3.61–3.49 (m, 3H, CH, CH2O), 3.31 (2H, CH2N, 
partly covered by solvent signal), 1.60–1.51 (m, 2H, CH2), 1.46–1.32 (m, 2H, CH2), 
0.96 (t, 3H, J=7.2 Hz, CH3); UV (MeOH) λmax 267 nm, ε = 10,300; HRESIMS calcd for 
C13H24N4NaO5: 339.1644, found: 339.1640 (M+Na)+. 
 
5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxyethyl]imidazole-4-(N-
benzyl)carboxamide (15e) 
 
Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3367, 3331, 1705, 1264, 
1176 cm-1; 1H NMR δH (CD3OD) 7.36–7.28 (m, 6H, Ph, H-2), 5.60 (t, 1H, J=5.6 Hz, 
H-1’), 4.51 (s, 2H, CH2Ph), 3.96–3.84 (m, 2H, CH2O), 3.78–3.64 (m, 2H, CH2O), 
3.61–3.49 (m, 3H, CH, CH2O); UV (MeOH) λmax 270 nm, ε =11,200; HRESIMS calcd 
for C16H22N4NaO5: 373.1488, found: 373.1476 (M+Na)+. 
 
5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxyethyl]imidazole-4-(N-
cyclohexyl)carboxamide (15f) 
 
Amorphous solid, mp 210–213 °C; νmax (neat) 3367, 3302, 1708, 1164 cm-1; 1H NMR 
δH (CD3OD) 7.33 (s, 1H, H-2), 5.59 (t, 1H, J=5.5 Hz, H-1’), 3.94–3.84 (m, 2H, CH2O), 
3.80–3.65 (m, 3H, CH2O, CHN), 3.61–3.49 (m, 3H, CH, CH2O), 2.00–1.30 (m, 10H, 
5CH2); UV (MeOH) λmax 267 nm, ε =10,800; HRESIMS calcd for C15H26N4NaO5: 
365.1801, found: 365.1810 (M+Na)+. 
 
5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxyethyl]imidazole-4-[N-
((1R,2S,3R,4R)-2,3-isopropylidenedioxy)-4 
(hydroxymethyl)cyclopentyl]carboxamide (15g) 
 
Amorphous solid, mp over 250 °C (decomp.); νmax (neat) 3404, 3387, 1693, 1287, 
1193 cm-1; 1H NMR δH (CD3OD) 7.25 (s, 1H, H-2), 5.60 (t,1H, J=4.7 Hz, H-1’), 5.20–
5.17 (m,1H, H-2’’), 4.56–5.50 (m, 2H, H-1’’, H-3’’), 3.93–3.86 (m, 2H,CH2O), 3.80–
3.67 (m, 2H,CH2O), 3.61–3.49 (m, 5H, CH, 2CH2O), 2.36–2.10 (m, 3H, H-4’’, H-
5’’a,b),1.32 (s, 3H, CH3),1.20 (s, 3H, CH3);UV(MeOH) λmax 268 nm, ε =10,200; 
HRESIMS calcd for C18H30N4NaO8: 453.1961, found: 453.1969 (M+Na)+. 
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Chapter 4 
 
Solid phase synthesis of cADPR analogs 
 
Introduction 
 
Cyclic ADP-ribose (cADPR) was discovered in 1987 as a Ca2+ mobilizing metabolite 
of the well known coenzyme β-nicotinamide adenine dinucleotide (NAD) by Lee and 
co-workers1. The cyclic structure of cADPR was initially predicted to originate from a 
N-glycosyl linkage between the anomeric carbon of the ribose, which in the precursor 
NAD is linked to nicotinamide, and the amino/imino group at C6 of the adenine 
moiety2.Spectroscopic data3 and finally a crystal structure revealed cyclization 
between the anomeric C1’’ of this ribose moiety (commonly termed “northern ribose” 
while the ribose linked to N-9 of adenine is called the “southern” ribose; Figure 4.1) 
and the N1 of the adenine ring4. For clarity atoms of “northern ribose” will be marked 
as double prime (‘’) while atoms in the southern ribose will be marked as a single 
prime (‘). Later, Jacobson and co-workers investigated the UV spectral properties of 
cADPR as a function of pH, compared them with those of N1- and N6-alkylated 
adenines and concluded that the structure should be the N1-cyclized ADP-ribose 
(Figure 4.1). Sekine and co-workers did a detailed investigation of the structure of 
cADPR in aqueous solution using NMR5. They concluded that the glycolsyl torsion 
angle of the adenosine moiety is in the syn conformation and that the ribose of 
adenosine (“southern ribose”) and the “northern ribose” have the C2-endo and the 
flat conformation, respectively. 
Besides D-myo-inositol 1,4,5-triphosphate (InsP3) and nicotinic acid adenine 
dinucleotide phosphate (NAADP), cADPR is one of the principal Ca2+-releasing 
second messengers involved in cellular Ca2+ homeostasis. Changes in the cellular 
Ca2+ homeostasis are among the fundamental signalling processes in multicellular 
organisms. Such changes occur in response to extracellular signals, e.g. hormones, 
mediators, cell-cell contacts or physical stimuli, and represent one of the most 
important, powerful and versatile intracellular signal transducers. Changes in cellular 
Ca2+ homeostasis finally in meaningful physiological response of the cell. Thus, 
intracellular Ca2+ signalling is one of the most important transduction systems to 
integrate physiological responses of multicellular organisms. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. cADPR 
 
The cADPR⁄Ca2+ signalling system is active in diverse cellular systems, including 
smooth, skeletal and cardiac muscle, neuronal and neuronal-related cells, 
N-9 
N-1 
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hemopoietic cells, acinar cells, and oocytes6. Because the cADPR⁄Ca2+ signalling 
system was also observed in protozoa and plant cells, it appears to be a 
phylogenetically old and conserved system. As for the InsP3 ⁄Ca2+ signalling 
system,in several cell types extracellular stimuli activate cADPR-forming enzymes 
called ADP-ribosyl cyclases (ADPRC) and thereby induce the formation of cADPR 
(Figure. 4.2). G-protein coupling and Tyr phosphorylation have been implicated in 
ADPRC activation7,8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Receptor-mediated formation, metabolism and site of action of cADPR. Dotted lines 
indicate minor pathway or relations not generally accepted or proven. Cx43, connexion 43, CRAC, 
Ca2+ release-activated Ca2+ channel, cADPRH, cADPR-hydrolase. 
 
The enzymes responsible for the synthesis of cADPR are still a matter of debate. An 
ADPRC that acts mainly as a cyclizing enzyme has been purified and cloned more 
than 10 years ago from the ovotestis of Aplysia californica9,10. Mammalian 
homologues of this enzyme are the membrane proteins CD38 and CD157. After their 
discovery it was surprising to note that their catalytic sites are located outside of the 
cell (or in intracellular vesicles), but obviously not in direct contact to the substrate 
NAD and the intracellular Ca2+ release channel sensitive to cADPR, the ryanodine 
receptor (RyR). This situation has been described as the ‘topological paradox’ of the 
cADPR⁄Ca2+ signalling system11. De Flora and coworkers have worked out a 
potential solution for this problem. They found that NAD can leave the cell via 
connexin 43 hemichannels. Outside the cell (or inside CD38 containing vesicles) 
NAD is then converted, at least in part, to cADPR. Evidence was presented that both 
CD38 and nucleoside transporters act as cADPR-transporting proteins (Figure 4.2). 
This system in principle represents a solution for the topological paradox. 
cADPR has the characteristic 18-membered cyclic structure including a 
pyrophosphate linkage. Although pyrophosphate linkages, e.g. the linkage in NAD+, 
can often be readily cleaved enzymatically, cADPR is resistant to pyrophosphatases 
from various sources12, probably due to its unusual cyclic structure. However, 
cADPR-BP 
CD38 
NAD 
cADPR (from 
other sources) 
plasma 
membrane 
ADPR 
Ca2+store 
membrane 
NAD 
Cx43 
ligand 
receptor 
TRPM2 
CRAC 
cADPR 
cADPR 
CD38 
cADPR 
Ca2+ ions 
Ca2+ channel 
RyR (type 2/3) 
Connexin 43 
Nuc. transporter 
 76 
treatment of cADPR with t-BuOK in DMSO selectively cleaved the pyrophosphate 
linkage. Under neutral conditions, cADPR is in a zwitterionic form with a positive 
charge around the N1-C6-N6 moiety (pKa = 8.3), making the molecule extremely 
unstable. The charged adenine moiety attached to the anomeric carbon of the 
"northern" ribose can be a very efficient leaving group. Accordingly, cADPR is readily 
hydrolyzed at the unstable N1-ribosyl linkage of its adenine moiety to produce 
ADPribose (ADPR, 1), even in neutral aqueous solution (Scheme 4.1)13. Under 
physiological conditions, cADPR is also hydrolyzed at the N1-ribosyl linkage by 
cADPR hydrolase to give the inactive ADPR (1)13. 
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Scheme 4.1. The protonated and deprotonated forms of cADPR and its hydrolysis in aqueous media. 
 
cADPR analogs can be used effectively in proving the mechanism of cADPR-
mediated Ca2+ signaling pathways. Agonists or antagonists of cADPR are also 
expected to be lead structures for the development of drugs, since cADPR has been 
shown to play important physiological roles, such as insulin release from β-cells14. 
Therefore, the synthesis of cADPR analogs has been extensively investigated15. 
However, because of the unique structure and instability of cADPR, chemical 
synthesis of cADPR and its analogs has proved to be rather difficult. Consequently 
cADPR analogs have been synthesized predominantly by enzymatic and chemo-
enzymatic methods using ADP-ribosyl cyclase-catalyzed cyclization under mild 
neutral conditions16. In recent years, on the other hand, methods for the chemical 
synthesis of cADPR analogs have been extensively studied, and useful cADPR 
analogs, which could not be prepared by the enzymatic and chemo-enzymatic 
methods, have been synthesized16. 
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4.1. Enzymatic and chemo-enzymatic synthesis 
 
Before discussing the chemical synthesis, I will briefly describe the enzymatic and 
chemo-enzymatic methods using ADP-ribosyl cyclase, by which a variety of cADPR 
analogs have been prepared since the discovery of cADPR. ADP-ribosyl cyclase, 
which is responsible for the biosynthesis of cADPR from β-NAD+, is present in all 
tissues, from mammalian species to marine invertebrates13. The well-known 
mammalian ADP-ribosyl cyclase, the lymphocyte antigen CD38, has both cADPR 
synthesizing and hydrolyzing activities17. The ADP-ribosyl cyclase from Aplysia 
Calfornica catalyzes a stoichiometric conversion of β-NAD+ to cADPR. The cyclase is 
commercially available and has been widely used for the synthesis of cADPR 
analogs. The enzyme mediates the intramolecular ribosylation of β-NAD+ and some 
modified β-NAD+ analogs, prepared chemically or enzymatically, at the N1-position of 
the purine moiety to yield cADPR or the corresponding analogues18. For example, 
using this method, cADPR analogs modified at the 8-position of the adenine ring and 
at the 2’- or 3’-position of the "southern" ribose”19 (Figure 4.3), have been prepared 
from the corresponding β–nicotinamide dinucleotide-type precursors. The method 
also provided the aristeromycin congener, cArisDPR (2)20 and 3-deaza-cADPR (3)21, 
Furthermore, a "northern" ribose modified analog, 2"-NH2-cADPR (4) was 
synthesized by this method. Biological evaluation of these analogs has identified 
some analogs as useful biological tools; e.g. the effective antagonist 8-NH2-cADPR 
(5)22, 3-deaza-cADPR (3)21 and the membrane permeable antagonist 8-Br-7-
deazacADPR (6)23. One drawback of the enzymatic and chemo-enzymatic 
procedures is that these methods require preparation of the nicotinamide 
dinucleotide-type precursors as the substrates, the synthesis of which is often 
troublesome. More importantly, the analogs that can be obtained by these methods 
are limited due to the substrate-specificity of the ADP-ribosyl cyclase. Furthermore, 
even though the enzyme catalyzes the cyclization of the NAD+ analogs, in some 
cases the newly formed N-ribosyl bond is not attached to the N1 nitrogen of the 
purine ring: e.g. the products of the enzymatic reaction of the inosine and guanosine 
analogs of β-NAD+ are not the desired N1-cyclized products 7 and 8, but rather the 
N7-cyclized products 9 and 10, respectively (Figure. 4.3)24. It is likely that the 
enzymatic cyclization of NAD+ and its analogs occurs at the most nucleophilic 
position of the purine bases, i.e. the N1 of adenine and 8-substituted adenine bases 
or the N7 of the guanine and hypoxanthine bases. 
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Figure 4.3. cADPR analogs synthesized by the enzymatic and chemo-enzymatic methods. 
 
4.2. Chemical synthesis 
 
The total synthesis of cADPR itself may not be of importance, since cADPR is easily 
prepared by the enzymatic synthesis from β-NAD+. On the other hand, because of 
the limitations of the enzymatic and chemoenzymatic methods described above, 
development of effective chemical synthetic methods for the preparation of a greater 
variety of cADPR analogs is required. Considerable efforts have been devoted to the 
chemical synthesis of cyclic ADP-carbocyclic-ribose (cADPcR, 11) and its related 
compounds, for example the inosine congener cIDP carbocyclic-ribose (cIDPcR, 12), 
in which the ring oxygen in the "northern" ribose is replaced by a methylene unit 
(Figure. 4.4). Since they lack the unstable N1-ribosyl linkage of cADPR, these 
carbocyclic analogs should be resistant to both enzymatic and chemical hydrolysis, 
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while still preserving most of the functional groups of cADPR, except for the ring 
oxygen.  
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Figure 4.4. Cyclic ADP-carbocyclic-ribose (cADPcR, 11) and its inosine congener cIDPcR (12). 
 
Therefore, they should have a conformation similar to that of cADPR. Accordingly, 
these analogs are expected to be very stable mimics of cADPR. These carbocyclic 
analogs lacking the N1-glycosyl linkage could not be synthesized by the enzymatic or 
the biomimetic method, because both these intramolecular ribosylations with NAD+-
type substrates probably proceed via an oxocarbenium intermediate 13 (Figure 4.5), 
or its enzymatically stabilized equivalent. 
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Figure 4.5. Oxocarbenium intermediate (13) forming probably during enzymatic synthesis of cADPR. 
 
4.3. Synthetic strategy 
 
cADPR (Figure 4.1) has the 18-membered ring consisting of an adenine, two 
riboses, and a pyrophosphate, that connects the two primary hydroxyl groups of the 
"southern" and"northern" riboses. In the synthesis of cADPR and its analogs, 
construction of the large 18-membered ring structure should be the key step. The 
highly-polar phosphate moiety seems to be detrimental to purification and reactions, 
and therefore it should be introduced later in the synthetic process, after which the 
construction of the large 18-membered ring could be accomplished by the 
intramolecular condensation of the two phosphate groups. A typical synthetic 
strategy, showing the retro-synthesis of cADPcR (11), is illustrated in Scheme 4.2. 
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All of the studies on the chemical synthesis of cADPR and its analogs reported so far 
have employed strategies similar to the one shown in Scheme 4.2. Although the key 
step of the synthesis is the intramolecular condensation forming the pyrophosphate 
linkage, an efficient construction of the N1-ribosyl (or carbocyclic-ribosyl) purine 
nucleoside structure, such as 15, is also essential. Two strategies for constructing 
the N1- substituted structures can be considered: i.e. i) the N1- selective nucleophilic 
substitution between a purine nucleoside (17) derivative and an electrophile having a 
leaving group at the 1-position of the ribose (or carbocyclic-ribose) derivative (16), or 
ii) condensation with an imidazole nucleoside (19) and 1-amino ribose (or 
carbocyclic-ribose) derivative (18) (Scheme 4.2). 
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Scheme 4.2. The retrosynthetic analysis of cADPcR (11). 
 
 
The N1-selective glycosylation of inosine derivatives has been studied by several 
groups25, probably because cyclic inosine-diphosphate (cIDPR, 7), the inosine 
congener of cADPR, could not be prepared by the above enzymatic cyclization even 
if, in 2003, Potter et al. synthesized enzimatically 8-Br-N1-cIDPR considering that the 
presence of bulky Br group at 8 position of nucleobase were sufficient to bring 
hypoxanthine N1 in spatial proximity to the anomeric carbon of the northern ribose26. 
The chemical synthesis of cIDPR and its analogs was also thought to be easier than 
that of the corresponding adenine congeners. The non-charged N1-substituted 
hypoxanthine structure can be more stable than the positively charged N1-
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substituted adenine moiety of the adenine congeners, during the reaction and 
purification steps. 
Matsuda’s group developed a total synthetic approach to construct cADPR 
analogues. They found an efficient intramolecular cyclization for the construction of 
cyclopyrophosphate, the key reaction of all synthetic route. Their strategy was to 
introduce a bulky group into the 8-position of purine nucleoside; this maneuver can 
restrict the conformation of diphosphate intermediate in a syn form in witch the two 
phosphate moieties are close to each other and facilitate intramolecular 
condensation. Matsuda and co-workers performed the intramolecular condensation 
between a phenylthiophosphate and a phosphomonoester27, using I2/3Ǻ MS as a 
promoter in pyridine to obtain cyclic compound in quantitative yieald28, (Scheme 4.3). 
The usual condensation between two phosphomonoesters using EDC [N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride] as promoter failed or gave 
rise to very low yield of cyclic compounds. 
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Scheme 4.3: Matsuda’s strategy for total synthesis of cADPRcR and cIDPcR. 
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Several cIDPR analogs, the structures of which are shown in Figure. 4.6, have been 
synthesized based on the established synthetic strategy.  
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Figure 4.6. Chemically synthesized cIDPR analogs. 
 
We synthesized the cIDPcR analog 20, the "southern" ribose of which was replaced 
by a butyl group29, and analog 21 where the “northern” ribose was replaced by a 
pentyl group30 (Figure 4.6). 
Considering, for example, the synthesis of 21, the key intramolecular condensation 
occurred effectively using I2/MS 3A-promoted method with the phenylthiophosphate 
substrate 27. Surprisingly, the intramolecular condensation also occurred in high 
yield by the usual EDC-promoted method with the corresponding bisphosphate 28. 
Conformational flexibility of the bisphosphate 28 due to the acyclic N1-pentyl chain 
may enable the cyclization to proceed. 
The synthesis of 21 was performed treating N1-(2,4-dinitrophenyl)inosine 
intermediate 29 with 5-amino-1-pentanol via nucleophilic addition of amine at the C2-
position of nucleobase followed by rearrangement (Scheme 4.4). This new method 
for construction of N-1 Inosine derivatives was clearly superior to method using SN2-
type condensation (Scheme 4.2, i).  
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Scheme 4.4. Synthesis of cIDPR analog 21. 
 
4.4. Structural cADPR analogues for SAR elucidation 
 
According to the biosynthesis of cADPR from β−NAD+, a variety of cADPR analogues 
were obtained by the enzymatic and chemo-enzymatic approach using nicotinamide 
dinucleotide-type precursors and ADP-ribosyl cyclase for the synthesis of the cyclic 
pyrophosphate. cADPR analogues with a substitution at the 8-position of the adenine 
ring (including 8-Br, -NH2, -CH3, and -OMe)22 were found to be antagonist of cADPR. 
8-Br-cADPR, although not as potent as 8-NH2-cADPR, has been shown to be cell-
permeant and can be used as a valuable tool. 7-deaza-8-Br-cADPR is a cell-
permeant antagonist and is about twice as effective as 8-Br-cADPR8. 7-Deaza-
cADPR was a partial agonist in sea urchin egg homogenates and 3-deaza-cADPR 
was about 70-fold more potent in sea urchin egg homogenates, as compared to 
cADPR31. In the case of the N1-coupled cyclic inosine diphosphate ribose mimics 
(cIDPR), different functional groups at the 8-position resulted in completely different 
biological activities; for example 8-Br-cIDPR acts as membrane-permeant agonist of 
Ca2+ signalling. However, due to the limitation of substrate-specificity of the ADP-
ribosyl cyclase, the enzymatic and chemo-enzymatic method cannot be used for the 
construction of a larger variety of mimics modified in the northern or southern ribose 
moiety of cADPR. To build up a more detailed structure-activity profile for the 
calcium-releasing activity of cADPR, a method for the total syntheses of cADPR and 
its mimics is urgently needed. 
Matsuda’s group developed a total synthetic approach to construct cADPR 
analogues25e. They found an efficient intramolecular cyclization for the construction of 
pyrophosphate. In this way they synthesized cIDP-carbocyclic-ribose (cIDPcR) and 
cyclic ADP-carbocylclic-rybose (cADPcR). cADPcR, in which the 4’-oxo in the 
northern ribose moiety of cADPR was substituted by a methylene group caused a 
significant release of Ca2+ in sea urchin eggs; in the same system, cADPcR is 3-4 
times more potent than cADPR while 8-substitued analogues were less efficacious. 
Carbocyclic analogs were synthesized expecting to possess properties of both the 
stable carbocyclic analogs and the antagonistic 8-subsitued cADPR analogs. These 
compounds were assed for their calcium mobilizing effects as well as cADPR-evoked 
calcium release with sea urchin egg homogenates32. Surprisingly, although 8-NH2-
cADPR is a potent antagonist, the corresponding carbocyclic analog 8-NH2cADPcR 
was shown to be a potent full agonist with EC50 value two times less than of cADPR. 
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8-Cl- and 8-N3-cADPcR analogs were also full agonists, though these were weaker 
than 8-NH2cADPcR22. 
In mammalian cells, cADPcR acted much more weakly, as compared to sea urchin 
system33. However, it was found that cIDPcR showed only an insignificant Ca2+-
mobilizing effect (EC50>106 μM), and 8-Br-cIDPcR was almost inactive in sea urchin 
egg homogenates16.  
Rat brain microsomes were one of the first mammalian cell preparations in which 
cADPR was shown to trigger Ca2+ release. Nucleotides 23, 24, 25, and 26 were 
tested for their abilities to release calcium from rat brain microsomes. In addition, 
Ca2+ mobilizing effect of extracellulary added compounds were analyzed in intact 
HeLa cells. cADPR or the syntetic samples 23, 24, 25, and 26 induced Ca2+ release 
from brain microsomes with a threshold concentration of less than 15 μM under these 
experimental conditions. Ca2+ was soon requestered into microsomes. It is interesting 
that 8-nonsubstitued analogues have more potent calcium-modulating activity than 
the corresponding 8-bromo cIDPR mimics. In addition to their activity in broken cell 
preparations, these cIDPR mimics modified at the N1-ribosyl moiety were also active 
in intact HeLa cells. The natural compound cADPR (200 μM) itself exhibited no Ca2+ 
releasing activity, presumably because it cannot cross the cell membrane. Taken 
together, these data suggest that the modification in the northern ribose moiety of 
cADPR could retain the calcium release activity and also increase the membrane 
permeability of cADPR. It seems that N1-ribosyl moiety and the 6-amino group in 
cADPR are not critical structural factors for biological activity. The data indicated that 
further modification in the northern ribose might also work, for example, a mimic of 
cADPR with complete replacement of northern ribose with an ether strand (cIDPRE, 
22a). A series of 8-substitued cIDPRE were also reported (22b-e). The results 
indicate that cIDPRE permeates the plasma membrane, releases calcium from an 
intracellular, cADPR-sensitive Ca2+ store, and subsequently initiates Ca2+ release-
activated Ca2+ entry. The Ca2+-releasing activity of cIDPRE resulted in a lower 
efficacy of cIDPRE as compared to cADPR. Analogues of cIDPRE modified at C8 
position of inosine had strikingly differential effects: while 8-N3-cIDPRE and 8-NH2-
cIDPRE were similiarly effective in their agonistic activity as compared to cIDPRE, 
the halogenated derivatives 8-Br- and 8-Cl-cIDPRE did not significantly elevate 
[Ca2+]. Comparison of the calcium-release activities of different cIDPRE derivatives 
revealed a remarkable structure-activity relationship: while any functional group 
larger than the natural H at C8 in cADPR turned the molecule into a cADPR 
antagonist, for example 8-NH2-cADPR, 8-Br-cADPR and so on, in the case on cyclic 
IDP-ribose mimics, different functional groups at the 8-position resulted in completely 
different biological activities.  
Thus, cIDPRE, 8-NH2-, and N3-cIDPRE are novel important agonist tools similiarly 
suitable for studying the structure-activity relationship of cADPR and for use as 
membrane permeant cADPR mimics in intact cells. 
Concerning modifications on the southern ribose moiety of cADPR, it was found that 
the 3’-hydroxyl group was essential for calcium release in the sea urchin egg system, 
whereas the 2’-hydroxyl group was not. O-methylation of the 3’-hydroxyl group 
generated an antagonist19 (30, Figure 4.7). The stable cyclic aristeromycin 
dipshosphoribose (c-Aris DPR, 31) contains a repleacement of the southern ribose 
with a carbocyclic five-membered ring and is an agonist slightly more potent as 
compared to cADPR in the T-limphocyte system20. Comparison of the calcium-
release activities of cIDPRE and cADPR revealed that the greater flexibility of the 
whole molecule introduced by replacement of the northern ribose by the ether strand 
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either still allows fitting into the binding site or allows the functional groups to support 
a conformation mush more like cADPR. Because of the same structure of the 
northern and southern ribose occurring in cADPR, it appeared interesting to 
synthesize the cIDPR analog with replacement of both northern and southern ribose 
using two ether strand. The evaluation of of the biological activity of cIDP-DE (32) 
indicates that it is a membrane permeant analog of cADPR with agonistic properties. 
In saponin-permealized Jurkat T cells, cIDP-DE releases Ca2+ from intracellular 
stores but was much weaker as compared to cADPR. Regardless of this weak direct 
effect, a pronounced activity of cIDP-DE on Ca2+ signalling was observed in intact 
Jurkat T cells. The biological activity of cIDP-DE in Jurkat cells was quite similar to 
cIDPRE (22a) in terms of (i) Ca2+ release activity in permeabilized cells and (ii) 
induction of both Ca2+ release and Ca2+ entry in a Ca2+-free/Ca2+-reintroduction 
protocol. The Ca2+-mobilizing activity was also confirmed in cardiac myocytes freshly 
prepared from muse heart. The similiarity of cIDP-DE and cIDPRE, especially in 
induction of Ca2+ signalling in intact T cells, indicate that the further replacement of 
the southern ribose by the second ether bridge in cIDP-DE did not significantly 
influence its biological activity. 
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Figure 4.7. The structure of 3’-O-methyl cADPR, c-ARIS-DPR and cIDP-DE. 
 
4.5. Cellular effect and metabolic stability of cADPR derivatives 
 
Cyclic ADP-ribose (cADPR) is a Ca2+ mobilizing cyclic mucleotide active in many cell 
types and tissues, both in animals, protists and plants. The role of cADPR as an 
important transducer in human cell types implies that analogues of the molecule may 
become relevant as therapeutical agents in future.The biological activity and 
metabolical stability of a number of such analogues have been studied34. Alterations 
in adenine base resulted in metabolic stable analogues: 3-deaza-cADPR is a potent 
and hydrolysis-resistant agonist, whereas 7-deaza-cADPR is also resistant to 
hydrolysis, but only a partial agonist. Modifications of the 8-position of adenine 
usually resulted in antagonists; thus, further substitution of 7- deaza-cADPR at the 8-
position converted the partial agonist 7-deaza-cADPR into the membrane-permeant, 
hydrolysis resistant antagonist 7-deaza-8-Br-cADPR. Metabolic stability was also 
achieved by converting either the ‘southern’ or the ‘northern’ ribose into carbocyclic 
moieties; the resulting analogues cyclic aristeromycin diphosphoribose and cyclic 
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adenosine diphospho-carbocyclic-ribose were biologically active, although at different 
magnitude, and hydrolysis-resistant. Likewise, 2’’-amino-cADPR, modified in the 
‘northern’ ribose, was a potent and hydrolysis-resistant agonist. 
Despite the wide acceptance of cADPR as a second messenger, its metabolism is 
still an enigma as the only well-described mammalian enzymes, CD38 and CD157, 
catalyse both the formation and breakdown of cADPR. In addition, the active sites of 
CD38 and CD157 are localized in the extracellular space (or in intracellular vesicles), 
making a direct involvement of these enzymes in the intracellular metabolism of 
cADPR difficult. However, to solve this topological paradox, transport systems for the 
export of nicotinamide adenine dinucleotide (NAD+) and the import of cADPR have 
been described in some cell types. Recently, N1-cyclic inosine diphosphoribose (N1-
cIDPR) and its derivatives have been introduced as stable mimics of cADPR.  
N1-cIDPR has recently been shown to mobilize Ca2+ from intracellular stores with an 
effector concentration for half-maximum response (EC50) of approximately 33 mM. 
The natural nucleotide cADPR gave almost identical results indicating that the 
replacement of the imino–group at C6 by an oxo–group does not change binding and 
interaction properties of the nucleotide at its receptor protein. As both compounds are 
very polar, only few experiments were conducted with intact cells; as expected, no 
Ca2+ mobilization was observed. 8-Br-N1-cIDPR induced a transient Ca2+ 
mobilization in intact cells; however, its Ca2+-releasing activity in permeabilized cells 
was very low. The latter may indicate that 8-Br-N1-cIDPR acts via a mechanism 
distinct from the one induced by cADPR and is presently under investigation. The 
compounds N1-cIDPRE and N1-cIDP-DE were less effective in permeabilized cells 
as compared to the maximal Ca2+ release obtained with cADPR. Concentrations of 
100 mM for N1-cIDPRE and 500 mM for N1-cIDP-DE did not even reach the 
magnitude of Ca2+ release obtained by cADPR. In intact cells, the EC50 for N1-
cIDPRE was approximately 500 mM, while an exact EC50 for N1-cIDP-DE could not 
be determined since at 1mM extracellular concentration there was still no saturation 
of the effect; however, it did not appear reasonable to further increase the 
concentration (Table 4.1)35. 
Antagonistic effects were not observed with any inosine based analogues of cADPR 
(data not shown). 
 
 
 
 
Table 4.1: Effects of N1-CIDPR and some its derivatives on Ca2+ mobilization in Jurkat T cells. 
 
As N1-cIDPR and some of its derivatives displayed Ca2+ mobilizing properties in 
mammalian cells (Table 4.1), these compounds are well suited as novel tools for 
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signal–transduction research and may further serve as starting material for the 
synthesis of novel pharmaceutical compounds. The latter ideally are metabolically 
stable to maintain a constant effective concentration during therapy. The stability of 
N1-cIDPR was studied under identical conditions as above for cADPR.  
To study the metabolism of cADPR by CD38, the nucleotide was incubated with 
intact Jurkat T–lymphocytes. These cells express CD38 as an integral type 2 
membrane protein with the active site located in the extracellular space). The well-
described cADPR-hydrolase activity of CD38 resulted in a slow decrease of cADPR 
with a concomitant increase in the hydrolysis product adenosine 5’-diphosphoribose 
(ADPR). 
As CD38 was the only enzyme capable of hydrolysing cADPR to ADPR to some 
extent, the cyclic inosine nucleotides were incubated with intact Jurkat T cells in a 
similar manner as for cADPR. Experiments in which CD38 expressed on Jurkat T 
cells was used were confirmed by replacement of the Jurkat cells by mouse 
recombinant soluble CD38. Data (Figure 4.8) confirm the idea that substitution of the 
amino/imino– group at C6 by an oxo-group, thus converting the bond between N1 
and C1’’ at the northern ribose into a much more chemically stable, amide bond, 
produces compounds that are also biologically stable. In fact cADPR was digested 
for 60% to ADPR within 18 h (Figure 4.8a) while there was no decrease in the peak 
area of N1-cIDPR at the same time (Figure 4.8b). 
 
 
 
 
Figure 4.8. RP-HPLC profiles of metabolism of CADPR and N1-cIDPR by CD38. cADPR (50 μM) or 
N1-cIDPR (50 μM) were incubated at RT either with 1 x 10-7 Jurkat T-lymphocytes for the times 
indicated with recombinant soluble mouse CD38 (0.75 μg mL-1).  
 
CADPR, N1-cIDPR and the anlogues were incubated with the autonomously 
proliferating Jurkat T-lymphonoma cells. Whereas cADPR and 8-Br-N1-cIDPR had 
no effect on proliferation, there was a dose dependent inhibition of proliferation by 
N1-cIDPR, N1-cIDP-DE and N1-cIDPRE. These antiproliferative effects of N1-cIDPR 
and N1-cIDPRE was further studied in primary T cells. Surprisingly, only a very 
modest and statistically not significant effect on proliferation induced by myelin-basic 
a)
b)
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protein in primary rat T cells was observed (data not shown). To find out whether the 
difference observed was due to the different species involved (human Jurkat T cells 
vs primary rat T cells), a similar experiment was carried out using human myelin-
basic protein-specific T cells. Again, at the concentrations of N1-cIDPR and N1-
cIDPRE almost completely blocking autonomous proliferation of Jurkat T-lymphoma 
cells no effect on the proliferation was observed in the human primary T cells (data 
not shown). 
Although the endogenous second messenger cADPR was degraded by CD38-type 
ADPRC, N1-cIDPR and its analogues were metabolically stable. Along with the 
proven Ca2+-mobilizing activity of these compounds and the newly discovered 
inhibitory effects on proliferation of T-lymphoma cells, but not on primary T cells, their 
metabolic stability is another advantage for the development of new tools for signal-
transduction research and potentially also for the design of novel pharmaceutical 
compounds. 
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4.6. The aim of the work 
 
The chemical synthesis and in particular the total synthetic approach proposed for 
the great part of these analogues, makes use of multistep and time-consuming 
solution processes which require the purification of the products after each reaction 
step. In an effort to facilitate the chemical synthesis of these substances, and to 
enlarge the number of accessible structurally diverse analogues, we report here a 
new and general solid-phase approach to prepare N-1-alkyl analogues of cIDPR 
(47a-d, Scheme 4.5) in good yields. 
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Scheme 4.5: Reagents and conditions: i) 4-(hydroxymethyl)-benzaldehyde dimethyl acetal (34) (5.0 
equiv), p-TsOH (0.5 equiv), DCM, 7 h, reflux; ii) MMTCl resin, 35 (1.5 equiv), Py (1.5 mL/250 mg of 
resin) DMAP (0.2 equiv) 24 h, r.t.; iii) NH4F (30 equiv), MeOH, reflux, 7 h, v) Ac2O (10 equiv), Py 30 
min., r.t.; vi) DNCB (5 equiv), K2CO3 (5 equiv), 3 h, 80 °C.; vii) OH-R1-NH2 (40 equiv), DMF, 8 h, 50 °C; 
viii) a) DCEA (20 equiv), 1-H-tetrazole (20 equiv), THF, 24 h, r.t., b) t-BuOOH (20 equiv), THF, rt, 3 h; 
ix) NH3-MeOH (1:1, v/v, 24 h, 55 °C; xi) CDI (1.0 equiv) DMF, 15 h, r.t.; iv) TFA 2% in DCM, 8 min, r.t., 
x) TFA 2% in DCM, 8 min, r.t. followed by H2O washings, 5 min. 
 
 
Our synthetic approach use as key intermediate solid support 36 in which 5’-TBDPS-
inosine 33 is bound to the solid matrix by a 2',3'-acetal linkage. 36 was then 
converted in two steps in the N-1-dinitrophenyl-inosine solid support 39 possessing a 
C-2 purine atom very reactive towards N-nucleophiles and easily convertible into N-
1-alkyl-inosine derivatives, as previously reported.36 Following that approach, the 
reaction of support 39 with several ω-hydroxyalkylamines (HO-(CH2)n-NH2, a-d, 
Table 4.2) furnished the N-1-alkyl-inosine supports 40a-d which were in turn 
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converted into the phosphate derivative 42a-d in high yields. After the complete 
deprotection of the phosphate groups, the intramolecular cyclization was performed 
by pyrophosphate bond formation, treating support 42a-d with carbonyldiimidazole 
(CDI). After detachment from the solid matrix, the target N-1-alkyl-analogues of 
cIDPR (47a-d) could be obtained in 25-30 % overall yields (Table 4.2).  
The intramolecular cyclization can be considered the key step in the chemical 
synthesis of cADPR, cIDPR and their derivatives, requiring the closure of a 18-
membered cycle. For this purpose the most employed method uses the condensation 
between a S-phenyl phosphorothioate and a phosphomonoester groups promoted by 
AgNO3. However, the above procedure requires two distinct phosphorylation 
reactions and suitable protection/deprotection steps of the involved alcoholic 
functions. In our synthetic strategy we successful uses the intramolecular 
condensation of two phosphomonoester functions (44a-d) which could be prepared 
by a one-step bis-phosphorylation reaction of 40a-d. In this work we have also 
investigated the effect of the alkyl amine length on the cyclization yields and the 
reaction conditions for the pyrophosphate bond formation.  
Support 36 was prepared binding the 4-(hydroxymethyl)-2’,3’-benzylidene-5’-TBDPS-
inosine 35 to the polystyrenemonomethoxytrityl chloride (MMTCl) resin by a benzyl-
O-trityl ether linkage. In this way inosine is bound to the trityl resin by a benzylidene 
linker having two acid labile functions: a benzyl-trityl ether and a 2’,3’-acetal linkage 
both selectively cleavable by treatment with anhydrous acids or aqueous acids, 
respectively. Inosine derivative 35 was synthesized by reaction of 33 with 4-
(hydroxymethyl)-benzaldehyde dimethyl acetal in the presence of catalytic amounts 
of p-TsOH (85% yield). The reaction of commercially available MMTCl resin (1.3 
meq/g) with 35, performed in anhydrous pyridine in the presence of 4-(N,N-
dimethylamino)-pyridine (DMAP), afforded support 36 in almost quantitative yield. 
Deprotection of the 5’-OH function, performed by NH4F treatment, furnished the 
support 38 in over 95% yield.  
In previous papers we demonstrated that N-1-(2,4-dinitrophenyl)-inosine, both in 
solution37 or 5’-bound to a polymeric support36b, is a good precursor to alkylate the N-
1-atom of the purine ring of inosine by reaction with primary alkylamines. In 
particular, reaction of the C-2 carbon with amino nucleophiles (R1-NH2) leads to the 
opening of the six member ring through the cleavage of the (N-1)-(C-2) bond. The 
successive fast ring re-closure, favoured by the loss of the 2,4-dinitroaniline as the 
leaving group, furnishes the N-1-alkyl inosine derivatives in high yields. Therefore, N-
1-(2,4-dinitrophenyl)-inosine-containing support 39 was synthesized by reaction of 37 
(previously protected on 5’-OH with acetyl group), suspended in DMF, with 2,4-
dinitrochlorobenzene (DNCB, 5 equiv) in the presence of K2CO3 (5 equiv). In this way 
39 was obtained in high yields (93-95%) thus demonstrating that this unprecedented 
solid-phase inosine reaction can successfully replace the time-consuming step 
required for the preparation of N-1-(2,4-dinitrophenyl)-inosine before its loading onto 
the solid support.36b Reaction of 39 with several ω-hydroxyalkylamines (HO-(CH2)n-
NH2, n = 2→a, 4→b, 5→c, n = 6→d, Table 4.2) furnished the N-1-alkyl-inosine 
supports 40a-d in 90-92% yields. In a typical reaction, 100 mg (0.12 mmol) of support 
39, swollen in DMF, was left in contact with the amine (5.0 mmol, DMF, 8 h, 50 °C). 
After washings with DMF and MeOH, the support was dried under reduced pressure 
and the reaction yield, as well as the structures of the N-1-alkyl-inosines were 
ascertained analyzing the plates TLC purified nucleoside material 41a-d released 
from a weighted amount of resin by treatment with a 2% TFA solution in dry DCM (8 
min, r.t.). 
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Treatment of 40a-d with N,N-diisopropyl-bis-(2-cianoethyl)phosphoramidite38 (DCEA, 
20 equiv) in the presence of 1-H-tetrazole (20 equiv) in dry THF, followed by 
oxidation with t-BuOOH in dry THF furnished the bis-phosphate derivatives 42a-d in 
90-92 % yield. The complete deprotection of phosphates was achieved by treating 
42a-d with NH3(aq)-MeOH (1:1, v/v, 24 h, 55 °C) followed by washings with H2O and 
MeOH. The dried support 44a-d was treated with 2% TFA in DCM and washed with 
water. The combined filtrate solution and washings, dried under reduced pressure, 
furnished the N-1-alkyl-inosine-diphosphate derivative 45a-d (Table 4.2) whose 
structures were confirmed, after HPLC purification, by spectroscopic data.  
Good cyclization yields (40-45% from 44a-d) were observed treating 44a-d with 
carbonyldiimidazole (CDI, 2.0 equiv, DMF, 24 h, 60 °C). In particular, we also 
observed that cyclization yields is slightly affected by the N-1-polymethylene chain 
length with best yields obtained with the shorter chain 44a. It is to be noted that 
notwithstanding pseudo-diluition conditions characterizing the solid-phase 
cyclizations, variable amounts of polymeric species were obtained (20-30%). These 
species are formed by intermolecular pyrophosphate bond formation, as demostrated 
from HPLC and MS analyses of the detached nucleotide material (data not shown). 
Finally, cleavage of the 47a-d from the solid support was achieved by acidic 
treatment as described for derivatives 45a-d. The structures of all HPLC purified final 
products were confirmed by 1H-, 31P-NMR and ESI-MS. In a typical reaction 
sequence, starting from 50 mg of solid support 36 (1.2 mmol/g) and considering an 
average molecular weight of 480 g/mol, 2-3 mg of pure 47a-d could be obtained (25-
30% overall yield from 36).  
In conclusion, we have successfully investigated the practical solid-phase synthesis 
of N-1-alkyl-substituted analogues of cIDPR by using solid support 36, where the 
inosine is anchored to a MMT-polystyrene resin by a benzylidene linker. The utility of 
this approach lies in the fact that it furnishes a general and fast synthetic 
methodology for i) nucleoside analogues; ii) their phosphorylated derivatives; iii) 
intramolecular solid-phase pyrophosphate bond formation. Particular attention has 
been devoted to the latter reaction which, after optimization, could lead to satisfactory 
cyclization yield by pyrophosphate bond formation. In our opinion this unprecedented 
solid-phase approach can be generally applied to the synthesis of a several cIDPR 
derivatives also combining a number of derivatization on the purine moiety. 
 
N-1-alkyl 
moiety 
40a-d 
(from 36) 
yield (%) 
42a-d 
(from 36) 
yield (%) 
44a-d 
(from 36) 
yield (%) 
 
46a-d 
(from 36) 
yield (%) 
 
a (CH2)2   90 77 77 30 
b (CH2)4   92 78 78 28 
c (CH2)5   90 77 77 26 
d (CH2)6  91 79 79 25 
 
Table 4.2. Products and reaction yields. 
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4.7. Experimental Session 
 
4.7.1. General  
 
4-Methoxytrityl chloride resin (1% divinylbenzene, 200–400 mesh, 1.3 mmol g-1 
substitution) was purchased from CBL Patras, Greece. Anhydrous solvents were 
used for reactions. All the other reagents were obtained from commercial sources 
and were used without further purification. The reactions on solid phase were 
performed using glass columns (10 mm diameter, 100 mm length) with fused-in 
sintered glass-disc PO (bore of plug 2.5 mm), which were shaken on an orbital 
shaker, or round bottom flask, when reactions were performed at high temperatures.. 
The 1H NMR spectra were performed on a Varian Mercury Plus 400 MHz using 
CD3OD and D2O as solvents; chemical shifts were reported in parts per million (δ) 
relative to residual solvent signals: CD2HOD 3.31, HDO 4.80, 31P NMR spectra 
(H3PO4 85% as an external standard) were performed on Varian Unity Inova 500 
MHz. RP-HPLC analyses of crude products were carried out on a Jasco UP-2075 
Plus pump using a 5 mm, 4.8 x 150 mm C-18 reverse phase column eluted with a 
linear gradient of CH3CN in 0.1 M TEAB (pH 7.0, from 0 to 60% in 60 min, flow 1.0 
mL min-1) equipped with a Jasco UV-2075 Plus UV detector. The UV spectra were 
recorded ona Jasco V-530 UV spectrophotometer. Mass spectra were recorded on 
an Applied Biosystems API 2000 mass spectrometer using electron spray ionization 
(ESI) technique. Column chromatography was performed on silica gel (Merck, 
Kieselgel 60, 0.063–0.200 mm); preparative plate chromatography was performed 
using F254 silica gel plates (0.5 mm, Merck), plates were developed in this system of 
solvents: [AcOET-MeOH (85:15, v/v)], analytic TLC detections were performed using 
F254 silica gel plates (0.2 mm, Merck). TLC spots were detected under UV light (254 
nm). Cationic exchanges were performed on Dowex 50W X8 (Na+ form, 50-100 
mesh, Fluka). 
The following abbreviations were used throughout the text: Ac2O = acetic anhydride, 
AcOEt = ethyl acetate, CDI = 1, 1’-carbonyldiimidazole, CH2Cl2 = dichloromethane, 
DCEA = N,N-diisopropyl-bis-(2-cianoethyl)phosphoramidite, DMAP = 4-(N,N-
dimethylamino)-pyridine, DMF = N,N-dimethylformammide, DNCB = 2,4-
dinitrochlorobenzene, EtOH = ethanol, K2CO3 = potassium carbonate, MeOH = 
methanol, NH4F = amonium fluoride, Py = pyridine, TEAB = triethylammonium 
bicarbonate, TBDPSCl = tert-butyldiphenylcholrosilane, t-BuOOH = tert-butyl 
hydroperoxide, TFA = trifluoroacetic acid, THF = tetrahydrofurane, pTsOH = p-
toluensulfonic acids, ’s =, singlets, d’s = doublets, m’s = multiplets, q’s = quartets. 
 
4.7.2. Synthesis  
 
 
Compound 35 
 
A mixture of 33 (1.00 g, 1.97 mmol), 4-(Hydroxymethyl)benzaldehyde dimethyl acetal 
34 (4.60 g, 25.3 mmol), and p-TsOH (460 mg, 2.53 mmol) was refluxed in anhydrous 
DCM (13 mL mL) and for 7 h. The reaction was monitored by TLC (AcOEt/MeOH, 
95:5). After cooling, the solvent was evapored and the crude was purified on a silica 
gel column eluted with increasing amounts of MeOH in AcOEt (from 0 to 5%) to give 
35 as a white amorphous solid (0.86 g, 70%), 1HNMR δH (CD3OD) 8.40 (s, 1H, H-2), 
7.80 (s, 1H, H-8), 7.62-7.25 (m, 12H, arom.), 6.35 (d, 1H, H-1’), 6.00 (s, 1H, CHPh), 
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5.50 (m, 1H, H-2’), 5.10 (m, 1H, H-3’), 4.63 (s, 2H, CH2Ph), 4.56 (m, 1H, H-4’), 3.89-
3.78 (m, 2H, H-5’), 1.02 (s, 9H, 3xCH3). ESI-MS calculated for C35H38N4O5Si 622.26, 
found 645.31 (M + Na)+. 
 
Loading of compound 35 on solid support 
 
Compound 35 (0.86 g, 1.38 mmol) was evaporated with dry Py (3 x 1.5 mL) and then 
coupled with the MMTCl resin (1.30 g, 1.66 mmol), in dry Py (8 mL) in the presence 
of DMAP (0.35 mmol, 42.0 mg) for 24 h at room temperature. The resin was filtered 
and washed with DCM (3x5 mL), DCM/MeOH (1:1, v/v, 3x5 mL), and MeOH (3x5 
mL), and finally dried in vacuo. The reaction yield was evaluated by cleavage of the 
nucleoside from the solid support and from acetal linkage by treatment with 2% (v/v) 
TFA in DCM (8 min, rt) followed by treatment with H2O (30’). Quantitative UV 
experiment was performed on detached inosine (λmax = 248 nm, ε = 12200, H2O). 
The solid support 36 was obtained in almost quantitative yield (1.26 mmol g -1, 97%). 
 
Support 37 
 
Support 36 (1,00 g, 1.30 mmol) was suspended in MeOH (20 mL) and then NH4F 
(1.45 g, 40 mmol) was added in one portion. The reaction was refluxed for 7 h. After 
cooling, the resin was filtered and washed with MeOH (3x5 mL), DCM/MeOH (1:1, 
v/v, 3x5 mL), and DCM (3x5 mL), and finally dried in vacuo. Support 37 was obtained 
and the yield of the reaction (98%) was calculated quantifying the product 38 
obtained by TLC plate purification (see General) of the crude nucleoside material 
released from a weighted amount of resin (as described above) and taking into 
account that the starting support 36 had a 1.26 mol g-1 nucleoside functionalization.  
Compund 38: 1HNMR δH (CD3OD) 8.36 (s, 1H, H-2), 8.08 (s, 1H, H-8), 7.57 (d, 1H, 
arom), 7.43 (d, 1H, arom), 6.36 (d, 1H, H-1’), 6.04 (s, 1H, CH), 5.42 (m, 1H, H-2’), 
5.13 (m, 1H, H-3’), 4.65 (s, 2H, CH2Ph), 4.52 (m, 1H, H-4’), 3.77 (m, 2H, 2xH-5’); 
ESI-MS calculated for C18H18N4O6 386.12 found 409.18 (M + Na)+. 
 
Support 39 
 
Support 37 (0.50 g, 0.65 mmol) was suspended in Py (3 mL) and Ac2O (0.60 mL, 6.5 
mmol) and was shaken for 30’ at RT; the resin was filtered and washed with DCM 
(3x5 mL), DCM/MeOH (1:1, v/v, 3x5 mL), and MeOH (3x5 mL), and finally dried in 
vacuo. The obtained support was suspended in dry DMF (16 mL) and then DNCB 
(0.66 g, 3.25 mmol) and K2CO3 (0.45 g, 3.25 mmol) were added in one portion. The 
reaction was stirred at 80 °C for 3 h. After cooling, the resin was washed with DMF 
(3x5 mL), DMF/MeOH (1:1, v/v, 3x5 mL), and MeOH (3x5 mL), and finally dried in 
vacuo. The resin 39 was used for the next step without detachment of nucleoside 
material from solid support. 
 
Supports 40a-d 
 
Solid support 39 (4x100 mg, 0.12 mmol), previously swollen in DMF, was left in 
contact with amines a–d (Table 4.2, 5.0 mmol) in DMF (1.5 mL) under shaking for 8 
h at 50 °C. The solid supports 40a-d were filtered and washed with DMF (3x5 mL), 
DMF/MeOH (1:1, v/v, 3x5 mL), and MeOH (3x5 mL), and finally dried in vacuo.  
 94 
The yields of N-1-alkyl-inosines 41a–d (from 36, Table 4.2) were calculated by 
quantifying the products obtained by plates TLC purification (see General) of the 
crude nucleoside material released from a weighted amount of resin (as described 
above) and taking into account that the starting support 36 had a 1.26 mol g-1 
nucleoside. 1H-NMR spectra (see later) confirmed the purity of the products 41a-d. 
 
Supports 42a-d 
 
Solid supports 40a-d (4x100 mg mg, 0.10-0.12 mmol), previously swollen in dry THF, 
were threated with DCEA (650 mg, 2.4 mmol) in dry THF (1.5 mL) under shaking for 
24 h at RT. The obtained solid supports were filtered and washed with THF (3x5 mL), 
THF/MeOH (1:1, v/v, 3x5 mL), and MeOH (3x5 mL), and finally dried in vacuo. After 
threatment with t-BuOOH (5-6 M in decane, 216 μL, 2.4 mmol) in THF (1.5 mL) for 3 
h at RT and after washings with THF (3x5 mL), THF/MeOH (1:1, v/v, 3x5 mL), and 
MeOH (3x5 mL), solid supports 42a-d were obtained. 
The yields of compounds 43a-d (from 36, Table 4.2) were calculated by quantifying 
the products obtained by plates TLC purification (see General) of the crude 
nucleoside material released from a weighted amount of resin (as described above) 
and taking into account that the starting support 36 had a 1.26 mol g-1 nucleoside. 
1H-NMR spectra (see later) confirmed the purity of the products 43a-d. 
 
Supports 44a-d 
 
Solid supports 42a-d (4x100 mg, 0.09-0.11 mmol) were shaken with NH3(aq)-MeOH 
solution (1:1, v/v, 1.5 mL) for 24 h at 55 °C. The solid support 44a-d were filtered and 
washed with H2O (3x5 mL), MeOH/H2O (1:1, v/v, 3x5 mL), MeOH (3x5 mL), and 
finally dried in vacuo. The yields of compounds 45a-d (from 36, Table 4.2) were 
calculated by quantifying the products obtained by HPLC purification (see General) of 
the crude nucleoside material released from a weighted amount of resin (as 
described above) and taking into account that the starting support 36 had a 1.26 mol 
g-1 nucleoside. 1H-NMR spectra (see later) confirmed the purity of the products 45a-
d. 
 
 
Support 46a-d 
 
Solid supports 44a-d (4x100 mg, 0.09-0.11 mmol) were left in contact with a mixture 
of CDI (32 mg, 0.20 mmol) in DMF (0.4 mL) for 15 h at RT. The solid supports 46a-d 
were filtered and washed with DMF (3x5 mL), DMF/MeOH (1:1, v/v, 3x5 mL), and 
MeOH (3x5 mL), and finally dried in vacuo. The yields of compounds 47a-d (from 36, 
Table 4.2) were calculated by quantifying the products obtained by HPLC purification 
(see General) of the crude nucleoside material released from a weighted amount of 
resin (as described above) and taking into account that the starting support 36 had a 
1.26 mol g-1 nucleoside. 1H-NMR spectra (see later) confirmed the purity of the 
products 47a-d. 
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4.7.3 Synthesized scaffolds 
 
Compound 41a 
 
Oil, 1H-NMR δH (CD3OD) 8.35 (s, 1H, H-2), 8.32 (s, 1H, H-8), 7.57 (d, 2H, arom), 7.43 
(d, 2H, arom), 6.03 (d, 1H, H-1’), 6.04 (s, 1H, CHPh), 5.42 (m, 1H, H-2’), 5.17 (m, 1H, 
H-3’), 4.65 (s, 2H, CH2Ph), 4.52 (m, 1H, H-4’), 4.20 (t, 3H, CH2N), 3.84-3.76 (m, 5H, 
CH2O, 2xH-5’), ESI-MS calculated for C20H22N4O7 430.15 found 453.19 (M + Na)+ 
 
Compound 41b 
 
Oil, 1H-NMR δH (CD3OD) 8.35 (s, 2H, H-2, H-8), 7.58 (d, 1H, arom), 7.43 (d, 1H, 
arom), 6.34 (d, 1H, H-1’), 6.03 (s, 1H, CH), 5.40 (m, 1H, H-2’), 5.11 (m, 1H, H-3’), 
4.65 (s, 2H, CH2Ph), 4.51 (m, 1H, H-4’), 4.14 (t, 2H, CH2N), 3.77 (m, 2H, 2xH-5’), 
3.60 (t, 2H, CH2O), 1.85 (m, 2H, CH2), 1.59 (m, 2H, CH2), ESI-MS calculated for 
C22H26N4O7 458.18 found 481.22 (M + Na)+. 
 
Compound 41c 
 
Oil, 1H-NMR δH (CD3OD), 8.35 (s, 1H, H-8), 8.34 (s, 1H, 8-H), 7.57 (d, 1H, arom), 
7.43 (d, 1H, arom), 6.34 (d, 1H, H-1’), 6.03 (s, 1H, CH), 5.41 (m, 1H, H-2’), 5.11 (m, 
1H, H-3’), 4.65 (s, 2H, CH2Ph), 4.52 (m, 1H, H-4’), 4.12 (t, 2H, CH2N), 3.76 (m, 2H, 
2xH-5’), 3.56 (t, 2H, CH2O), 1.81 (m, 2H, CH2), 1.59 (m, 2H, CH2), 1.44 (m, 2H, CH2), 
ESI-MS calculated for C23H28N4O7 472.20 found 500.24 (M + Na)+. 
 
Compound 41d 
 
Oil, 1H-NMR δH (CD3OD), 8.36 (s, 1H, H-2), 8.32 (s, 1H, H-8), 7.58 (d, 1H, arom), 
7.44 (d, 1H, arom), 6.34 (d, 1H, H-1’), 6.04 (s, 1H, CH), 5.41 (m, 1H, H-2’), 5.11 (m, 
1H, H-3’), 4.65 (s, 2H, CH2Ph), 4.53 (m, 1H, H-4’), 4.12 (t, 2H, CH2N), 3.80 (m, 2H, 
2xH-5’), 3.54 (t, 2H, CH2O), 1.80 (m, 2H, CH2), 1.55 (m, 2H, CH2), 1.42 (m, 4H, 
2xCH2). ESI-MS calculated for C24H30N4O7 486.21 found 509.26 (M + Na)+. 
 
Compound 43a 
 
Oil, 1HNMR δH (CD3OD) 8.37 (s, 1H, H-2), 8.25 (s, 1H, H-8), 7.57 (d, 2H, arom), 7.43 
(d, 2H, arom), 6.41 (d, 1H, H-1’), 6.07 (s, 1H, CH), 5.60 (m, 1H, H-2’), 5.28 (m, 1H, H-
3’), 4.64 (m, 3H, H-4’, CH2Ph), 4.47-4.36 (m, 2H, 2x5’-H), 4.31-4.17 (m, 12H, 
4xOCH2CH2CN, CH2N, CH2OP(OCE)2), 2.92-2.82 (m, 8H, 4xOCH2CH2CN), 31P-NMR 
δ (D2O) -1.55, -1.67. ESI-MS calculated for C32H36N8O13P2 802.19.12 found 825.24 
(M + Na)+. 
 
Compound 43b 
 
Oil, 1H-NMR δH (CD3OD) 8.38 (s, 1H, H-2), 8.25 (s, 1H, H-8), 7.57 (d, 2H, arom), 7.43 
(d, 2H, arom), 6.42 (d, 1H, H-1’), 6.05 (s, 1H, CH), 5.60 (m, 1H, H-2’), 5.26 (m, 1H, H-
3’), 4.65 (m, 3H, H-4’, CH2Ph), 4.48-4.36 (m, 2H, 2x5’-H), 4.32-4.15 (m, 12H, 
4xOCH2CH2CN, CH2N, CH2OP(OCE)2), 2.92-2.82 (m, 8H, 4xOCH2CH2CN), 1.92 (m, 
2H, CH2), 1.86 (m, 2H, CH2), 31P-NMR δ (D2O) -1.55, -1.67. ESI-MS calculated for 
C34H40N8O13P2 830.22 found 853.27 (M + Na)+. 
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Compound 43c 
 
Oil, 1H-NMR δH (CD3OD) 8.35 (s, 1H, H-2), 8.22 (s, 1H, H-8), 7.57 (d, 2H, arom), 7.43 
(d, 2H, arom), 6.40 (d, 1H, H-1’), 6.05 (s, 1H, CH), 5.61 (m, 1H, H-2’), 5.29 (m,1H, H-
3’), 4.62 (m, 3H, H-4’, CH2Ph), 4.48-4.36 (m, 2H, 2x5’-H), 4.32-4.15 (m, 12H, 
4xOCH2CH2CN, CH2N, CH2OP(OCE)2), 2.90-2.81 (m, 8H, 4xOCH2CH2CN), 1.92 (m, 
2H, CH2), 1.86 (m, 2H, CH2) 1.59 (m, 2H, CH2), 31P-NMR δ (D2O) -1.54, -1.68. ESI-
MS calculated for C35H42N8O13P2 844.23 found 867.31 (M + Na)+. 
 
Compound 43d 
 
Oil, 1H-NMR δH (CD3OD) 8.38 (s, 1H, H-2), 8.25 (s, 1H, H-8), 7.57 (d, 2H, arom), 7.43 
(d, 2H, arom), 6.42 (d, 1H, H-1’), 6.01 (s, 1H, CH), 5.60 (m, 1H, H-2’), 5.24 (m, 1H, H-
3’), 4.63 (m, 3H, H-4’, CH2Ph), 4.48-4.36 (m, 2H, 2x5’-H), 4.32-4.15 (m, 12H, 
4xOCH2CH2CN, CH2N, CH2OP(OCE)2), 2.92-2.82 (m, 8H, 4xOCH2CH2CN), 1.92 (m, 
4H, 2xCH2), 1.86 (m, 4H, 2xCH2), 31P-NMR δ (D2O) -1.55, -1.67. ESI-MS calculated 
for C36H44N8O13P2 858.25 found 881.24 (M + Na)+. 
 
Compound 45a 
 
Solid (sodium salt), 1H-NMR δH (D2O) 8.50 (1H, bs, H-2); 8.45 (1H, s, H-8); 6.16 (d, 
1H, H-1’); 4.77 (1H, m, H-2’); 4.45 (1H, m, H-3’), 4.38 (m, 3H, CH2O, H-4’); 4.13 (m, 
4H, CH2-N and 2xH-5’), 31P-NMR δ (D2O) 0.40, -0.11. ESI-MS calculated for 
C12H18N4O12P2 472.04 found 471.06 (M - H)-.  
 
Compound 45b 
 
Solid (sodium salt), 1H-NMR δH (D2O) 8.45 (bs, 1H, H-2); 8.40 (1H, s, H-8); 6.12 (d, 
1H, H-1’); 4.77 (1H, m, H-2’); 4.47 (1H, m, H-3’), 4.35 (m, 1H, H-4’); 4.16 (m, 2H. 
CH2-N), 4.07 (m, 2H, CH2O), 3.87 (m, 2H, 2xH-5’), 1.87 (m, 2H, CH2), 1.67 (m, 2H, 
CH2), 31P-NMR δ (D2O) 0.51, -0.20. ESI-MS calculated for C14H22N4O12P2 500.07 
found 499.10 (M - H)-. 
 
Compound 45c 
 
Solid (sodium salt), 1H-NMR δH (D2O) 8.42 (bs, 1H, H-2); 8.38 (1H, s, H-8); 6.11 (d, 
1H, H-1’); 4.77 (1H, m, H-2’); 4.47 (1H, m, H-3’), 4.35 (m, 1H, H-4’); 4.11 (m, 4H. 
CH2N, CH2O), 3.83 (m, 2H, 2xH-5’), 1.81 (m, 2H, CH2), 1.59 (m, 2H, CH2), 1.44 (m, 
2H, CH2), 31P-NMR δ (D2O) 0.42, -0.16. ESI-MS calculated for C15H24N4O12P2 
514.09, found 513.15 (M - H)-. 
 
Compound 45d 
 
Solid (sodium salt), 1H-NMR δH (D2O) 8.50 (bs, 1H, H-2); 8.40 (1H, s, H-8); 6.13 (d, 
1H, H-1’); 4.77 (1H, m, H-2’); 4.50 (1H, m, H-3’), 4.37 (m, 1H, H-4’); 4.14 (m, 2H. 
CH2-N), 4.06 (m, 2H, CH2O), 3.82 (m, 2H, 2xH-5’), 1.82 (m, 2H, CH2), 1.62 (m, 2H, 
CH2), 1.41 (m, 4H, 2xCH2), 31P-NMR δ (D2O) 0.46, -0.17. ESI-MS calculated for 
C16H26N4O12P2 528.10 found 528.11 (M - H)-. 
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Compound 47a 
 
Solid (sodium salt), 1H-NMR δH (D2O) 8.39 and 8.21 (s, 1 H each, H-2 and H-8), 6.04 
(br. s, 1 H, H-1’), 5.38 (m, 1 H, H-2’), 4.50 (m, 1 H, H-3’), 4.31 (m, 1 H, H-4’), 3.96 
and 3.84 (m’s, 2 H each, CH2O and CH2N), 3.76 (m, 2 H, 2xH-5’), 31P NMR δ (D2O) -
10.21, -11.12 . ESI-MS calculated for C12H16N4O11P2 454.03 found 453.06 (M - H)-. 
 
Compound 47b 
 
Solid (sodium salt), 1H-NMR δH (D2O) 8.39 and 8.21 (s, 1 H each, H-2 and H-8), 6.04 
(br. s, 1 H, H-1’), 5.38 (m, 1 H, H-2’), 4.50 (m, 1 H, H-3’), 4.31 (m, 1 H, H-4’), 3.96 
and 3.84 (m’s, 2 H each, CH2O and CH2N), 3.76 (m, 2 H, 2xH-5’), 1.85, 1.58 (m’s, 2 
H each, methylene groups), 31P NMR δ (D2O) -10.34, -11.25. ESI-MS calculated for 
C14H20N4O11P2 482.06 found 481.09 (M - H)-. 
 
Compound 47c 
 
Solid (sodium salt), 1H-NMR δH (D2O) 8.39 and 8.21 (s, 1 H each, H-2 and H-8), 6.04 
(br. s, 1 H, H-1’), 5.38 (m, 1 H, H-2’), 4.50 (m, 1 H, H-3’), 4.31 (m, 1 H, H-4’), 3.96 
and 3.84 (m’s, 2 H each, CH2O and CH2N), 3.76 (m, 2 H, 2xH-5’), 1.85, 1.58 and 
1.32 (m’s, 2 H each, methylene groups), 31P NMR δ (D2O) -10.30, -11.45. ESI-MS 
calculated for C15H22N4O11P2 496.08 found 495.12 (M - H)-. 
 
Compound 47d 
 
Solid (sodium salt), 1H-NMR δH (D2O) 8.39 and 8.21 (s, 1 H each, H-2 and H-8), 6.04 
(br. s, 1 H, H-1’), 5.38 (m, 1 H, H-2’), 4.50 (m, 1 H, H-3’), 4.31 (m, 1 H, H-4’), 3.96 
and 3.84 (m’s, 2 H each, CH2O and CH2N), 3.76 (m, 2 H, 2xH-5’), 1.85, 1.58 (m’s 2H 
each, methylene groups), 1.42 (m, 4 H, methylene groups), 31P NMR δ (D2O) -10.29, 
-11.11. ESI-MS calculated for C16H24N4O11P2 510.09 found 509.02 (M - H)-. 
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Abstract—Herein, we report the synthesis and the use of new N-1-dinitrophenyl-inosine based solid supports, in which the C-2 of
the purine base is strongly activated toward the attack of N-nucleophiles. The synthesized supports, binding the nucleoside by a 5 0-
O-monomethoxytrityl function, have been used to accomplish the synthesis of a small library of N-1 alkylated inosine and AICAR
derivatives. In addition, cleavage of the 2 0-3 0 ribose bond of N-1 alkylated inosine derivatives anchored to the supports allowed to
prepare a new set of N-1 alkylated-2 0,3 0-secoinosine derivatives in high yields.
 2006 Elsevier Ltd. All rights reserved.
Solid phase reactions have been extensively applied to a
variety of organic reactions, furnishing an easy and
rapid procedure for modifying functional groups and/or
to conjugate speciﬁc molecules to target products. Solid
phase reactions facilitate the synthesis of large libraries
of compounds endowed with a series of molecular diver-
sity motifs around a single core scaﬀold. Screening
libraries of synthetic compounds for biological activity
is currently the most widely used approach toward drug
discovery. Nucleosides are biomolecules possessing a
pivotal role in the metabolism. In fact, they are involved,
as tri-phosphate derivatives, in the nucleic acid replica-
tions and in a very wide number of interactions with
enzymes, structural proteins and other biological targets
of therapeutic importance. In this light, it is not surprising
that the most important antiviral drugs1 currently used
in therapy, and other active compounds exhibiting anti-
neoplastic,2 antibiotic, and antifungal properties,3 have
been developed starting from this class of molecules.
Recently, the interest toward large nucleoside libraries
has emerged as an important synthetic goal to allow a
wide range of biological screenings. A variety of solid
phase combinatorial strategies have been reported for
the preparation of nucleoside and small oligonucleotide
analogues libraries. In these approaches, both the chem-
ical stability and the position of the linkage with the
polymeric support play an important role in the selec-
tion of the chemical treatments allowing the nucleobase
or sugar–phosphate modiﬁcations. For example, a solid
support binding uridine or thymidine by the acid labile
5 0-O-trityl function has been used to prepare libraries
of N-4-alkylated cytidine derivatives.4 Another recently
reported nucleoside-bearing support has exploited the
alkaline labile 5 0-O-succinyl linkage to bind the
6-chloro-2-nitro-inosine to synthesize a set of N-6- or
N-2-alkylated adenosine derivatives.5 Also the 2 0,3 0-ace-
tal linkage has been used to bind nucleosides to a solid
matrix which has been employed to introduce chemical
diversities both on the base (C-6 of purine and C-4 of
pyrimidine) and on the 5 0-ribose position.6 In another
approach, recently proposed by some of us, a purine
or pyrimidine nucleoside was anchored to the solid
support by the N-3 or N-1 base position, respectively,
through a N-alkyl-b-thioether function7,8 which resulted
stable to both the acidic and basic conditions. The above
supports have been used to synthesize 2 0-,3 0-ribose mod-
iﬁed nucleoside or nucleotide analogues. Furthermore,
controlled pore glass (CPG) supports, loading
0040-4039/$ - see front matter  2006 Elsevier Ltd. All rights reserved.
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50-DMT-nucleosides by the classical 30-succinyl linkage9–11
or by the 30-acyloxyaryl phosphate linker,12 have been
successful exploited to prepare very large nucleic-acid-
bases (NABTM) libraries of 5 0-phosphoramidate nucleo-
side derivatives and nucleic acid fragments to be tested
in their antiviral activity.
In an eﬀort to enlarge the nucleoside chemical reactivity
on the solid phase and consequently the number of
accessible structurally diverse analogues, we report here
the synthesis and exploitation of the new nucleoside
functionalized supports 4 and 5 which bind the N-1-di-
nitrophenyl-inosine derivatives 2 or 3 through the 5 0-O-
trityl function. These supports have been employed in
the synthesis of the N-1 substituted inosine 8a–e, 9a–e,
the related 2 0,3 0-seconucleoside derivatives 11a–e and
the 5-aminoimidazole-4-carboxamide riboside (AICAR)
derivatives 14 and 15. The here proposed solid phase
strategy is based on our previous studies on the C-2
reactivity of the N-1-dinitrophenyl-2 0-deoxyinosine
toward N-nucleophiles13,14 that allowed to obtain N-1
substituted inosine and AICAR derivatives. In particu-
lar, according to the reported reaction mechanism, when
a strong electron-withdrawing group (such as the 2,4-
dinitrophenyl, nitro,15 or arylsulfonyl16 group) is
attached to the N-1 atom of the hypoxanthine ring,
the C-2 carbon becomes electrophilic enough to react
with amino nucleophiles (R2–NH2). This leads to the
opening of the six membered ring through the cleavage
of the (N-1)–(C-2) bond. The successive fast ring re-clo-
sure, favoured by the loss of the 2,4-dinitroaniline as the
leaving group, furnished the N-1 alkyl inosine deriva-
tives. It is to be noted that as a consequence of the
purine rearrangement, the endocyclic N-1 atom is
substituted by the nitrogen atom of the nucleophilic
reactant. This purine reactivity has also been used by
others to introduce modiﬁed purine bases into oligo-
nucleotides.17 Thus, to obtain a small library of N-1 alkyl
inosine derivatives, we bound the 1-(2,4-dinitrophenyl)-
2 0,3 0-O-isopropylideneinosine 2, or the corresponding
unprotected inosine derivative 3 (Scheme 1 and 2), to
the commercially available polystyrenemonomethoxy-
trityl chloride (MMTCl) resin by 50-O-trityl ether linkage.
Inosine derivative 2 was synthesized by reaction of the
commercially available 2 0,3 0-O-isopropylidene inosine 1
with 2,4-dinitrochlorobenzene (DNCB) essentially as
previously described.18 The 2 0-3 0 deprotected inosine
derivative 3 was obtained treating 2 with aqueous for-
mic acid (90% yield). The reaction of the MMTCl poly-
styrene resin (1.3 mequiv/g) with 2 or 3 in anhydrous
pyridine at room temperature and in the presence of
4-(N,N-dimethylamino)pyridine (DMAP) aﬀorded
support 4 or 5, respectively, in almost quantitative yield.
The structure and the loading of supports 4 and 5 were
conﬁrmed by NMR analysis and quantitative UV exper-
iments, on the released inosine derivatives 2 and 3 ob-
tained by treating the support with 2% TFA in DCM
(8 min, rt). Supports 4 and 5 were then reacted with sev-
eral N-nucleophiles (R2–NH2, Table 1, entries a–e) to
give supports 6a–e and 7a–e, respectively. In a typical
reaction, 100 mg (0.13 mmol) of support 4 (or 5), swol-
len in DMF, was left in contact with the R2–NH2 nucleo-
phile (5.0 mmol) in 1.5 mL of DMF under shaking
(8 h, at 50 C). After washings with DMF and MeOH,
the support was dried under reduced pressure and the
reaction yield was evaluated detaching the nucleoside
material from a weighted amount of resin. The reaction
of 4 or 5 with ethylenediamine (Table 1, entry f) fur-
nished, as expected,14 supports 12 and 13 bearing the
2 0-3 0-isopropylidene-AICAR and the AICAR, respec-
tively, in almost quantitative yields. The structure and
the loading of supports 6, 7, 12, and 13 were ascertained
by analyzing with HPLC, 1H NMR (Table 1) and MS§
the corresponding detached N-1 alkyl inosine deriva-
tives 8a–e, 9a–e as well as AICAR 14 and its derivative
15. The purity and the yield of the above detached
nucleosides, conﬁrmed by HPLC analysis and quantita-
tive UV experiments, resulted to be always over 90–95%,
(Table 1). Starting from 20 mg of solid support (4 or 5),
and considering an average molecular weight of 300 g/
mol, 6–7 mg of each nucleoside derivative could be
obtained in 90–98% purity, thanks to the almost quanti-
tative reaction yields.
The second goal of this work was to combine the set of
the N-1 alkylated inosine derivatives (from supports 7)
with a ribose modiﬁcation. As an example we have
examined the well known 2 0,3 0-oxidative cleavage of
the ribose moiety generally carried out by reaction with
metaperiodate followed by reduction of the di-aldehyde
derivative which leads to 2 0,3 0-seconucleosides.19 In a
typical reaction, supports 7a–e (100 mg, 0.13 mmol)
were left in contact with a solution of NaIO4 (1.3 mmol)
in DMF/H2O (1.5 mL, 1:1, v/v) and shaken for 12 h at
60 C. The resulting support, after washings with DMF
and EtOH, was treated with NaBH4 (2.6 mmol) in
O
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Scheme 1. Reagents and conditions: (i) DNCB (2.2 equiv), K2CO3
(2.0 equiv) 2 h, 80 C; (ii) HCOOH/H2O (6:4, v/v), 4 h, rt.
Product 3, as a 1:1 mixture of atropisomers at N-1 phenyl bond; 1H
NMR (400 MHz, CD3OD): d 9.05 (s, 1H, H-3 DNP); 8.77 (dd, 1H,
H-5 DNP); 8.49, 8.49, 8.48, 8.40 (s’s, H-2 and H-8); 8.02 (dd, 1H, H-6
DNP); 6.10 and 6.12 (d’s, 0.5 H each, H-1 0); 4.69 and 4.64 (dd’s, 0.5 H
each, H-2 0); 4.35 (m, 1H, H-30); 4.15 (m, 1H, H-4 0); 3.88 and 3.77 (m,
1H each, H-50).
HPLC analyses: RP18 analytic column eluted with a linear gradient
of CH3CN in 0.1 M TEAB (pH 7.0, from 0% to 60% in 60 min, ﬂow
1.0 mL/min).
§ESI MS datam/z (calcd): 9a 325.2 (M+H+) (324.1); 9b 313.2 (M+H+)
(312.1); 9c 327.1 (M+H+) (326.1); 9d 355.1 (M+H+) (354.1); 9e 343.2
(M+H+) (342.1); 11a 349.1 (M+Na+) (326.2); 11b 337.2 (M+Na+)
(314.1); 11c 351.2 (M+Na+) (328.1); 11d 379.2 (M+Na+) 356.2; 11e
367.2 (M+Na+) 344.1; 15 259.0 (M+H+) (258.1).
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1.5 mL of EtOH and shaken for 2.0 h at rt. After wash-
ings, the obtained supports 10a–e were dried under
reduced pressure and analyzed by detaching the nucleo-
side material by TFA treatment. HPLC analyses indi-
cated that the 2 0,3 0-secoinosine derivatives 11a–e were
obtained in 75–85% yield and with almost the same pur-
ity degree. The sole side-products, obtained in 15–25%
yields, were the corresponding uncleaved nucleoside.
All the structures were conﬁrmed by 1H NMR (Table
1) and MS analyses.§ When the above oxidative cleavage
was performed in EtOH/H2O (various solvent ratios
and temperatures were used), the corresponding seco-
nucleosides were obtained in lower yields, most
probably due to the negligible swelling of the polystyrene
matrix in these solvent mixtures.
In conclusion, we have reported the synthesis of new N-
1-dinitrophenyl-inosine based solid supports (4 and 5) in
O
R1O OR1
N
N N
N
O
HO
O2N
O2N
MMTCl
MMT O
R1O OR1
N
N N
N
O
O
O2N
O2N
O
R1O OR1
H2N
H2N N
N
O
HO
i
MMT O
R1O OR1
N
N N
N
O
O
R2
O
R1O OR1
N
N N
N
O
HO
R2
O
R1O OR1
H2N
H2N N
N
O
OMMT MMT O
HO OH
N
N N
N
O
O
R2
O
HO OH
N
N N
N
O
HO
R2
R2-NH2
2 : R1-R1 = acetonide
3 : R1 = H
4 : R1-R1 = acetonide
5 : R1 = H
6a-e : R1-R1 = acetonide
7a-e : R1 = H
8a-e : R1-R1 = acetonide
9a-e : R1 = H
10a-e 11a-e14 : R1-R1 = acetonide
15 : R1 = H
12 : R1-R1 = acetonide
13 : R1 = H
ii iii
iii iii
iv v
(from 7a-e)
Scheme 2. Reagents and conditions: (i) compound 2 or 3 (1.5 equiv) in pyridine (1.5 mL/250 mg of resin), DMAP (0.2 equiv), 24 h, rt; (ii) R2–NH2
(38.0 equiv) in DMF, 8 h, 50 C; (iii) TFA 2% solution in DCM; (iv) EDA/DMF (1:1, w/w) 8 h, 50 C; (v) NaIO4 (10 equiv) in DMF/H2O (1:1, v/v),
12 h, 60 C; resin washings and treatment with NaBH4 (20 equiv) in EtOH, 2 h, rt.
Table 1. Reactions of the supports 4 and 5; products 8, 9, 11, 14, and 15
Entry R2–NH2 8, 9, 14, 15
Yielda (%)
9a–e and 15 1H NMRb 11a–e 1H NMRb
H-2; H-8; H-1 0 R2 Moiety Yield
c (%) H-2; H-8; H-1 0 (seco) R2 Moiety
a NH2 8 (98) 9 (98) 8.41; 8.36; 6.02 4.12; 1.76; 1.40; 0.98 11a (85) 8.30; 8.26; 6.04 4.00; 1.75; 1.38; 0.96
b HO
NH2 8 (96) 9 (95) 8.42; 8.26; 6.01 4.19; 3.82 11b (85) 8.28; 8.24; 6.04 4.20; 3.83
c HO NH2 8 (98) 9 (96) 8.41; 8.32; 6.02 4.20; 3.60; 1.98 11c (84) 8.31; 8.26; 6.03 4.21; 3.60; 1.98
d HO NH23 8 (98) 9 (98) 8.40; 8.35; 6.02 4.12; 3.56; 1.81;
1.59; 1.42
11d (82) 8.33; 8.27; 6.03 4.11; 3.55; 1.79;
1.58; 1.43
e NH2
HO
HO
8 (92) 9 (90) 8.38; 8.32; 6.00 3.98 (2CH2OH);
3.92 (CH)
11e (75) 8.29; 8.04; 6.05 4.02 (2CH2OH)
3.95 (CH)
f H2N
NH2 1 (98) 1 (98) 8.04; 5.66 NT NT
a Starting from resin 4 or 5 respectively; the yield is almost coincident with the purity degree of the product.
b 400 MHz, (CD3OD) signiﬁcative protons at ppm.
c Starting from resin 5; the yield (before HPLC puriﬁcation) is almost coincident with the purity degree of the product.
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which the nucleosides are anchored to a MMT–poly-
styrene resin by the 5 0 position. Supports 4 and 5 were
converted into the N-1 alkylated inosine supports (6
and 7) and AICAR derivatives supports (12 and 13) in
very high yields, by reacting at C-2 position of the purine
base with R–NH2 nucleophiles. Detachment of the
nucleosidic material from the above supports furnished,
in high yields and purities, small libraries of N-1 alkyl-
ated inosines (8a–e, 9a–e) and AICAR derivatives (14
and 15) (90–98%) possessing the ribose moiety either
protected or unprotected at the 2 0-3 0-hydroxyl func-
tions. In a further solid phase reaction, we have com-
bined the set of the N-1 alkylated inosine of supports
7a–e with the cleavage of the 2 0,3 0 ribose bond. These
reactions furnished the new group of solid supports
10a–e bearing the corresponding acyclo-nucleosides.
Supports 10a–e released, under acidic conditions, the
N-1 alkylated-2 0,3 0-secoinosine derivatives 11a–e in
good yields and purity (75–85%). In our opinion, sup-
ports 6, 7, 10, 12, and 13 bearing nucleoside derivatives
with high purity degree can be fruitfully utilized in a
combinatorial manner to obtain a number of further
derivatizations/conjugations both on the 1-(x-hydroxy-
alkyl) function and/or on the ribose or secoribose moi-
eties. Further studies are currently in progress in this
direction to obtain new large libraries of nucleoside
analogues that will be screened against a wide range of
biological assays.
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ABSTRACT
A stereoselective procedure for the preparation of non-naturally occurring deoxy iminosugars belonging to L-series has been developed. The
synthesis involves the construction of the key intermediate bicycle pyperidine 8, available in few steps by the coupling of the heterocyclic
synthon 3 and the readily available Garner aldehyde 4.
Polyhydroxylated piperidines (commonly known as imino-
sugars or azasugars) represent sugar analogues with the
nitrogen atom in place of the ring oxygen of the correspond-
ing carbohydrate. Since their first discovery over 40 years
ago, iminosugars have gained a great deal of attention as
inhibitors of carbohydrate-processing enzymes glycosidases
and glycosyltransferases. As extensively described,1 their
inhibitory aptitude has been linked with their structural
resemblance to the glycone moiety of glycosides that interact
with such enzymes.
As alterations in biosynthesis and function of these
enzymes are implicated in a wide variety of diseases, the
significant inhibitory properties of iminosugars make them
excellent targets for medical intervention. Their prospective
therapeutical uses range from diabetes2 through cancer3 and
viral diseases4 to metabolic and neurological disorders.5 As
a result, R-glucosidase inhibitors 1-deoxynojirimycin (DNJ,
1) and N-butyl-1-deoxynojirimycin (NB-DNJ, Zavesca 2)
(Figure 1) have been shown to inhibit human immunodefi-
ciency virus (HIV) replication and HIV-mediated syncytium
formation in vitro.6 Moreover, NB-DNJ has been the first
iminosugar medicine to receive approval, in 2002 in the
European Union and in 2003 in the United States, for use in
patients with mild to moderate type 1 Gaucher disease.
The principal advances in total and stereoselective syn-
theses of such compounds have recently been reviewed.7 As
reported, most syntheses have focused attention on the
* To whom correspondence should be addressed. Phone: + 39 081 674
118. Fax: + 39 081 674 119.
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Figure 1. Bioactive iminosugars DNJ and NB-DNJ.
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preparation of iminosugars with D-configuration, whereas few
routes are available for the synthesis of their corresponding
L-analogues.8 This fact is evidently due to the larger
commercial availability of D-series sugars as starting materi-
als, as well as to the fact that glycosides belonging to D-series
are the natural substrates of almost all glycosidases. However,
it is worth recalling that iminosugars mimicking the sugar
moiety structure of the natural substrate are not always
inhibitors of the corresponding glycosidase. D-manno-DNJ
(DMJ) is known as a much better inhibitor of R-L-fucosidase
than R-D-mannosidase; on the other hand L-allo-DNJ is a
better inhibitor of R-D-mannosidase than D-DMJ.9 As recently
shown,10 an explanation of this behavior could be found
considering that D-enantiomers are competitive inhibitors of
D-glycosidases, whereas their L-enantiomers are noncompeti-
tive inhibitors of the same enzymes.
In the context of our ongoing program directed toward
the achievement of a new synthetic methodology for the
preparation of polyhydroxylated molecules, we have devel-
oped a versatile strategy for the synthesis of non-naturally
occurring deoxy-iminopyranoses belonging to L-series, through
a non-carbohydrate based route.
As outlined in Scheme 1, the synthesis involves the use
of an heterocyclic synthon, the 5,6-dihydro-1,4-dithiin-2-yl-
[(4-methoxybenzyl)oxy]methane11 (3), a reagent capable of
three-carbon homologation of electrophiles by the introduc-
tion of a fully protected allylic alcohol moiety, already
devoted to the preparation of several polyhydroxylated
compounds.12
The synthesis began with the coupling of the in situ
prepared C-3 lithiated carbanion of 3 with the Garner13
aldehyde 4 (Table 1) to afford a syn/anti diastereomeric
mixture of alcohols 5. As highlighted in Table 1, the best
stereoselectivity was achieved by the use of Et2O without
catalyst, providing anti-5 in good stereoselectivity (91:9 dr).
Interestingly, the stereochemical outcome of the reaction
seemed to be mainly influenced by the nature of the solvent,14
whereas any significant stereoselective induction was not
observed in the presence of the catalysts.15
The secondary alcohol16 anti-5, obtained by the coupling
reaction, was separated from its diastereomer by flash
chromatography; the stereochemical assignment at the newly
generated C-4 was clearly deduced by X-ray analysis (Figure
2).
With the educt 5 in hand, our interest was focused on the
achievement of key intermediate 9 (Scheme 2). To this
purpose, we converted the alcohol 5 in its diacetate 6 by
deprotection of the oxazolidine ring and acetylation of the
(7) For comprehensive reviews see: (a) Afarinkia, K.; Bahar, A.
Tetrahedron: Asymmetry 2005, 16, 1239-1287. (b) Pearson, M. S. M.;
Allaimat, M. M.; Fargeas, V.; Lebreton, J. Eur. J. Org. Chem. 2005, 2159-
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Scheme 1. Retrosynthetic Path
Table 1. Three-Carbon Homologation
solvent catalyst (20%) (anti/syn) dr yield(%)
THF none 60:40 83
THF Ti(O-i-Pr)4 60:40 80
THF Cp2TiCl2 60:40 85
Et2O Cp2TiCl2 70:30 49
Et2O ZnBr2 82:18 73
Et2O none 91:9 72
Figure 2. X-ray analysis of anti-5.
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crude residue (86% overall yield). Removal of MPM group
by treatment of 6 with DDQ in a CH2Cl2/H2O (9:1) emulsion
gave the primary alcohol 7 with an excellent yield (95%).
Intramolecular cyclization was then carried out under mild
conditions by treatment of 7 with Ag2O/TsCl in THF at 40
°C (85%). Finally, removal of the dithioethylene bridge on
intermediate 8 was achieved by treatment with Raney-Ni in
ethanol at 0 °C for 2 h leading to the olefin 9. Moreover,
when the reaction was carried out with a Raney-Ni excess
in THF, at room temperature, the over-reduction product was
obtained with a satisfactory yield (83%), affording the 1,2,3-
trideoxy-L-iminosugar 10.
With the promising olefin 9 in hand our interest was
directed to the stereoselective double-bond dihydroxylation
(Scheme 3). Exposure of 9 to the common Upjohn conditions
(OsO4/NMO) followed by acetylation of the crude residue
yielded a fully separable mixture of the protected L-manno-
DNJ 11 and L-allo-DNJ 12 in low diastereomeric ratio
(6:4). Both diastereomers were deprotected by means of
refluxing aq 6 N HCl solution, obtaining deoxy-L-mannojiri-
mycin (13) and deoxy-L-allonojirimycin (14) in remarkable
yields (91% and 90%, respectively). Further attempts to
improve the stereoselectivity of dihydroxylation reaction (i.e.,
using the bidentate complex OsO4/TMEDA17 and the Sharp-
less catalysts18) showed no significant effects.19 The observed
low selectivity in the above dihydroxylation reactions might
be attributed to the relatively small size of the C-4 acetyl
group and thus both faces of the double bond were almost
equally hindered. As a matter of fact, the replacement of
the Ac groups of 9 with the much bigger TBDPS ethers (15,
88% overall yield, Scheme 3), afforded after dihydroxylation
of 15, under Upjohn conditions, the protected L-manno-DNJ
16 with a high stereoselectivity (97:3 dr). Then, treatment
with aq 6 N HCl allowed removal of all protective groups
to obtain deoxy-L-mannojirimycin (13) in 93% yield.
It is noteworthy to recall that the stereochemistry of
compounds 13 and 14 is consistent with X-ray analysis of
the anti-5 compound and with the spectroscopic data.
However, observing the coupling constant values in the 1H
NMR spectra (Scheme 4), it is evident that the N-Boc
compounds 11 and 12 do not conform to the expected 1C4
chair conformation, typical of L-sugars adopting a conforma-
tion close to 3S1.20
(14) The solvent-dependent stereoselective effect should be related to
the nature of the organolithium intermediate: as already reported (see farther
on), a “nude” and more reactive ionic couple prevails in THF, while a less
reactive non-ionized species is formed in Et2O, driving the reaction towards
a better stereoselective outcome: (a) Seyferth, D.; King, R. B. Annual
SurVeys of Organometallic Chemistry, Vol. 1-3, Elsevier Publishing Co.:
Amsterdam, 1965-1967. (b) Maercker, A.; Roberts, J. D. J. Am Chem.
Soc. 1966, 88, 1742-1759.
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medium the catalyst does not complex Garner aldehyde, but it can be
sequestrated by the negatively-charged heterocyclic system, without induc-
tion of stereoselectivity.
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Scheme 2. Synthesis of the Key Intermediate 9 Scheme 3. Syn Dihydroxylation of 9
Scheme 4. Preferred Conformations for Compounds 11, 12
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The above successes led us to consider the anti dihydroxy-
lation of the key olefin 9. Treatment of this latter with in
situ generated21 DMDO (oxone/trifluoroacetone) afforded
exclusively the anti-epoxide 17 in 90% yield (Scheme 5).
Ring opening22 of the 2,3-anhydro derivative 17 along
with the removal of all protecting groups by means of
refluxing HClO4 gave the deoxy-L-altronojirimycin (18) in
94% yield.
In summary, a versatile pathway for the synthesis of
L-deoxyiminosugars belonging to L-series has been opened
up in this paper. Together with L-manno-, L-allo-and L-altro-
deoxyiminosugars 13, 14, and 18, whose synthesis has been
described, this path will be profitably employed for the
synthesis of all the epimers with galacto configuration,
simply applying the same procedure on the syn-5 diastere-
omer. Furthermore, the whole synthetic procedure so far
described, carried out from 3 and the ent-4 (prepared from
D-serine) enables the preparation of D-series iminosugars as
well.
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leading to a 3S1 conformation. For similar results see: (a) Kilonda, A.;
Compernolle, F.; Hoornaert, G. J. J. Org. Chem. 1995, 60, 5820-5824.
(b) Kazmaier, U.; Grandel, R. Eur. J. Org. Chem. 1998, 1833-1840.
(21) Yang, D.; Wong, M.-K.; Yip, Y.-C. J. Org. Chem. 1995, 60, 3887-
3889.
(22) On the basis of 1H NMR coupling constant values we established
that also 17 essentially exists in a 3S1 conformation and that the formation
of trans-diaxial ring opening product 18 could be explained assuming that
the HClO4 first removes the N-Boc group, allowing the chair inversion from
3S1 to 1C4, and then leads to the epoxide cleavage.
Scheme 5. Anti Dihydroxylation of 9
3476 Org. Lett., Vol. 9, No. 17, 2007
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SYNTHESIS OF A NEW RIBOSE MODIFIED ANALOGUE
OF CYCLIC INOSINE DIPHOSPHATE RIBOSE
Giorgia Oliviero, Nicola Borbone, Jussara Amato, Stefano D’Errico, Gennaro
Piccialli, Michela Varra, and Luciano Mayol  Dipartimento di Chimica delle
Sostanze Naturali, Universita` di Napoli “Federico II,” Napoli, Italy
 A new analogue of cyclic inosine diphosphate ribose (cIDPR), in which the N-1 and N-9 ribosyl
moieties were substituted by an alkyl moiety and an hydroxy-alkyl chain, has been synthesized and
characterized.
Keywords cADPR; cIDPR; IP3; Ca2+
INTRODUCTION
Cyclic ADP-ribose is an endogenous metabolite synthesized from NAD+
by ADP-ribosyl cyclase in cells.[1] In recent years cADPR has been attracting
much attention because of its potent calcium-mobilizing activities as well as
for its important role as a potent second messenger in cellular Ca2+ home-
ostasis, insulin secretion, and T-lymphocites activation.[2,3] It is also known
to mobilize intracellular Ca+2 more actively than inositol-1,4,5-triphosphate
(IP3) by a mechanism completely IP3 independent. Since Ca+2 ion regulate
diverse cell functions, the cADPR signalling pathway may become a valuable
target for pharmaceutical intervention.
cADPR is characterized by a very labile N-1 glycosidic bond which is
rapidly hydrolyzed, both enzymatically or not, to give ADP-ribose even
in neutral aqueous solution. This biological and chemical instability can
hinder the studies on cADPR aimed at elucidating its physiological role.
Many nonhydrolyzable mimics of cADPR which retained a similar cal-
cium release profile to that of cADPR are reported.[4] Some structural
modifications on cADPR adenine moiety make the mimic more potent
than its parent—e.g. the 3-deaza-cADPR is 70-fold more potent than
cADPR.[5] Additional structural modification includes the pyrophosphate
Address correspondence to Giorgia Oliviero, Dipartimento di Chimica delle Sostanze Naturali,
Universita` di Napoli “Federico II” via D. Montesano 49, Napoli I-80131, Italy. E-mail: golivier@unina.it
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FIGURE 1 N -1 and/or N -9 modified analogues of cIDPR.
moiety. Cyclic adenosine triphosphate ribose was more potent in in-
ducing Ca2+ release as compared to cADPR.[6] Furthermore, N-1 deri-
bosylated derivatives of cIDPR (methoxyethyl-8-substituted inosine) are
found to be novel membrane permeant cADPR mimics causing the re-
lease of Ca2+ in human Jurkat T-lymphocytes.[7] Recently we have pro-
posed the syntheses of several analogues of cIDPR in which the N-1 or
the N-9 ribosyl moiety has been replaced by an alkyl[8,9] or hydroxyalkyl
chain[10] (products A–C Figure 1). To collect more information on the
role of the N-1 and N-9 ribosyl moieties into Ca2+ release activity, we
synthesized the new cIDPR analogue 8 (Scheme 1) containing a penthyl
and an hydroxyalkyl chain at N-1 and N-9 hypoxanthine base positions,
respectively.
The synthetic strategy adopted for 8 is shown in Scheme 1. The N-9
acyclic ribose inosine derivative 2 was obtained by reaction of the 2′,3′-
O-isopropilidene-inosine 1 with DIBALH.[11] After protection of the al-
coholic functions of 2 the N-1 nitro derivative 4 was obtained in good
yield by reacting the diacetyl derivative 3 with ammonium nitrate and
trifluoroacetic anhydride.[12] The reaction of 4 with 5-amino-penthan-
1-ol furnished the derivative 5 which in turn was converted into the
bis-phosphorylated compound 6 (80%) by treatment with S,S-diphenyl-
phosphorodithioate (cycloesilammonium salt) in the presence of 2,4,6-
triisopropylbenzen-sulfonylchloride (TPSCl) and tetrazole in pyridine. In
this reaction we observed the formation of the corresponding triphosphate
derivative in 20% yield. 6 was acetylated at secondary alcoholic function
and then treated with silver acetate to remove the phosphate protecting
group.[13] The obtained product 7 was purified by HPLC (RP18) before the
cyclization step which was performed as previously described,[10] thus ob-
taining 8 (10% overall yield starting from 1), whose structure was confirmed
by 1H-NMR, 31P-NMR, and MS data. Studies on the biological activity of 8
are currently in progress.
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SCHEME 1 Reagents and conditions: a) DIBALH, THF; b) Ac2O, pyridine, r.t., c) NH4NO3, TFA,
CH2Cl2; d) 5-aminopenthanol, DMF, r.t. 8 hours; e) S,S-diphenylphosphorodithioate, TPSCl, pyridine,
r.t., 8 hours; f) Ac2O, AgAc, pyridine/H2O; g) EDC, NMP, r.t.; 60 hours; h) aq. HCO2H, r.t., 3.5 hours.
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SYNTHESIS AND CHARACTERIZATION OF TETRA-END LINKED
OLIGONUCLEOTIDES CAPABLE OF FORMING MONOMOLECULAR
G-QUADRUPLEXES
Nicola Borbone, Giorgia Oliviero, Jussara Amato, Stefano D’Errico,
Aldo Galeone, Gennaro Piccialli, and Luciano Mayol  Dipartimento di
Chimica delle Sostanze Naturali, Universita` di Napoli “Federico II,” Napoli, Italy
 The chemical synthesis of two new G-rich Tetra-End-Linked-oligodeoxyribonucleotides (TEL-
ODNs) as well as 1H-NMR and CD spectra of the corresponding monomolecular quadruplexes (IVa
and IVb) has been reported. The new TEL-ODNs, characterized by the presence of short branches
in the linker moiety, could be very useful for the achievement of monomolecular quadruplexes with
predetermined strand orientation.
Keywords TEL-ODN; G-quadruplex; NMR
INTRODUCTION
DNA quadruple helices (quadruplexes) based on guanine (G) tetrads
(Figure 1a) have recently emerged as biologically important structures.[1]
G-rich sequences, which are found primarily in telomeric region at the 3′-
end of chromosomes, are able to fold into G-quadruplex structures. It has
been suggested that quadruplex formation could inhibit the telomere main-
tenance provided by telomerase activity, thus affecting the lifespan of the
cells of a number of cancer types characterized by a high level of telomerase
expression.[2] Furthermore, G-quadruplex structures are present in the scaf-
fold of several aptamers provided with useful biological properties.[3] G
quadruplexes can be classified on the basis of the number and the polarity
of the strands (Figure 1b–d), as well as for loop composition and confor-
mation. Several studies have investigated the effect of loops on quadruplex
stability and typology.[4] We recently proposed the synthesis of a new class
of modified tetra-end-linked G-rich ODNs (TEL-ODNs) capable of forming
This work is supported by Italian MURST (PRIN 2005). The authors are grateful to Centro di Servizi
Interdipartimentale di Analisi Strumentale (CSIAS), for supplying the NMR facilities.
Address correspondence to Nicola Borbone, Dipartimento di Chimica, delle Sostanze Natu-
rali, Universita` di Napoli “Federico II,” via Domenico Montesano 49, Napoli 80131, Italy. E-mail:
borbone@unina.it
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FIGURE 1 a) G-tetrad structure; b) tetramolecular parallel quadruplex; c) bimolecular antiparallel
quadruplex; d) monomolecular antiparallel quadruplex.
monomolecular parallel G-quadruplexes characterized by faster kinetics
and higher thermal stability than the correspondent tetramolecular coun-
terparts (Scheme 1).[5,6] Moreover, in the attempt to obtain monomolecular
quadruplex structures characterized by predetermined strands stoichiome-
try and polarity, to be used as simple and stable models for structural studies
SCHEME 1 Schematic representation of unfolded (left) and folded (right) TEL-ODNs.
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Tetra-End Linked Oligonucleotides 1233
SCHEME 2 i) Two coupling procedures with 2a,b; ii) ODN synthesis with 3′-phosphoramidites; iii)
detachment and deprotection by NH4OH conc. 32% (7 hours, 55◦C); iv) HPLC purification and
annealing.
on the quadruplex-ligand interaction, we recently synthesized a set of TEL-
d(TGGGGT)4 in which the ODN strands were linked with different orien-
tations to the tetra-end linker. Structural studies performed on such com-
pounds indicated that the TEL-d(TGGGGT)4 assembled with two pairs of
antiparallel ODN strands lead to parallel G-quadruplexes thanks to the con-
siderable folding of the tetra-branched-linker around the whole quadruplex
scaffold.[7]
In this article, we report the syntheses of two new TEL-d(TGGGGT)4
molecules (Scheme 2, 4a and 4b) characterized by the presence of one
or three shorter branches in the TEL moieties (sl-TEL and ss-TEL, respec-
tively). These structural features were chosen in the attempt to hinder the
folding of the linker around the whole quadruplex structure thus forcing
the predetermination of quadruplex strands polarity upon the basis of the
relative orientation of the ODN strands into the TEL-ODN molecules.
RESULTS AND DISCUSSION
In the attempt to obtain monomolecular quadruplexes having pre-
determined strands polarity we designed the synthesis of two new tetra-
branchedlinker moieties characterized by the shortening of the primary or
both primary and secondary TEL branches (sl-TEL or ss-TEL, Scheme 2).
To test if the sl-TEL and ss-TEL moieties were still able to allow the for-
mation of stable quadruplex structures, we synthesized 4a and 4b via the
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Tetra-End Linked Oligonucleotides 1235
FIGURE 3 CD spectra (top; 25◦C) and CD melting profiles (bottom; 264 nm, 1◦C/minute) of IVa (left)
and IVb (right) in 100 mM K+ buffer.
recently reported solid-phase procedure[5] using the CPG support and the
branching bi-functional linkers 2a and 2b as described in Scheme 2. We de-
cided to not synthesize the ls-TEL-d(TGGGGT)4 (4c in Scheme 2) because
its primary branch is long enough to span the distance between the quadru-
plex edges, thus allowing the loss of strands polarity predetermination.
In order to assess if 4a and 4b could still fold into the quadruplex struc-
tures IVa and IVb, respectively, and if such were the case, to estimate their
stabilities, we performed 1H-NMR (at 25, 65, and 85◦C using pulse field
gradient WATERGATE[8] sequences for H2O suppression) and CD studies.
Comparison of 1H-NMR stacked spectra of IVa and IVb (Figure 2) showed
that both adopted parallel quadruplex structures in the presence of K+ ions.
However, it appeared that the presence of the ss-TEL moiety in 4b lead to
the lowering of the thermal stability of IVb, and to the partial loss of the mag-
netic equivalence between the imino protons in each G tetrad. On the other
hand, IVa, characterized by the presence of the sl-TEL moiety, appeared to
be very stable up to 85◦C. Indeed, in the case of IVa no loss of imino pro-
tons magnetic equivalence was observed. Finally, the CD spectra and the CD
melting curves were well in agreement with the NMR data (Figure 3). Upon
the basis of these findings, the sl-TEL seems to be very promising for the
achieving of monomolecular multistranded quadruplex structures charac-
terized by both high thermal stability and predeterminable strands orienta-
tion. The synthesis of the antiparallel sl-TEL-d(TGGGGT)4 is currently in
progress in our laboratories.
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SOLID PHASE SYNTHESIS OF NUCLEOBASE AND RIBOSE MODIFIED
INOSINE NUCLEOSIDE ANALOGUES
Giorgia Oliviero, Jussara Amato, Stefano D’Errico, Nicola Borbone,
Gennaro Piccialli, and Luciano Mayol  Dipartimento di Chimica delle Sostanze
Naturali, Universita` di Napoli Federico II, Napoli, Italy
 The synthesis and the use of new N-1-dinitrophenyl-inosine based solid support is reported.
The support, which binds the nucleoside by a 5 ′-O-monomethoxytrityl function, reacting with N-
nucleophiles allowed the synthesis of a small library of N-1 alkylated inosine and AICAR deriva-
tives. Moreover, the obtained supports, after the cleavage of the 2 ′-3 ′ ribose bond, furnished a set of
new N-1 alkylated-2 ′-3 ′-secoinosine derivatives in high yields.
Keywords N-1-Dinitrophenyl-inosine based solid support; N-nucleophiles;
2′-3′-seconucleosides
Nucleosides are biomolecules possessing a pivotal role in the metabolism.
In fact, they are involved, as tri-phosphate derivatives, in the nucleic acid
replications and in a very wide number of interactions with enzymes, struc-
tural proteins, and nucleic acids. Furthermore, nucleosides are involved
with a broad array of biological targets of therapeutic importance and a
number of their derivatives exhibit antineoplastic,[1] antibiotic,[2] and an-
tiviral properties.[3] A variety of solid phase combinatorial strategies have
been reported for the preparation of nucleoside and small oligonucleotide
analogues libraries.[4] In an effort to enlarge the nucleoside chemical reac-
tivity on the solid phase, and, thus, the number of accessible structurally
diverse analogues, we report here the new acid labile nucleoside func-
tionalized support 2, which binds the N-1-dinitrophenyl-inosine derivative
1 through the 5′-O-ribose position. These support has been employed in
the solid phase synthesis of N-1 substituted inosine 4a-e, the related 2′-,3′-
seconucleoside derivatives 6a–e and the 5-aminoimidazole-4-carboxamide
riboside (AICAR) 8. The solid phase strategy is based on our previous stud-
ies on the C-2 reactivity of N-1-dinitrophenyl-2′-deoxyinosine towards N-
nucleophiles[5,6] to obtain N-1 substituted inosine and AICAR derivatives.
Address correspondence to Giorgia Oliviero, Dipartimento di Chimica delle Sostanze Naturali,
Universita` di Napoli Federico II, via D. Montesano 49, Napoli I-80131, Italy. E-mail: golivier@unina.it
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SCHEME 1 i) 2 or 3 (1.5 eq.) in pyridine (1.5 mL/250 mg of resin), DMAP (0.2 eq.), 24 hours r.t;
ii: R1-NH2/DMF (38.0 eq), 8 hours 50◦C; iii) TFA 2% solution in DCM; iv: EDA/DMF (1:1, w/w) 8
hours 50◦C; v: NaIO4 (10 eq.) in DMF/H2O (1:1,v/v), 12 hours, 60◦C; resin washings and treatment
with NaBH4 (20 eq.) in EtOH, 2 hours, r.t.
The reported reaction mechanism indicates that when a strong electron-
withdrawing group (such as the 2,4-dinitrophenyl or the nitro group[7]) is
attached to the N-1 atom of the hypoxanthine ring, the C-2 carbon become
electrophilic enough to react with amino nucleophiles (R1-NH2) leading to
R1-N-1 substituted inosine derivatives by a fast opening and re-closure of the
six terms purine cycle.
Support 2 was obtained by reaction of the commercially avail-
able polystyrenemonomethoxytrityl chloride (MMTCl) with the 1-(2,4-
dinitrophenyl)-inosine[8] 1 (Scheme 1). The structure and the loading of
the support 2 (1.2–1.3 meq/g) was confirmed analyzing, by 1H NMR and
quantitative UV experiments, the released inosine 1 by treatment with 2%
TFA in DCM. The reaction of support 2 (100 mg, 0.13 mmol) with N-
nucleophiles (5.0 mmol, R1-NH2, Table 1 entry a–e) in DMF (8 hours, at
50◦C) gave supports 3a–e. The reaction of 2 with ethylenediamine (Table 1,
entry f) furnished, as expected,[9] the support 7 bearing AICAR in almost
quantitative yields. The structures of the supports 3a–e and 7 were ascer-
tained by HPLC, 1H NMR, and MS analyses of the corresponding detached
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crude materials 4a–e and 8. The product yields and the 1H NMR selected
data are reported in Table 1. The second goal of this work was aimed to
combining the set of the N-1 alkylations of the supports 3a–e with the 2′-
3′-oxidative cleavage of the ribose to obtain the related 2′-3′-seconucleoside
derivatives.[10] In a typical reaction the support 3a–e (100 mg) was left in
contact with a solution of NaIO4 (1.3 mmol) in DMF/H2O (1:1,v/v) and
shaken for 12 hours at 60◦C. The resulting support was treated with NaBH4
(2.6 mmol) in EtOH and shaken for 2.0 hours at room temperature. Af-
ter washings, the resins 5a–e were analyzed by detachment of the nucle-
osidic material by TFA treatment. HPLC analyses indicated that the 2′-3′-
secoinosine derivatives 6a–e were obtained in 75–85% yields. The structures
of 6a–e were confirmed by 1H NMR (Table 1) and MS analyses.
In conclusion, we have reported the synthesis of the new N-1-
dinitrophenyl-inosine based solid support 2, which allowed the synthesis of
small libraries of N-1 alkylated inosine derivatives 4a–e and N-1 alkylated 2′-
3′-secoinosine derivatives 6a–e in good yields. Further studies are currently
in progress in this direction to obtain new series of modified nucleoside
analogues.
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a b s t r a c t
Herein, we report the solid-phase synthesis of several 5-aminoimidazole-4-(N-alkyl)carboxamide-1-
ribosides (4-N-alkyl AICARs) and the corresponding 20 ,30-secoriboside derivatives. The method uses the
N-1-dinitrophenyl-inosine 50-bonded to a solid support. This inosine derivative has the C-2 of the purine
base strongly activated towards the attack of N-nucleophiles thus allowing the preparation of several N-1
alkylated inosine supports from which a small library of 4-N-alkyl AICAR derivatives has been synthe-
sized. A set of new 4-N-alkyl AICA-20 ,30-secoriboside derivatives have also been obtained in high yields
by solid-phase cleavage of the 20 ,30-ribose bond.
 2008 Elsevier Ltd. All rights reserved.
1. Introduction
Nucleosides and their phosphorylated counterparts constitute
an important class of biomolecules possessing a pivotal role in
cellular metabolism and signal transmission. For example, they are
involved in nucleic acid replication and in a very wide number of
interactions with enzymes, structural proteins, and other biological
targets of therapeutic importance. Many nucleoside analogues are
currently used in therapy as antivirals1 and others are active
compounds exhibiting antineoplastic,2 antibiotic, and antifungal
properties.3 The research of new active nucleosides is still very
dynamic and promising; substances such as nelarabine,4 entecavir,5
clofarabine,6 and azacitidine7 are examples of anticancer and an-
tiviral drugs recently approved by U.S. FDA. Particular attention has
recently been paid to 5-aminoimidazole-4-carboxamide-1-b-
D-ribofuranosyde (AICAR) since its 50-phosphorylated derivative
(ZMP), a key biosynthetic precursor of purine nucleotides, is an
activator of AMP-activated protein kinase (AMPK).8 A possible
therapeutic importance of its exploitation arises from the fact that
the AICAR-induced AMPK activation strongly inhibits the basal and
the insulin-stimulated glucose uptake, the lipogenesis, the glucose
oxidation, as well as the lactate production in fat cells.9 It has been
also found that the control of protein kinase C (PKC) activation is
correlated with the pathogenesis of diabetic retinopathy.10 Fur-
thermore, the extracellular role of adenosine and other nucleosides
as endogenous cell function modulators indicates the adenosine
receptors as signiﬁcant targets with wide therapeutic potential. In
this context, AICAR has been indicated as a promising prodrug,
which induces beneﬁts in patients suffering from autism, cerebral
palsy, insomnia, schizophrenia, and other neuropsychiatric symp-
toms generally associated to chronic low levels of adenosine.11
However, AICAR has short half-life in the cell, it does not efﬁciently
cross the blood–brain barrier and is poorly adsorbed from the
gastrointestinal tract. Consequently, the production of new AICAR
derivatives is an appealing objective in the ﬁeld of medicinal
chemistry. In recent years, the syntheses of a number of AICAR
derivatives, such as the 2-aryl,12 4-N-benzyl,13 4-substituted,14 5-
substituted,15 5-hydroxyl (Bredinin),16 triazolyl-riboside (Ribavi-
rin),17 20,30-secoriboside derivatives,18 have been reported in the
literature.
Recently, the production of large nucleoside analogue libraries
has emerged as an important synthetic goal to chase the high
efﬁciency and velocity of the current biological screenings. In this
frame, the solid-phase synthesis, associated with a combinatorial
approach, offers the advantage of combining the rapid synthesis
with an easily obtainable molecular diversity around a single core
scaffold.
In this paper, we report a new solid-phase synthetic strategy to
obtain AICAR analogue libraries. The methodology has been tested
in the synthesis of the two small AICAR libraries 10a–g and 15a–g
* Corresponding author. Tel.: þ39 081 678541; fax: þ39 081 678552.
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(Scheme 1) where the nucleosides are modiﬁed on the 4-carbox-
amide residue or both at the 4-carboxamide and the ribose moiety,
respectively.
2. Results and discussion
Our synthetic approach uses as starting material the recently
proposed N-1-dinitrophenyl-inosine solid support 4 synthesized as
depicted in Scheme 2. Support 4 reacting with R–NH2 nucleophiles
is converted into N-1 alkyl-inosine solid supports 8a–g fromwhich
the AICAR libraries 10a–g and 15a–g could be obtained (Scheme 1).
In a previous paper, we utilized support 4 to prepare small libraries
of N-1 alkyl-inosines and their corresponding 20,30-secoriboside
derivatives.19 We also demonstrated that when 4 reacts with eth-
ylenediamine (EDA), the AICAR support 7 can be obtained in an
almost quantitative yield.19,20 It is well known that, under alkaline
conditions, N-1 alkyl-inosines react at the C-2 of the purine system
to give 4-N-alkyl AICAR derivatives by pyrimidine ring cleavage and
concomitant extrusion of the C-2 carbon itself.21 Therefore, we
decided to extend this process to the solid-phase chemistry aiming
at two main targets: (i) to efﬁciently prepare a set of 4-N-alkyl
AICAR derivatives (10a–g) as well as the corresponding precursor
solid supports (9a–g) from N-1 alkyl-inosine supports 8a–g; (ii) to
combine the set of AICAR derivatives with a ribose modiﬁcation
(20,30-secoribosyl derivatives) thus producing the new kind of
products 15a–g, as well as the related solid supports 13a–g, which
are in turn potentially useful for further AICAR derivatization/
modiﬁcation.
Support 4 was obtained by binding 1-(2,4-dinitrophenyl)-
inosine 3 (Scheme 2) to the commercially available poly-
styrenemonomethoxytrityl chloride (MMTCl) resin by 50-O-trityl
ether linkage. Inosine derivative 3 was synthesized by the reaction
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of the commercially available 20-30-O-isopropylidene inosine 2with
2,4-dinitrochlorobenzene (DNCB), followed by 20-30 deprotection
by aqueous formic acid treatment as previously described.19 The
reaction of the MMTCl resin (1.3 mequiv g-1) with 3 in the presence
of 4-(N,N-dimethylamino)pyridine (DMAP), in anhydrous pyridine,
afforded support 4 in almost quantitative yield. Reaction of 4 with
several N-nucleophiles (R–NH2, Table 1) furnished the N-1 alkyl-
inosine supports 8a–g. In the above reactions, the R–NH2 nucleo-
philes react with the strongly activated purine C-2 atom to give the
open intermediates 5 possessing an N-alkyl formamidine group.
The successive fast ring re-closure, favored by the loss of 2,4-dini-
troaniline as leaving group, led to N-1-alkyl-inosines 8a–e (93–95%
yields). We observed that in the case of sterically hindered amines
(entries f and g), the reaction stopped at intermediate products 5,
which, after detachment from the support, could be isolated and
characterized (6f and g). As previously demonstrated, treatment
with carbonate in DMF (at 50 C) converted these open-pyrimidine
species 5 in theN-1-alkyl-inosine supports 8f and g (80–85% yields)
by the six-membered ring re-closure.22 Reaction yields obtained for
8a–g were evaluated quantifying the N-1-alkyl-inosines 11a–g
released from a weighted amount of supports 8a–g by treatment
with 2% (v/v) TFA in DCM taking into account that the starting
support 4 had a nucleoside functionalization of 1.26 mequiv g-1. The
corresponding 4-N-alkyl AICAR supports 9a–g were then obtained
by cleavage of the pyrimidine ring in supports 8a–g by NaOH
treatment (5 M in EtOH, reﬂux, 85–90% reaction yields). TFA
treatment of supports 9a–g released the crude AICAR derivatives
10a–g, which were puriﬁed by HPLC. The overall yield (starting
from support 4) of the pure obtained nucleosides 10 and 11 are
reported in Table 1. The structures and the purity of the products
were conﬁrmed by 1H NMR spectroscopy and ESIMS data. In
a typical reaction starting from 20 mg of solid support 4, and con-
sidering an average molecular weight of 320 gmol1, 6–7 mg of
each crude AICAR derivatives 10a–g could be obtained in 70–85%
purity.
Next, we explored the possibility of performing the 20,30-oxi-
dative cleavage of the ribose moiety in supports 9a–g. In a ﬁrst
attempt, we employed the previously tested19 reaction conditions,
namely sodium metaperiodate followed by borohydride reduction
of the di-aldehyde products. In a typical reaction, the supports 9a–g
were left in contact with a solution of NaIO4 (10 equiv excess) in
DMF/H2O and shaken for 12 h at 60 C. The resulting supports, after
washing, were treated with NaBH4 in EtOH and shaken for 2.0 h at
room temperature to give supports 13a–g that were analyzed by
detaching the nucleosidic material by TFA treatment. The HPLC
analyses and puriﬁcations indicated that the above reactions,
leading to 15c–f, proceeded with 75–80% yields, whereas complex
reaction mixtures were obtained for supports 13a,b,g leading to
very low quantities of the corresponding products 15a,b,g (5–7%
yields). These results suggest that the presence of the 4-N-(u-
hydroxyalkyl) portion on the AICAR supports 9a,b,g leads to large
side reactions when the products were reacted with sodium met-
aperiodate. In the case of AICAR support 7, the reaction furnished
support 14 from which the AICA-20,30-secoriboside 1618 could be
obtained in 70% overall yield (from 4) after the usual TFA treatment.
This prompted us to test the alternative pathway where the C2–C3
scission of the ribose moiety, with formation of 20,30-secoribosides
12a–g, was accomplished prior to the pyrimidine ring degradation.
Following this route, ribose cleavage of 8a–g furnished 12a–g in
good reaction yields (75–80%, from 8), which in turn were con-
verted into the pyrimidine-degraded supports 13a–g from which
the products 15a–g were obtained as described above (80–88%
yields from 12). The success of this pathway demonstrated that the
presence of a 20,30-secoribosyl moiety does not interfere with the
alkaline degradation of the purine ring leading to the AICA het-
erocyclic system. Though a 75–80% yield for the ribose cleavage
could seem acceptable, we considered this result not completely
satisfactory for a solid-phase reaction supporting a combinatorial
synthetic strategy. In fact, the above reaction causes a reduction in
the overall yield and purity of the derivatives 15a–g (60–70% yields
from 4). In order to further improve the yield of the C2–C3 bond
cleavage in ribose, lead tetraacetate (LTA)23 was used in DCM or
DMF. Though the process was accomplished at several LTA/8a–g
ratios and varying the reaction time, no signiﬁcant improvement of
the 20,30-secoribosyl derivatives 12a–gwas obtained after the usual
NaBH4 treatment (60–65% yields). However, it is to be noted that in
both oxidative cleavage procedures (i.e., sodium metaperiodate or
LTA) the predominant side products resulted to be the corre-
sponding unreacted inosines 11a–g.
2.1. Biological results
All compounds were tested for their effect on cellular pro-
liferation using a human breast cancer cell line (MCF-7). The pro-
liferative effects were evaluated in the absence of 5% fetal calf
serum (FCS), while the anti-proliferative effects were evaluated in
the absence of serum. The proliferationwas evaluated by a standard
colorimetric procedure (MTT test)24 after 24 and 48 h in triplicate
using 1 mM of each compound dissolved in water or in 10% ethanol
to improve solubility. The toxicity of the 10:90 ethanol/water so-
lution was tested separately. No signiﬁcant effect on proliferation
was observed for any compound tested. Further experiments using
different conditions and cell lines are currently undergoing.
3. Conclusions
In conclusion, we have successfully utilized the N-1-dini-
trophenyl-inosine solid support 4, where the nucleoside is an-
chored to an MMT-polystyrene resin by the 50-ribose position, to
synthesize small libraries of inosine and AICAR derivatives. The
following solid-phase reactions have been carried out on this
support and its derivatives: (i) the N-1 alkylation of purine by
reaction of 4 with a variety of amines (90–95% yields); (ii) the
alkaline cleavage of the N-1 alkyl-inosine base leading to AICAR
derivatives (85–90% yields); (iii) the 20,30-oxidative cleavage of the
ribose moiety (75–80% yields). The proposed synthetic pathways
allowed the preparation of small libraries of the N-1 alkyl-inosines
11a–g, 4-N-alkyl AICAR derivatives 10a–g, and the corresponding
20,30-secoriboside derivatives 15a–g. It is to be noted that the
reported solid-phase reactions proceed with yields comparable
to, or higher than, those obtainable from the corresponding
Table 1
Reactions on the support 4
Entry R–NH2 6, 11, Yield
a (%) 10, 15, Yielda (%)
a HO NH2 6 (NI), 11 (95) 10 (81), 15 (60)
b NH2HO 3 6 (NI), 11 (95) 10 (83), 15 (67)
c NH2 6 (NI), 11 (93) 10 (84), 15 (63)
d NH2 6 (NI), 11 (95) 10 (86), 15 (69)
e
NH2
6 (NI), 11 (94) 10 (83), 15 (62)
f NH2 6 (90), 11 (85) 10 (76), 15 (59)
g
NH2
O O
HO
6 (85), 11 (80) 10 (72), 15 (58)
NI: not isolated.
a Starting from support 4.
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procedures in solution. Furthermore, the proposed solid-phase
procedures furnished a new group of solid supports bearing ino-
sine derivatives (8a–g, 12a–g) or AICAR derivatives (9a–g, 13a–g),
which can be utilized in a combinatorial manner to achieve
a number of further derivatizations/conjugations both on the
imidazolyl residue and/or on the ribose or 20,30-secoribose moiety.
4. Experimental
4.1. General
4-Methoxytrityl chloride resin (1% divinylbenzene, 200–400
mesh, 1.3 mmol g-1 substitution) was purchased from CBL Patras,
Greece. Anhydrous solvents were used for reactions. All the other
reagents were obtained from commercial sources and were used
without further puriﬁcation. The reactions on solid phase were
performed using glass columns (10 mm diameter, 100 mm length)
with fused-in sintered glass-disc PO (bore of plug 2.5 mm), which
were shaken on an orbital shaker, or round bottom ﬂask, when
reactions were performed at high temperatures. Mps were de-
termined on a Reichert Thermovar apparatus. IR spectra were
collected on a Jasco FT-IR-430 spectrometer. The 1H NMR spectra
were performed on a Varian Mercury Plus 400 MHz using CD3OD
and CDCl3 as solvents; chemical shifts were reported in parts per
million (d) relative to residual solvent signals: CD2HOD 3.31, CHCl3
7.26. RP-HPLC analyses of crude products were carried out on a
Jasco UP-2075 Plus pump using a 5 mm, 4.8150 mm C-18 reverse-
phase column eluted with a linear gradient of CH3CN in 0.1 M TEAB
(pH 7.0, from 0 to 60% in 60 min, ﬂow 1.0 mLmin-1) equipped with
a Jasco UV-2075 Plus UV detector. The UV spectrawere recorded on
a Jasco V-530 UV spectrophotometer. Mass spectra were recorded
on an Applied Biosystems API 2000 mass spectrometer using
electron spray ionization (ESI) technique in positive mode. The
High Resolution MS were recorded on a Bruker APEX II FT-ICR mass
spectrometer using electron spray ionization (ESI) technique in
positive mode. Column chromatography was performed on silica
gel (Merck, Kieselgel 60, 0.063–0.200 mm). Analytic TLC detections
were performed using F254 silica gel plates (0.2 mm, Merck). TLC
spots were detected under UV light (254 nm).
4.2. Synthesis
4.2.1. 1-(2,4-Dinitrophenyl)-20,30-O-isopropylideninosine (2)
A mixture of 20,30-O-isopropylideninosine (1) (1.00 g,
3.24 mmol), 2,4-dinitrochlorobenzene (820 mg, 4.05 mmol), and
K2CO3 (560 mg, 4.05 mmol) was suspended in anhydrous DMF
(5 mL) and stirred at 80 C for 3 h. The reaction was monitored by
TLC (CHCl3/MeOH, 95:5). After cooling, themixturewas ﬁltered and
the solid was washed with CHCl3. The ﬁltrates and washings,
collected and evaporated to dryness, were puriﬁed on a silica gel
columnelutedwith increasing amounts ofMeOH inCHCl3 (from0 to
5%) to give 2 as a pale yellow amorphous solid consisting of a 1:1
mixture of atropisomers at the N(1)–phenyl bond (1.20 g, 80%); mp
235–237 C; nmax (CHCl3) 3417, 3106,1710,1538,1348 cm1; 1HNMR
dH (CDCl3) 9.04 (br s,1H, H-3 DNP), 8.72–8.62 (m,1H, H-5 DNP), 8.11,
8.14 (2´s, 2H,H-2 andH-8), 7.81–7.72 (m,1H, H-6DNP), 6.07–5.96 (m,
1H,H-10), 5.22–5.11 (m,1H,H-20), 5.10–5.02 (br s,1H,H-30), 4.53 (br s,
1H, H-40), 4.02–3.75 (m, 2H, H-50a,b), 2.90 (br s, 1H, OH, exchange
with D2O), 1.64, 1.39 (2s, 6H, 2CH3); UV (MeOH) lmax 246 nm,
3¼20,200; HRESIMS calcd for C19H18N6NaO9: 497.1033, found:
497.1056 (MþNa)þ.
4.2.2. 1-(2,4-Dinitrophenyl)inosine (3)
Compound 2 (1.20 g, 2.60 mmol) was dissolved in HCOOH/H2O
(6:4, v/v, 16 mL) and left at room temperature for 4 h. The reaction
was monitored by TLC (CHCl3/MeOH, 6:4). The mixture was
evaporated to dryness to furnish 3 (1.13 g, 99%) as a pale yellow
amorphous solid that constituted a 1:1 mixture of atropisomers
at the N(1)–phenyl bond. The product was used without further
puriﬁcation; mp 210–212 C; nmax (neat) 3402, 3098, 1704, 1546,
1343, 1217 cm1; 1H NMR dH (CD3OD) 9.05 (s, 1H, H-3 DNP), 8.82–
8.72 (m, 1H, H-5 DNP), 8.49, 8.52 (2s, 2H, H-2 and H-8), 8.08–7.98
(m, 1H, H-6 DNP), 6.14–6.06 (m, 1H, H-10), 4.70–4.60 (m, 1H, H-20),
4.40–4.32 (m, 1H, H-30), 4.19–4.12 (m, 1H, H-40), 3.94–3.74 (m, 2H,
H-50a,b); UV (H2O) lmax 246 nm, 3¼20,100; HRESIMS calcd for
C16H14N6NaO9: 457.0720, found: 457.0715 (MþNa)þ.
4.3. General procedure for the scaffold synthesis
4.3.1. Loading of 3 on solid support
1-(2,4-Dinitrophenyl)inosine (3) (1.13 g, 2.60 mmol) was evap-
orated with dry pyridine (31.5 mL) and then coupled with the
MMTCl resin (1.30 g, 1.69 mmol), and swollen with dry pyridine
(8 mL) in the presence of DMAP (0.35 mmol, 42.0 mg) for 24 h at
room temperature. The resin was ﬁltered and washed with CH2Cl2
(35 mL), CH2Cl2/MeOH (1:1, v/v, 35 mL), and MeOH (35 mL),
and ﬁnally dried in vacuo. The reaction yield was evaluated by
cleavage of the nucleoside from the solid support by treatmentwith
2% (v/v) TFA in DCM (8 min, rt) followed by quantitative UV ex-
periment (3, lmax¼246 nm, 3¼20,100, H2O). The solid support 4was
obtained in almost quantitative yield (1.26 mmol g -1, 97%).
4.3.2. Treatment of solid support 4 with N-nucleophiles a–g
(products 8a–g and 11a–g)
Solid support 4 (100 mg, 0.13 mmol), previously swollen in
DMF, was left in contact with amines a–g (5.0 mmol) in DMF
(1.5 mL) under shaking for 8 h at 50 C. The reaction of 4 with
amines a–e furnished, after usual washings, supports 8a–e. In the
case of amines f and g, after detachment from the support as
described above, intermediates 6f and g could be obtained, after
HPLC puriﬁcation, in 90 and 85% yields, respectively. Alternatively,
supports 5f–g were treated with a 1 M solution of K2CO3 in DMF
(15 h, 50 C) thus giving supports 8f and g. After ﬁltration and
washings with DMF (35 mL), DMF/MeOH (1:1, v/v, 35 mL), and
MeOH (35 mL), supports 8a–g were dried under reduced pres-
sure. The yields of N-1-alkyl-inosines 11a–g (80–95%, from 4, Table
1) were calculated by quantifying the products obtained by HPLC
puriﬁcation of the crude nucleoside material released from
a weighted amount of resin (as described above) and taking into
account that the starting support 4 had a 1.26 mol g-1 nucleoside
functionalization.
4.3.3. Formation of 4-N-alkyl AICAR derivatives 10a–g
Supports 8a–g (100 mg, 0.10–0.12 mmol) were treated with
NaOH (5 M in EtOH) for 6 h at reﬂux. After ﬁltration and washings
with EtOH (35 mL), EtOH/H2O (1:1, v/v, 35 mL), H2O (35 mL),
and MeOH (35 mL), supports 9a–g were dried under reduced
pressure. The reaction yields (8/9, 80–90%) and the overall yields
of 4-N-alkyl AICAR derivatives 10a–g (72–86% from 4) were eval-
uated on isolated products after HPLC puriﬁcation of the material
released from a weighted amount of resin, as described above. 1H
NMR spectra (see later) conﬁrmed the purity of the products.
4.3.4. Formation of 4-N-alkyl AICA-20,30-secoriboside derivatives
15c–f (pathway 9/13/15)
Supports 9c–f (100 mg, 0.09–0.11 mmol) were left in contact
with a solution of NaIO4 (235 mg, 1.1 mmol) in DMF/H2O (1.5 mL,
1:1, v/v) and shaken for 12 h at 60 C. The resulting supports, after
washings with DMF (35 mL), DMF/H2O (1:1, v/v, 35 mL), H2O
(35 mL), and then with EtOH (35 mL), were treated with NaBH4
(2.2 mmol) in EtOH (1.5 mL) and shaken for 2.0 h at room
temperature. After ﬁltration and washings with EtOH (35 mL),
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EtOH/H2O (1:1, v/v, 35 mL), H2O (35 mL), and MeOH (35 mL),
supports 13c–fwere dried under reduced pressure. Reaction yields
(9/13, 75–80%, Table 1) were evaluated by HPLC analysis and
puriﬁcation of the crude 4-N-alkyl AICA-20,30-secoriboside de-
rivatives 15c–f released from a weighted amount of resin, as de-
scribed above. The same reactions, performed on 9a,b,e furnished
very low quantities of the corresponding 15a,b,e.
4.3.5. Formation of 4-N-alkyl AICA-20,30-secoriboside derivatives
15a–g (pathway 8/12/13/15)
Supports 8a–g (100 mg, 0.10–0.12 mmol) were left in contact
with a solution of NaIO4 (235 mg, 1.1 mmol) in DMF/H2O (1.5 mL,
1:1, v/v) and shaken for 12 h at 60 C. The resulting supports, after
washings with DMF (35 mL), DMF/H2O (1:1, v/v, 35 mL), H2O
(35 mL), and then with EtOH (35 mL), were treated with NaBH4
(2.2 mmol) in EtOH (1.5 mL) and shaken for 2.0 h at room tem-
perature. After ﬁltration and washings with EtOH (35 mL), EtOH/
H2O (1:1, v/v, 35 mL), H2O (35 mL), and MeOH (35 mL), sup-
ports 12a–g were dried under reduced pressure. Reaction yields
(8/12, 75–80%) were evaluated by HPLC analysis and puriﬁcation
of the crude 1-N-alkyl-inosine-20,30-secoriboside derivatives re-
leased from a weighted amount of resin, as described above.19
Alternatively, supports 8a–g (100 mg, 0.10–0.12 mmol) were left
into contact with a solution of LTA (235 mg, 1.1 mmol) in DCM
(1.5 mL) and shaken for 24 h at room temperature. The resulting
supports, after usual washings, were treatedwith NaBH4 (2.2 mmol)
in EtOH (1.5 mL) as described above, thus obtaining supports 12a–g
in 60–65% reaction yield (8/12) calculated by HPLC on the re-
leased material. Then, supports 12a–gwere treated with 5 M NaOH
in EtOH as described above for the reaction 8/9 thus giving sup-
ports 13a–g. The TFA treatment of 13a–g furnished 15a–g (80–88%
from 12a–g), which were puriﬁed by HPLC as described above for
10a–g. The overall yields of pure 15a–g (from 4) resulted to be in
the range 58–67% (Table 1). 1H NMR spectra (see later) conﬁrmed
the purity of the products.
4.4. Synthesized scaffolds
4.4.1. 5-[(Cyclohexylamino)methyleneamino]-1-(b-D-ribo-
furanosyl)imidazole-4[N-(2,4-dinitrophenyl)]carboxamide (6f)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3423,
3302, 2917, 1656, 1204, 1111 cm1; 1H NMR dH (CDCl3) 12.36 (s, 1H,
NH, exchange with D2O), 9.18–9.13 (m, 2H, H-6 and H-3 DNP), 8.70
(br s, 1H, H-2), 8.48 (dd, 1H, J¼9.8, 2.4 Hz, H-5 DNP), 7.47 (s, 1H,
CH]N), 5.78 (br s, 1H, H-10), 4.62–4.59 (m, 1H, H-20), 4.38–4.41 (m,
2H, H-30, H-40), 3.94–3.87 (m, 2H, 2H-50), 3.45 (br s, 1H, CHN), 2.20–
1.20 (m, 10H, 5CH2); UV (MeOH) lmax 275 nm, 3¼13,300; HRESIMS
calcd for C22H27N7NaO9: 556.1768, found: 556.1779 (MþNa)þ.
4.4.2. 5-[(1R,2S,3R,4R)-2,3-Dihydroxy-4-((hydroxymethyl)-
cyclopentyl)aminomethyleneamino]-1-(b-D-ribofuranosyl)imid-
azole-4[N-(2,4-dinitrophenyl)]carboxamide (6g)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3430,
3320, 2904, 1668, 1264, 1128 cm1; 1H NMR dH (CDCl3) 9.20 (d, 1H,
H-5 DNP), 9.03 (s, 1H, H-3 DNP), 8.64 (s, 1H, H-2), 8.42 (d, 1H, H-6
DNP), 7.73 (s, 1H, CHN), 6.03 (d, 1H, H-10), 4.63–4.60 (m, 1H, H-20),
4.40–4.36 (m, 2H, H-30, H-20), 4.22–4.18 (m, 2H, H-40, H-30), 3.76–
3.72 (m, 2H, CH2O), 3.62–3.59 (m, 2H, CH2O), 3.23–3.20 (m, 1H,
H-100), 2.02–1.98 (m, 2H, H-400, H-500a), 1.62–1.59 (m, 1H, H-500b), 1.18
(s, 3H, CH3), 1.31 (s, 3H, CH3); UV (CHCl3) lmax 276 nm, 3¼12,900;
HRESIMS calcd for C25H31N7NaO12: 644.1928, found: 644.1945
(MþNa)þ.
4.4.3. 1-(3-Hydroxypropyl)inosine (11a)
Amorphous solid, mp 215–218 C; nmax (neat) 3390, 2930, 1700,
1450, 1232 cm1; 1H NMR dH (CD3OD) 8.41 (br s, 1H, H-2), 8.34 (s,
1H, H-8), 6.00 (d, 1H, J¼5.0 Hz, H-10), 4.64–4.60 (m, 1H, H-20), 4.34–
4.29 (m, 1H, H-30), 4.20 (t, 2H, J¼4.0 Hz, CH2N), 4.15–4.11 (m, 1H,
H-40), 3.86 (dd, 1H, J¼12.2, 2.6 Hz, H-50a), 3.75 (dd, 1H, J¼12.2,
2.6 Hz, H-50b), 3.60 (t, 2H, J¼6.3 Hz, CH2O), 2.03–1.94 (m, 2H,
CH2CH2N); UV (MeOH) lmax 249 nm, 3¼9900; HRESIMS calcd for
C13H19N4O6: 327.1305, found: 327.1291 (MþH)þ.
4.4.4. 1-(5-Hydroxypentyl)inosine (11b)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3375,
2929, 1679, 1427, 1240 cm1; 1H NMR dH (CD3OD) 8.40 (br s, 1H,
H-2), 8.35 (s,1H, H-8), 6.02 (d,1H, J¼5.5 Hz, H-10), 4.64–4.60 (m,1H,
H-20), 4.33–4.29 (m, 1H, H-30), 4.14–4.08 (m, 3H, H-40, CH2N), 3.87
(dd, 1H, J¼12.1, 2.6 Hz, H-50a), 3.75 (dd, 1H, J¼12.1, 2.6 Hz, H-50b),
3.60 (t, 2H, J¼6.2 Hz, CH2O), 1.85–1.77 (m, 2H, CH2), 1.61–1.56 (m,
2H, CH2), 1.48–1.38 (m, 2H, CH2); UV (MeOH) lmax 249 nm,
3¼10,000; HRESIMS calcd for C15H22N4NaO6: 377.1437, found:
377.1453 (MþNa)þ.
4.4.5. 1-Propylinosine (11c)
Amorphous solid, mp 185–187 C; nmax (neat) 3324, 3302, 1702,
1240 cm1; 1H NMR dH (CD3OD) 8.43 (br s, 1H, H-2), 8.35 (s, 1H,
H-8), 6.01 (d, 1H, J¼5.5 Hz, H-10), 4.64–4.60 (m,1H, H-20), 4.34–4.31
(m, 1H, H-30), 4.18–4.11 (m, 1H, H-40), 4.07 (t, 2H, J¼7.3 Hz, CH2N),
3.87 (dd, 1H, J¼12.5, 2.6 Hz, H-50a), 3.75 (dd, 1H, J¼12.5, 2.6 Hz,
H-50b), 1.83–178 (m, 2H, CH2CH3), 0.98 (t, 3H, J¼7.0 Hz); UV (MeOH)
lmax 252 nm, 3¼9700; HRESIMS calcd for C13H18N4NaO5: 333.1175,
found: 333.1207 (MþNa)þ.
4.4.6. 1-Butylinosine (11d)
Amorphous solid, mp 170–172 C; nmax (neat) 3334, 3296, 1693,
1384, 1232 cm1; 1H NMR dH (CD3OD) 8.41 (br s, 1H, H-2), 8.36 (s,
1H, H-8), 6.02 (d, 1H, J¼5.5 Hz, H-10), 4.64–4.60 (m, 1H, H-20), 4.34–
4.30 (m, 1H, H-30), 4.14–4.08 (m, 3H, H-40, CH2N), 3.87 (dd, 1H,
J¼12.1, 2.6 Hz, H-50a), 3.75 (dd, 1H, J¼12.1, 2.6 Hz, H-50b), 1.80–1.71
(m, 2H, CH2), 1.45–1.35 (m, 2H, CH2), 0.98 (t, 3H, J¼7.7 Hz, CH3); UV
(MeOH) lmax 252 nm, 3¼9800; HRESIMS calcd for C14H21N4O5:
325.1512, found: 325.1490 (MþH)þ.
4.4.7. 1-Benzylinosine (11e)
Amorphous solid, mp 217–220 C (lit.25 219–222 C); nmax (neat)
3383, 3298, 1698, 1490, 1212 cm1; 1H NMR dH (CD3OD) 8.44, 8.33
(2s, 2H, H-2, H-8), 7.32–7.26 (m, 5H, Ph), 6.00 (d,1H, J¼5.9 Hz, H-10),
5.29 (s, 2H, CH2Ph), 4.69–4.63 (m,1H, H-20), 4.33–4.30 (m,1H, H-30),
4.13–4.09 (m,1H, H-40), 3.87 (dd,1H, J¼12.5, 2.9 Hz, H-50a), 3.75 (dd,
1H, J¼12.5, 2.9 Hz, H-50b); UV (MeOH) lmax 249 nm, 3¼10,100;
HRESIMS calcd for C17H18N4NaO5: 381.1175, found: 381.1173
(MþNa)þ.
4.4.8. 1-Cyclohexylinosine (11f)
Amorphous solid, mp 188–191 C; nmax (neat) 3344, 3286, 1706,
1368, 1238 cm1; 1H NMR dH (CD3OD) 8.37, 8.32 (2s, 2H, H-2,
H-8), 6.00 (d,1H, J¼5.9 Hz, H-10), 4.64–4.60 (m,1H, H-20), 4.34–4.30
(m, 1H, H-30), 4.22–4.19 (m, 1H, CHN), 4.11–4.10 (m, 1H, H-40),
3.85 (dd, 1H, J¼12.0, 2.9 Hz, H-50a), 3.72 (dd, 1H, J¼12.0, 2.9 Hz,
H-50b), 2.00–1.30 (m, 10H, 5CH2); UV (MeOH) lmax 246 nm,
3¼9800; HRESIMS calcd for C16H23N4O5: 351.1668, found: 351.1699
(MþH)þ.
4.4.9. 1-[(1R,2S,3R,4R)-2,3-(Isopropylidenedioxy)-4-
(hydroxymethyl)cyclopentyl]inosine (11g)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3380,
3298, 1685, 1703, 1430, 1210; 1H NMR dH (CD3OD) 8.40 (br s, 1H,
H-2), 8.36 (s, 1H, H-8), 6.04 (d, 1H, J¼5.4 Hz, H-10), 5.23–5.19 (m,1H,
H-200), 4.73–4.70 (m, 1H, H-300), 4.60–4.58 (m, 2H, H-100, H-20),
4.33–4.29 (m, 1H, H-30), 4.10–4.09 (m, 1H, H-40), 3.75–3.83 (m, 4H,
H-50a,b, H-600a,b), 2.40–2.12 (m, 3H, H-400, H-500a,b), 1.16 (s, 3H, CH3),
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1.30 (s, 3H, CH3); UV (MeOH) lmax 253 nm, 3¼9500; HRESIMS calcd
for C19H26N4NaO8: 461.1648, found: 461.1620 (MþNa)þ.
4.4.10. 5-Amino-1-(b-D-ribofuranosyl)imidazole-4-
[N-(3-hydroxypropyl)]carboxamide (10a)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3402,
3322, 1678, 1220 cm1; 1H NMR dH (CD3OD) 7.31 (s, 1H, H-2), 5.54
(d, 1H, J¼6.6 Hz, H-10), 4.50–4.45 (m, 1H, H-20), 4.24–4.20 (m, 1H,
H-30), 4.06–4.03 (m, 1H, H-40), 3.79 (dd, 1H, J¼12.1, 2.6 Hz, H-50a),
3.74 (dd, 1H, J¼12.1, 2.6 Hz, H-50b), 3.63 (t, 2H, J¼6.2 Hz, CH2O),
3.31 (2H, CH2N, partly covered by solvent signal), 1.81–1.74 (m, 2H,
CH2); UV (MeOH) lmax 268 nm, 3¼10,700; HRESIMS calcd for
C12H20N4NaO6: 339.1280, found: 339.1302 (MþNa)þ.
4.4.11. 5-Amino-1-(b-D-ribofuranosyl)imidazole-4-
[N-(5-hydroxypentyl)]carboxamide (10b)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3409,
3338, 2934, 1623, 1255 cm1; 1H NMR dH (CD3OD) 7.38 (s, 1H, H-2),
5.56 (d, 1H, J¼6.2 Hz, H-10), 4.50–4.46 (m, 1H, H-20), 4.23–4.19 (m,
1H, H-30), 4.08–4.05 (m,1H, H-40), 3.77–3.72 (m, 2H, H-50a,b), 3.55 (t,
2H, J¼6.2 Hz, CH2O), 3.31 (2H, CH2N, partly covered by solvent
signal), 1.62–1.55 (m, 4H, 2CH2), 1.48–1.42 (m, 2H, CH2); UV (MeOH)
lmax 268 nm, 3¼10,900; HRESIMS calcd for C14H24N4NaO6:
367.1594, found: 367.1586 (MþNa)þ.
4.4.12. 5-Amino-1-(b-D-ribofuranosyl)imidazole-4-
(N-propyl)carboxamide (10c)
Amorphous solid, mp 202–205 C; nmax (neat) 3330, 2980, 1702,
1210, 1166 cm1; 1H NMR dH (CD3OD) 7.36 (s, 1H, H-2), 5.54 (d, 1H,
J¼6.6 Hz, H-10), 4.50–4.45 (m, 1H, H-20), 4.24–4.20 (m, 1H, H-30),
4.09–4.06 (m,1H, H-40), 3.79 (dd, 1H, J¼11.7, 2.6 Hz, H-50a), 3.74 (dd,
1H, J¼11.7, 2.6 Hz, H-50b), 3.31 (2H, CH2N, partly covered by solvent
signal), 1.63–1.57 (m, 2H, CH2CH3), 0.98 (t, 3H, J¼7.3 Hz, CH3); UV
(MeOH) lmax 267 nm, 3¼10,400; HRESIMS calcd for C12H20N4NaO5:
323.1331, found: 323.1324 (MþNa)þ.
4.4.13. 5-Amino-1-(b-D-ribofuranosyl)imidazole-4-
(N-butyl)carboxamide (10d)
Amorphous solid, mp 222–225 C; nmax (neat) 3398, 3347, 1702,
1239, 1120 cm1; 1H NMR dH (CD3OD) 7.32 (s, 1H, H-2), 5.52 (d,
1H, J¼5.5 Hz, H-10), 4.50–4.46 (m, 1H, H-20), 4.20–4.16 (m, 1H,
H-30), 4.13–4.10 (m, 1H, H-40), 3.79 (dd, 1H, J¼12.5, 2.9 Hz, H-50a),
3.74 (dd, 1H, J¼12.5, 2.9 Hz, H-50b), 3.31 (2H, CH2N, partly covered
by solvent signal), 1.60–1.51 (m, 2H, CH2), 1.45–1.36 (m, 2H, CH2),
0.96 (t, 3H, J¼7.3 Hz, CH3); UV (MeOH) lmax 267 nm, 3¼10,300;
HRESIMS calcd for C13H22N4NaO5: 337.1488, found: 337.1480
(MþNa)þ.
4.4.14. 5-Amino-1-(b-D-ribofuranosyl)imidazole-4-
(N-benzyl)carboxamide (10e)
Amorphous solid, mp 170–173 C (lit.25 171–172 C); nmax (neat)
3334, 3256, 1456, 1696, 1198 cm1; 1H NMR dH (CD3OD) 7.38–7.30
(m, 6H, Ph, H-2), 5.55 (d, 1H, J¼6.6 Hz, H-10), 4.54–4.48 (s, 3H,
CH2Ph, H-20), 4.19–4.16 (m, 1H, H-30), 4.08–4.05 (m, 1H, H-40), 3.79
(dd,1H, J¼12.1, 2.9 Hz, H-50a), 3.74 (dd,1H, J¼12.1, 2.9 Hz, H-50b); UV
(MeOH) lmax 270 nm, 3¼11,400; HRESIMS calcd for C16H20N4NaO5:
371.1331, found: 371.1325 (MþNa)þ.
4.4.15. 5-Amino-1-(b-D-ribofuranosyl)imidazole-4-
(N-cyclohexyl)carboxamide (10f)
Amorphous solid, mp 210–212 C; nmax (neat) 3320, 3295, 1689,
1197, 1172 cm1; 1H NMR dH (CD3OD) 7.35 (s, 1H, H-2), 5.54 (d, 1H,
J¼7.0 Hz, H-10), 4.50–4.45 (m, 1H, H-20), 4.24–4.19 (m, 1H, H-30),
4.07–4.04 (m, 1H, H-40), 3.82–3.72 (m, 3H, H-50a,b, CHN), 2.00–1.30
(m,10H, 5CH2); UV (MeOH) lmax 267 nm, 3¼10,800; HRESIMS calcd
for C15H24N4NaO5: 363.1644, found: 363.1635 (MþNa)þ.
4.4.16. 5-Amino-1-(b-D-ribofuranosyl)imidazole-4-
[N-((1R,2S,3R,4R)-2,3-isopropylidenedioxy)-4-
(hydroxymethyl)cyclopentyl]carboxamide (10g)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3349,
3325, 1706, 1217, 1122 cm1; 1H NMR dH (CD3OD) 7.37 (br s, 1H, H-
2), 5.57 (d, 1H, J¼5.5 Hz, H-10), 5.19–5.15 (m, 1H, H-200), 4.55–4.40
(m, 3H, H-20, H-100, H-300), 4.26–4.22 (m, 1H, H-30), 4.13–4.09 (m, 1H,
H-40), 3.80–3.68 (m, 4H, H-50a,b, H-600a,b), 2.30–2.10 (m, 3H, H-400,
H-500a,b), 1.18 (s, 3H, CH3), 1.31 (s, 3H, CH3); UV (MeOH) lmax 268 nm,
3¼10,500; HRESIMS calcd for C18H28N4NaO8: 451.1805, found:
451.1812 (MþNa)þ.
4.4.17. 5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxy-
ethyl]imidazole-4-[N-(3-hydroxypropyl)]carboxamide (15a)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3378,
3327,1698,1220 cm1; 1H NMR dH (CD3OD) 7.34 (s,1H, H-2), 5.60 (t,
1H, J¼5.7 Hz, H-10), 3.87–3.83 (m, 2H, CH2O), 3.75–3.64 (m, 2H,
CH2O), 3.61–3.49 (m, 5H, CH, 2CH2O), 3.31 (2H, CH2N, partly cov-
ered by solvent signal), 1.80–1.75 (m, 2H, CH2); UV (MeOH) lmax
268 nm, 3¼10,200; HRESIMS calcd for C12H22N4NaO6: 341.1437,
found: 341.1445 (MþNa)þ.
4.4.18. 5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxy-
ethyl]imidazole-4-[N-(5-hydroxypentyl)]carboxamide (15b)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3370,
3323,1702,1210 cm1; 1H NMR dH (CD3OD) 7.35 (s,1H, H-2), 5.62 (t,
1H, J¼5.9 Hz, H-10), 3.95–3.85 (m, 2H, CH2O), 3.78–3.64 (m, 2H,
CH2O), 3.60–3.50 (m, 5H, CH, 2CH2O), 3.32 (2H, CH2N, partly cov-
ered by solvent signal), 1.64–1.54 (m, 4H, 2CH2), 1.48–1.38 (m, 2H,
CH2); UV (MeOH) lmax 268 nm, 3¼10,100; HRESIMS calcd for
C14H26N4NaO6: 369.1750, found: 369.1756 (MþNa)þ.
4.4.19. 5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxy-
ethyl]imidazole-4-(N-propyl)carboxamide (15c)
Amorphous solid, mp 225–229 C; nmax (neat) 3384, 3332, 1705,
1264, 1176 cm1; 1H NMR dH (CD3OD) 7.36 (s, 1H, H-2), 5.62 (t, 1H,
J¼3.3 Hz, H-10), 3.90–3.83 (m, 2H, CH2O), 3.78–3.62 (m, 2H, CH2O),
3.61–3.49 (m, 3H, CH, CH2O), 3.30 (2H, CH2N, partly covered by
solvent signal), 1.65–1.56 (m, 2H, CH2), 0.96 (t, 3H, J¼7.2 Hz, CH3);
UV (MeOH) lmax 267 nm, 3¼10,300; HRESIMS calcd for
C12H22N4NaO5: 325.1488, found: 325.1480 (MþNa)þ.
4.4.20. 5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-
hydroxyethyl]imidazole-4-(N-butyl)carboxamide (15d)
Amorphous solid, mp 218–222 C; nmax (neat) 3398, 3340, 1702,
1241, 1160 cm1; 1H NMR dH (CD3OD) 7.34 (s, 1H, H-2), 5.60 (t, 1H,
J¼3.3 Hz, H-10), 3.91–3.84 (m, 2H, CH2O), 3.79–3.65 (m, 2H, CH2O),
3.61–3.49 (m, 3H, CH, CH2O), 3.31 (2H, CH2N, partly covered by
solvent signal), 1.60–1.51 (m, 2H, CH2), 1.46–1.32 (m, 2H, CH2), 0.96
(t, 3H, J¼7.2 Hz, CH3); UV (MeOH) lmax 267 nm, 3¼10,300; HRESIMS
calcd for C13H24N4NaO5: 339.1644, found: 339.1640 (MþNa)þ.
4.4.21. 5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-
hydroxyethyl]imidazole-4-(N-benzyl)carboxamide (15e)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3367,
3331, 1705, 1264, 1176 cm1; 1H NMR dH (CD3OD) 7.36–7.28 (m, 6H,
Ph, H-2), 5.60 (t, 1H, J¼5.6 Hz, H-10), 4.51 (s, 2H, CH2Ph), 3.96–3.84
(m, 2H, CH2O), 3.78–3.64 (m, 2H, CH2O), 3.61–3.49 (m, 3H, CH,
CH2O); UV (MeOH) lmax 270 nm, 3¼11,200; HRESIMS calcd for
C16H22N4NaO5: 373.1488, found: 373.1476 (MþNa)þ.
4.4.22. 5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-
hydroxyethyl]imidazole-4-(N-cyclohexyl)carboxamide (15f)
Amorphous solid, mp 210–213 C; nmax (neat) 3367, 3302, 1708,
1164 cm1; 1H NMR dH (CD3OD) 7.33 (s, 1H, H-2), 5.59 (t, 1H,
J¼5.5 Hz, H-10), 3.94–3.84 (m, 2H, CH2O), 3.80–3.65 (m, 3H, CH2O,
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CHN), 3.61–3.49 (m, 3H, CH, CH2O), 2.00–1.30 (m, 10H, 5CH2); UV
(MeOH) lmax 267 nm, 3¼10,800; HRESIMS calcd for C15H26N4NaO5:
365.1801, found: 365.1810 (MþNa)þ.
4.4.23. 5-Amino-1-[1-(1,3-dihydroxypropan-2-yloxy)-2-hydroxy-
ethyl]imidazole-4-[N-((1R,2S,3R,4R)-2,3-isopropylidenedioxy)-
4-(hydroxymethyl)cyclopentyl]carboxamide (15g)
Amorphous solid, mp over 250 C (decomp.); nmax (neat) 3404,
3387, 1693, 1287, 1193 cm1; 1H NMR dH (CD3OD) 7.25 (s, 1H, H-2),
5.60 (t,1H, J¼4.7 Hz,H-10), 5.20–5.17 (m,1H,H-200), 4.56–5.50 (m,2H,
H-100, H-300), 3.93–3.86 (m, 2H, CH2O), 3.80–3.67 (m,2H, CH2O), 3.61–
3.49 (m, 5H, CH, 2CH2O), 2.36–2.10 (m, 3H, H-400, H-500a,b),1.32 (s, 3H,
CH3),1.20 (s, 3H, CH3); UV (MeOH) lmax 268 nm, 3¼10,200;HRESIMS
calcd for C18H30N4NaO8: 453.1961, found: 453.1969 (MþNa)þ.
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